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Abstract  
 Human breast cancer research faces limitations necessitating a comparative 
oncogenomic approach and use of models, in which the environment and genetic 
background can be controlled.  The Mcm4Chaos3 (Chaos3) mouse model contains the 
only endogenous mutation in mice known to lead exclusively to spontaneous 
development of mammary adenocarcinomas.  My comparative analysis of Chaos3 and 
human oncogenomic data implicate NF1 deficiency as a major driver of breast cancer.  
Traditionally known for its tumor suppressive role in preventing neurofibromas, I find 
NF1 is deficient in Chaos3 mammary tumors and 27.7% of human breast tumors, 
including >40% of Her2-enriched and basal-like subtypes.  NF1 loss triggered 
hyperactivation of the RAS oncogene, and these tumor cells were sensitive to RAS 
pathway drugs.  As NF1 deficiency confers increased resistance to standard tamoxifen 
treatment, my findings have considerable implications for NF1 testing and 
personalized treatment that we project impacts ~383,230 women who develop breast 
cancer with NF1 deficiency annually.  ~25% of breast cancer cases have a 
heritable/familial basis, but underlying susceptibility genes remain largely unknown.  
While, Chaos3-C3H mice develop mammary tumors, Chaos3-C57BL/6 mice develop 
lymphomas and histiocytic sarcomas, indicating that cancer type is highly influenced 
 by background strain.  We utilized Chaos3 mice of mixed backgrounds to identify 
mammary tumor susceptibility and resistance loci.  Quantitative trait loci (QTL) 
analysis of ~200 C3H x C57BL/6 F2 Chaos3 females revealed candidate genes 
involved in cell proliferation, DNA repair, cell signaling, and cancer-associated genes.  
One locus contained Tln1, a gene required for integrin activation, in which a germline 
mutation was discovered.  Chaos3 Tln1 mutants were aged, and a significantly higher 
proportion developed mammary tumors, validating Tln1 impact on mammary tumor 
susceptibility.  In another set of studies, I found that DNA damage response (DDR) 
deficiency and reproductive hormones have a significant impact on carcinogenesis 
when MCM DNA replication machinery is defective.  ATM pathway deficiency in 
Chaos3 mice resulted in decreased tumor latency and/or increased tumor 
susceptibility.  Oophorectomized Chaos3 mice had decreased mammary tumor 
incidence, but increased susceptibility to other cancer types.   Together, my results in 
four areas of breast cancer research demonstrate significant advancement in the 
understanding of mechanisms involved in mammary tumorigenesis.   
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CHAPTER 1 
Introduction 
 
Breast cancer is the most prevalent cancer in women (29% of all cases), with 
an expected 226,870 new cases and 40,000 deaths in 2012 in the United States alone 1.  
Efforts are being placed on identifying events and factors driving carcinogenesis as 
well as determining loci contributing to breast cancer susceptibility.  This dissertation 
will focus on four main areas of research in breast cancer:  
1. Genomic alterations in mammary tumors to identify drivers 
2. Identification of mammary tumor susceptibility loci 
3. Impact of DNA damage response perturbation on mammary carcinogenesis 
4. Role of reproductive hormones in mammary carcinogenesis 
 
1.1 Areas of Breast Cancer Research  
One challenge facing cancer researchers is that cancer is not a singular disease, 
rather a complex set of diseases.  Human breast tumors can be divided into multiple 
subtypes based on reproductive hormone receptor status and expression signature 2-4.  
Estrogen and Progesterone receptor positive (ER+, PR+) tumors can respond to the 
presence of estrogen and progesterone.  Luminal A breast tumors tend to be ER+ and 
low grade (well differentiated) 5,6.  Luminal B mammary tumors also tend to be ER+ 
but are often high grade (poorly differentiated) 5,6.  In the HER2/neu+ subtype, 
epidermal growth factor receptor Her2/neu/ErbB2 is amplified 5,6.  Basal-like 
mammary tumors are triple negative (ER-, PR- and HER2-) and associated with 
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poorer prognosis 7.  Claudin-low mammary tumors are often triple-negative, and 
additionally have low expression of cell-cell junction proteins (E-cadherin), which is 
associated with increased invasion and metastasis 8. 
The majority of breast cancer cases (~75%) are believed to have a sporadic, 
rather than heritable basis 9.  Therefore, research focus is directed at genomic analysis 
of somatic tissue, contrasting normal tissue to the tumors to identify genes and 
pathways that are frequently spontaneously mutated, misregulated, or have copy 
number alterations (CNAs), which may thus represent cancer “drivers” with causative 
roles.  However, the prevalence of passenger mutations, heterogeneity, and the 
diversity of tumor etiologies and subtypes complicates conclusions about genes 
identified in these studies 4,10,11.  These genes are only putative drivers, being 
established solely by statistical association, and mechanistic validation remains to be 
tested directly.  
Twin and family studies indicate that ~25% of breast cancer cases have a 
heritable basis 9.  However, mutations in the most penetrant susceptibility genes 
known, BRCA1 and BRCA2, account for only ~5% of breast cancer cases in the 
general population 12-14.  The majority of susceptibility genes underlying heritable 
breast cancer remain unknown.  To identify additional susceptibility genes and drivers, 
large-scale genome wide association studies and genome cancer resequencing projects 
have been conducted 10,15-18.  Overall, it appears that the majority of genetically-based 
breast cancers are caused by low-penetrance modifier alleles 19.  This complicates 
attempts at genetic mapping by GWAS in humans. 
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DNA damage response (DDR) pathways are responsible for helping maintain 
genomic stability and suppressing tumorigenesis.  Ataxia Telangiectasia Mutated 
(ATM) as well as ATM and Ataxia-Telangiectasia-and-Rad3-related (ATR) are DNA 
damage sensors that head DNA checkpoint and repair pathways, including signaling to 
Tumor Protein 53 (TP53), the tumor suppressor most frequently compromised in 
human cancer 20,21.  Genomic studies have shown that many genes are misregulated or 
altered at low frequencies in human cancers, but together comprise significant 
alterations in key pathways, specifically DDR pathways 15,22,23.   
Reproductive hormones and their receptors also have a profound impact on 
mammary tumorigenesis.  Approximately 75% of all human breast tumors are positive 
for estrogen receptor (ER+), and growth of these tumors can be stimulated by estrogen 
24
.  Nulliparous women have twice the risk of developing breast cancer as women who 
have undergone a full term pregnancy before 20 years of age 25.  In women, multiple 
early pregnancies confer a lifelong reduced risk of breast cancer 26,27.  This protection 
can be mimicked in rodents through administration of estrogen and progesterone 
treatments 28,29, and hormonal treatment causes increased long-term expression of 
Trp53 and other pro-apoptotic genes 26,27.    
 
1.2 Mouse Models  
With the challenges and limitations of human studies, mouse cancer models 
are powerful for untangling the genomic basis of cancers.  Genetic backgrounds can 
be precisely defined, and phenotypic variation can be minimized, allowing mouse 
models to be used to identify genetic loci that modify cancer risk.  Whereas the 
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heterogeneity of human populations and the diversity in breast cancer etiology 
complicates genetic analysis, within a given cancer mouse model, the tumors that arise 
have a consistent underlying basis.  Additionally, mice can be experimentally 
manipulated to solidify evidence of candidate genes and validate genomic findings.   
However, the majority of mouse models have drawbacks for breast cancer 
research.  With the singular eitiology of mammary tumors within a mouse model in a 
single strain, the universality of effects of a mutation across different backgrounds is 
unknown.  In the worst case, results could be restricted to that background.  Currently, 
the most widely used mouse models of mammary cancer are transgenics, in which the 
Mouse Mammary Tumor Virus (MMTV) is driving overexpression of an oncogene 
30,31
. This is artificial and may not be relevant to the human situation.  Also, despite 
the powerful genetics in mice, there has been little success in cloning modifier loci or 
identifying new mammary cancer drivers on a large scale.    
 
1.3 Utilizing the Chaos3 Mouse Model to Study Mammary Carcinogenesis  
The Chaos3 (Chromosome aberrations occurring spontaneously 3) mouse 
model has several advantages to elucidate mechanisms of carcinogenesis, including 
that tumors arise spontaneously rather than the mice being genetically engineered or 
treated with carcinogens.  The mcm4Chaos3 (Chaos3) nonsynonomous point mutation in 
the C3H genetic background is the only endogenous gene mutation in mice that leads 
exclusively to mammary carcinogenesis 32.  Nearly all Chaos3 homozygous 
nulliparous females in the C3H strain inbred background succumb to mammary 
adenocarcinomas with a mean latency of 12 months 32.  The Chaos3 cancer model was 
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isolated in an N-ethyl-N-nitrosourea (ENU) mutagenesis screen for mutations causing 
genomic instability (GIN) 32.  The nonsynonomous mutation identified in mcm4 
(minichromosome maintenance 4) causes a dramatic increase in micronuclei (a 
hallmark of GIN), a destabilized MCM helicase, pan-reduction of all MCMs, and a 
decreased number of dormant origins 33-37.  MCM4 is a highly conserved subunit of 
the MCM2-7 DNA replicative helicase, an essential component of pre-replication 
(pre-RC) complexes 38.  These complexes are “licensed” at replication origins for 
activation in S phase, and regulatory mechanisms inhibit reloading of the MCMs 
during S phase to prevent re-replication of the genome 38.   
Here, I took a comparative oncogenomic approach to identify breast cancer 
drivers, utilizing the Chaos3-C3H mouse model. The controlled genetic background 
and singular tumor etiology allows identification of recurrent mutational events likely 
to be involved in driving tumorigenesis.  
While the Chaos3 mice were being bred to be congenic in C3H, some Chaos3 
mice of mixed background between C3H and C57BL/6J ("B6") developed lymphomas 
39
, as did Chaos3 MCM2-deficient mice in a mixed C3H x B6 background (Figure 
A1-1).  This suggested that Chaos3 predisposes to cancer, but other loci in the genome 
determine tumor type susceptibility.  These other loci could either be mammary tumor 
predisposition genes (in C3H) and/or mammary tumor preventative genes (in B6).  
Thus, we can exploit the Chaos3 model to identify breast cancer modifiers. 
In Chaos3 mouse embryonic fibroblasts (MEFs), significant chromosome 
breakage (compared to wild-type controls) occurred only under conditions of 
replication stress, indicating that the damage was a consequence of a defect(s) in some 
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aspect of DNA replication 32,33.  Work in yeast carrying the Chaos3 mutation suggests 
that the stress can cause the replication fork to collapse, leading to double strand 
breaks which then activates the HR (homologous recombination) pathway 40.  
Evidence from other model systems support the conclusion that MCM dysfunction can 
cause DNA damage and rearrangements 41.  DDR genes target components of the core 
DNA replication complex, including the MCM helicase.  MCM2 is a direct target of 
ATR, and MCM3 is a target of ATM 42,43.  Additionally, Chaos3 cells demonstrate 
elevated activation of DDR pathways in the form of increased levels of RAD51 and 
BLM foci 36, and  upregulation of p53 and p21 are observed in Chaos3 MEFs 37.  
Chaos3 animals also deficient for p53 have decreased time to cancer onset 37.  This 
evidence suggests the Chaos3 model may be sensitive to DDR gene perturbation.  
Here we generate double mutant lines between Chaos3 and an additional DDR gene to 
examine the impact of components in DDR pathways on carcinogenesis when the core 
DNA replication machinery is defective.   
Additional mechanistic variables, such as reproductive hormones and their 
receptors, may tie MCMs to Chaos3 carcinogenesis and mammary tumor specificity.  
The reproductive hormones estrogen and progesterone control DNA replication in 
uterine epithelial cells by regulating MCM proteins 44.  Progesterone inhibits DNA 
synthesis by decreasing Mcm transcription (particularly Mcm4), MCM protein levels, 
and CDT1, the protein that facilitates loading MCMs onto replication origins.   
Progesterone also leads to the sequestration of MCMs into the cytoplasm even though 
these proteins are primarily nuclear 44.  Progesterone may regulate the MCMs through 
miRNAs in uterine epithelial cells 45, and normal MCM levels are restored in Chaos3 
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cells with the dicer or drosha pathways are knocked down 35.  In normal human breast 
cells, progesterone increases transcription of the Mcms and other DNA licensing 
factors 46.   
Together, the characteristics of the Chaos3 model make it an excellent tool to 
study mammary carcinogenesis and the consequences of defects in the core DNA 
replication machinery on cancer. 
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One Sentence Summary: Comparative analysis of a mouse mammary tumor model 
and human oncogenomic data implicate NF1 deficiency as a major driver of breast 
cancer. 
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2.1 Abstract 
Most large-scale genomic studies of human breast cancer lack experimental 
evidence to support computationally implicated driver genes, a task complicated by 
the genetic diversity amongst tumors and people. To overcome these issues, we 
incorporated human genomic tumor data with experimental data from the C3H-
Chaos3 mouse model to provide evidence of NF1 deficiency as a leading driver in 
breast cancer. Recurrent Chaos3 mammary tumor copy number alterations (CNAs) 
overlap with those found in human breast cancer, most strikingly loss of the Nf1 tumor 
suppressor in nearly all cases. Analysis of The Cancer Genome Atlas (TCGA) data 
revealed NF1 deficiency in 27.7% of all human breast tumors, including >40% of 
Her2-enriched and basal-like subtypes. We show that NF1 loss triggers 
hyperactivation of the RAS oncogene in Chaos3 tumors and cell lines, rendering them 
sensitive to drugs targeting the RAS pathway. These data implicate NF1 deficiency as 
a major breast cancer driver that we project to impact ~383,330 women annually, a 
finding that will be informative for personalized treatments. 
2.2 Main Text  
Twin and family studies indicate that only ~25% of breast cancer cases have a 
heritable/familial basis, and thus the majority (~75%) appear to be “sporadic” 1. 
Hence, much effort is being placed on genomic analysis of breast tumors and other 
cancers. The goal is to identify genes and pathways that are commonly altered and 
which may thus represent cancer “drivers” with causative roles.  However, the 
prevalence of passenger mutations, genetic heterogeneity, and the diversity of tumor 
etiologies and subtypes complicates unequivocal identification of drivers, 
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necessitating experimental validation. Here, we took a comparative oncogenomic 
approach for breast cancer driver identification, exploiting a highly relevant mouse 
model, C3H-Chaos3. These mice bear a point mutation in the minichromosome 
maintenance 4 (Mcm4) gene that destabilizes the MCM2-7 helicase that is essential for 
faithful DNA replication. The resulting genomic instability (GIN) causes >80% of 
nulliparous females to develop mammary adenocarcinomas exclusively 2. The 
controlled genetic background and singular tumor etiology allows identification of 
recurrent mutational events likely to be involved in driving tumorigenesis.  
Human breast tumors can be classified into subtypes using gene expression 
signatures that are also present within mouse models of mammary cancers 3,4. 
Expression profiling of Chaos3 mammary tumors revealed that they cluster near three 
luminal adenocarcinoma mouse models (Figure 2-1A). Consistent with this, the 
Chaos3 gene signature was most highly expressed in the Human Luminal A subtype, 
and was also high in HER2-enriched and Luminal B tumors (Figure 2-1B). Luminal 
breast tumors are the most prevalent type in humans 5. Significance Analysis of 
Microarray (SAM) revealed that Chaos3 tumors have a distinct gene expression 
pattern from all other mouse models, including dramatic upregulation of Mucl1, a 
diagnostic marker in human breast cancer (Table A2-1) 6. Tumor differentiation score 
(D-Score) analysis showed that Chaos3 tumors more closely resemble mature human 
luminal cells than any mouse model analyzed to date (Figure 2-1C). Together, these 
results show that Chaos3 mice, which are not genetically engineered, are an excellent 
human breast cancer model. 
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Figure 2-1: Chaos3 tumors model key human features. (A) Expression microarray 
dendrogram of Chaos3 mammary tumors and 185 other mouse mammary carcinomas and 
normal mammary tissue samples. The Chaos3 tumors cluster together as a distinct group near 
luminal mouse models: WAP-MYC, PyMT, and Her2/Neu. (B) Boxplot of the Chaos3 gene 
signature in the UNC337 human breast tumor dataset. Chaos3 tumors have higher signature 
expression in human luminal, HER2-enriched, and normal-like intrinsic subtypes. (C) Chaos3 
Differentiation Score (D score) in relationship with other GEMMs. The high D-Score shows 
that Chaos3 tumors more closely resembles the expression signature of mature human luminal 
cells relative to all other mouse models analyzed. (B, C) P-values reflect statistical 
significance of ANOVAs. Key: MaSC - Mammary Stem Cell.  
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Primary Chaos3 cells have increased stalled replication forks that persist 
through metaphase, leading to chromosome breaks and improper chromosomal 
segregation  2,7. Similar to human breast tumors 8, Chaos3 tumors had high levels of 
aneuploidy and drastic variation in chromosome number, even within the cells of a 
single tumor (Figure 2-2). With such intratumor variation, we expect that only early 
and/or highly selected mutations would be readily detectable and highly recurrent 
across multiple cases. To uncover mutations potentially driving carcinogenesis in 
Chaos3 mice, we first performed partial exome resequencing of mammary tumors 
(Figure 2-3; Table A2-2 through Table A2-7). Surprisingly, we discovered few 
somatic point mutations in the targeted exonic regions and calculated the mutation rate 
at 1.1 x 10-7, or 0.25 mutations/Mb, which is not above the background rate in other 
genomic studies of breast cancer (Table A2-8) 9,10. The mutated genes are involved in 
diverse functions, and together they do not implicate a commonly affected pathway 
underlying carcinogenesis (Figure 2-3). These results indicated that elevated 
intragenic mutagenesis is not the primary mechanism driving Chaos3 carcinogenesis, 
suggesting that other initiators such as CNAs may be responsible. 
 17 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2: Chaos3 tumors demonstrate high levels of GIN and aneuploidy.  (A) 
Metaphase spreads from cells of 3 Chaos3 mammary tumors.  Note aneuploidy in left and 
middle spreads compared to the normal 40 chromosomes (left to right: 414, 83, 40).  (B) 
Examination of 16 Chaos3 tumors reveal a normal chromosome count in an average of only 
1/3 of the cells (>Tetra= Beyond Tetraploidy; Tetra=Tetraploid; Amp=Amplification; 
Del=Deletion).  (C) Metaphase spreads from one Chaos3 mammary tumor (16864a).  
Chromosome count is indicated beneath the images.  Note the extreme variation of aneuploidy 
found within a single tumor.  (D) Additional abnormal features displayed by tumor cells, 
including: cruciform structures (left) and abnormal multi-nucleated cells (middle and right). 
48 75 139 207 271 383
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B
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Chr Count
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Figure 2-3: Low point mutation rate in coding regions of Chaos3 mammary 
tumors.  (A) Partial exome resequencing depth coverage for Sequence Capture on-
target reads.  An average read depth coverage of 52.6 was achieved for the target 
regions, with >85% of the bases in the capture target region represented by at least 5x 
coverage. NT=nucleotide.  A single 88 nt read length run was conducted on sample 
2042, and reads were subsequently shortened during analysis to both 64 and 44 nt to 
reduce error rate.  The 44 nt length was used for SNP and mutation calling.  (B) 
Somatic mutations in Chaos3 tumors.  Shown are aligned Sequence Capture reads and 
validated sequence trace from Sanger sequencing, reflecting the five somatic 
mutations discovered in target regions from four Chaos3 tumor samples: Acsl6, 
Myo1g,Tdrd6, Ttn. Note: one Chaos3 primary mammary tumor (12352) had no 
validated somatic point mutations.  C3H is the wild type control; Mut is the tumor.  
Nucleotide positions in gray indicate no deviation from wild type C57BL/6 reference.  
MT= Mammary tumor; CL= Cell Line.  The Chaos3 calculated tumor mutation rate is 
1.1 x 10-7, or 0.25 Mutations/Mb.  Chaos3 tumors do not exhibit an increased 
mutation rate above background breast tumor mutation rates.  
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To examine genomic copy number changes, we performed array comparative 
genomic hybridization (aCGH) on twelve Chaos3 tumors, including 9 Chaos3 
mammary tumors and 3 non-mammary tumors, and two MMTV-Neu mammary 
tumors. Chaos3 non-mammary tumors can be obtained by genetic perturbations or 
altering the strain background 11,12. Strikingly, the Chaos3 tumors exhibited recurrent 
chromosomal aberrations. Nearly all had specific amplifications on Chromosomes 
(Chr) 12 and 16 (Figure 2-4A; Table A2-9 through Table A2-11). CNAs on Chrs 4, 5, 
and 11 were found in mammary tumors specifically (Table A2-9 through Table A2-
12). We screened breast cancer data from The Cancer Genome Atlas (TCGA) and the 
Catalogue of Somatic Mutations in Cancer (COSMIC) databases and found 
overlapping syntenic CNAs in human mammary tumors (Figure 2-4B; Table A2-13 
through Table A2-15). The Chr 12 amplification has remarkably precise breakpoints 
that flank an Immunoglobulin (Ig) gene locus, and curiously, the Chr 16 amplified 
regions are also replete with immunity-related genes (Table A2-9 and Table A2-10). 
Additional genes in these regions have roles in metastasis, pluripotency, signal 
transduction, or are known to be upregulated in cancer (Table 2-1; Table A2-10). 
Genes in the deleted regions function in apoptosis/necrosis, DNA checkpoint/repair, 
signal transduction, and tumor suppression (Table 2-1; Table A2-10).  
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Figure 2-4. Recurrent CNAs in Chaos3 mammary tumors are frequently altered 
in human breast cancer, including one quarter of human cases with Nf1 
deficiency. (A) KCSmart analysis of combined aCGH data from 12 Chaos3 tumors, (9 
mammary and 3 non-mammary). The most significant amplification peaks (red) lie on 
Chrs 12 and 16, and deletions (green) on Chrs 4, 5, and 11. (B) Overlap of mouse 
(Mmu) Chaos3 recurrent mammary tumor deletions (thick red bars) with recurrent 
human (Hs) breast tumor segmental CNAs (thick black bars). Human gene orders are 
shown. Refer to Table A2-13 and Table A2-14 for complete comparison. Asterisks 
indicate juxtaposed and contiguous sequences in the mouse genome. See Figure 2-8 
and Methods for details.  (C) Percentage of NF1 CNA and mutation in 511 human 
breast tumors, including 57 Her2-Enriched and 93 Basal breast tumors. Note that 
27.7% of human breast tumors have NF1 deletion or mutation, and HER2-Enriched 
and Basal breast tumor subtypes have >40% of cases with NF1 deletion or mutation. 
(D) Boxplot of NF1 mRNA expression (microarray) vs. copy number (GISTIC 
analysis) in human breast cancer. Horizontal gray bars are the means of each group.  
Blue X’s represent individual tumor or normal samples.  Homdel = homozygous 
deletion; Hetloss = heterozygous deletion; Amp = high level amplification. Expression 
levels significantly correlate with genomic copy number status (ANOVA between 
Hetloss and Diploid groups, p=3.32 * 10-13). Human data were from unpublished 
TCGA (see Materials and Methods). 
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Table 2-1: Cancer and Immunity Related Genes in Chaos3 CNAs 
  
  Amplified     Deleted 
Function Chr 16 Chr 12   Function Chr 4 Chr 5 Chr 11 Chr 10 Chr 19 
Pluripotency 
Dppa4, 
Dppa2  
    
Tumor 
Suppressor   Cdk2ap1 Nf1     
Signal 
Transduction    Adam6    
DNA 
Checkpoint/ 
Repair   
Kntc1, 
Gtf2h3, 
Setd8 
    
Rad9 
Immunity/ 
Inflammation 
Pvrl3, 
Retnlb, 
Retnla  Ig/abParts    
Apoptosis/ 
Necrosis 
Dffa, 
Ube4b, 
Kif1b,      Oaz1   
Upregulated 
in Cancer Igsf11     
Signal 
Transduction  Pik3cd,     Ksr1 
Csnk1g2, 
Mknk2   
      
  
Immunity/ 
Inflammation        Lingo3   
      
  
Other 
Cancer 
Related 
Arid1a, 
Sfn Sbno1,      Minpp1 
 
 
Legend: Genes altered in a high percentage of Chaos3 mammary tumors specifically 
are underlined. Critical regions of central overlap across multiple Chaos3 tumors 
were defined within CNAs (Refer to Figure 2-4B, Table A2-13, and Supplementary 
Methods). Genes within critical regions of CNAs are bolded, and these genes that 
additionally have CNAs in human breast cancers are italicized. Ig/abParts= Ig locus 
and Antibody Parts gene feature conserved between mice and humans. See Table A2-
10, Table A2-13, and Table A2-14 for extended lists and complete analysis. 
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Of particular interest is a set of Chaos3 deletions on Chr 11 that overlaps with 
a recurring cluster of CNAs on human Chr 17. All Chaos3 mammary tumors 
examined by aCGH but none of the MMTV-Neu driven mammary tumors or Chaos3 
non-mammary tumors contained Chr 11 deletions (Figure 2-5; Table A2-9, Table A2-
11, and Table A2-12). The small deletions have nested breakpoints that define a 
commonly-deleted region containing the tumor suppressor Neurofibromin 1 (Nf1) 
(Figure 2-5B). We then analyzed the DNA of these and additional Chaos3 mammary 
tumors by qPCR. Overall, 59/60 contained Nf1 deletions, with 51.6% appearing 
homozygous and 46.6% heterozygous (Table A2-12). Nf1-deleted tumors showed 
absence or severe reduction of mRNA and protein (Figure 2-6A, Figure 2-5C). NF1 
negatively regulates RAS, which controls proliferation, differentiation, cell adhesion, 
apoptosis, and cell migration through the MAPK and PI3K signal transduction 
pathways (Figure 2-6B). The RAS pathway is misregulated in many cancer types, 
including recent studies implicating it in breast cancer 13-15.  RAS deregulation leads to 
increased invasion and metastasis and decreased apoptosis 16. 
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Figure 2-5: Nf1 is deleted in Chaos3 mammary tumors.  (A) Recurrent significant 
deletion detected by aCGH on Chr 11 at ~79 Mb, specific to Chaos3 mammary 
tumors.  The broken red line indicates significant log2 ratios.  17883 is a mediastinal 
lymphoma/leukemic tumor, 16862 is a histiocytic sarcoma in the uterus, 10658 is a 
bone tumor, and the other tumors are mammary.  Note that 16168 and 12352 
mammary tumors did not have significant detectable deletion by Nimblegen aCGH 
software, but deletion was determined by qPCR (Table A2-11 and Table A2-12).  (B) 
Top: Shown are aCGH results of 2 primary Chaos3 mammary tumors and 1 Chaos3 
mammary tumor cell line.  Dots substantially above the log2 ratio line correspond to 
loci amplified in the tumor, and dots below are underrepresented.  Arrows mark loci 
commonly amplified in Chaos3 tumors regardless of tumor type, and asterisks mark 
commonly deleted loci segregating specifically with mammary tumors.  Bottom: 
Expanded view of Chr 11 deletion.  Red bars indicate aCGH or qPCR confirmed 
deletion in all 9 Chaos3 mammary tumors overlapping the Nf1 tumor suppressor gene.  
Note MMTV-neu mammary tumors and Chaos3 non-mammary tumors do not 
demonstrate Nf1 deletion. (C) qRT-PCR analysis of Nf1 mRNA levels across the 
transcript in Chaos3 tumors. Percent expression is relative to an MMTV-PyVT tumor 
as control, which does not have loss of Nf1. Error bars show Standard Error of the 
Mean (SEM). Mammary tumor 15259 is classified as being heterozygously deleted for 
Nf1, and the other mammary tumors are homozygously deleted. Residual signal may 
reflect biopsy contamination or tumor heterogeneity.  
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Figure 2-6: Nf1 deletion leads to increased activated RAS and sensitivity to PI3K 
and MAPK inhibitors. (A) Western Blot analysis of Chaos3 tumors for NF1 and 
active RAS levels. Mammary tumors without detectable NF1 have homozygous 
deletions of Nf1, whereas the bone tumor and mammary tumor 22418 have both 
genomic copies of Nf1 (Table A2-12). The presence of NF1 protein is inversely 
proportional with the level of activated (GTP-bound) RAS. (B) NF1 loss leads to 
increased cell proliferation and transcription of anti-apoptosis genes. Inhibitors used in 
this study to slow proliferation of NF1-deficient tumor cells are shown in red type. Not 
all downstream targets are shown. RTK = receptor tyrosine kinase. (C) Cell 
proliferation assays showing sensitivity of Chaos3 tumors to Rapamycin and MEK1 
Inhibitor PD98059. Line colors: Red=HeLa, Brown=MCF-7 and MDA-MB231, 
Blue=PyVT, and Black=Chaos3. BT= bone tumor; MT= mammary tumor; MTCL= 
mammary tumor cell line. Zero concentration is DMSO solvent only.
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Best known for causing neurofibromas in the autosomal dominant genetic 
disorder Neurofibromatosis type 1, women with inherited NF1 deficiency also have an 
increased risk of, or association with, breast cancer 17,18. Though there are few reports 
implicating spontaneous Nf1 loss in breast tumorigenesis 19,20, upon screening TCGA 
breast cancer datasets we found that 27.7% of human breast tumors have NF1 
deletions or mutations, most being hemizygous (Figure 2-4C; Table A2-16). 
Furthermore, >40% of Basal and HER2-enriched tumor subtypes have NF1 loss or 
mutations (Figure 2-4C, Table A2-16). Genomic NF1 deficiency in human breast 
tumors significantly correlated with decreased expression levels (p=3.32 * 10-13) 
(Figure 2-4D).  Canonically, tumor suppressors are thought to require loss of both 
copies to have functional impact. However, there is accumulating evidence that 
haploinsufficiency or reduced expression of tumor suppressor genes can have a 
carcinogenic impact 21. Together these data indicate that NF1 loss in conjunction with 
other CNAs is important for initiation and maintenance of mammary tumorigenesis in 
Chaos3 mice and a substantial subset of human patients. 
Cancer genome resequencing studies are finding evidence that NF1 is mutated 
at significant rates in multiple cancers. NF1 is the third most prevalently mutated or 
deleted gene in Glioblastoma multiforme (GBM) 22, one of the most significantly 
mutated genes in lung adenocarcinoma 23, and the 4th most (intragenically) mutated 
gene in ovarian carcinoma 24. We examined NF1 status in TCGA datasets available 
from 20 types of cancer.  While most cancer types rarely contained NF1losses (<5% 
of cases), five cancer types showed >10% of cases with deletions (Table 2-2), 
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including an astounding 85.8% of serous ovarian cancers which also correlated with 
decreased NF1 mRNA expression (p=4.22 * 10-8) and patient survival (p=0.05) (Table 
2-2, Figure 2-7).  Only the 8% of cases with NF1 homozygous deletion was 
emphasized in the TCGA serous ovarian publication 24.   
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Figure 2-7: NF1 alteration in human ovarian cancer. (A) Boxplot of NF1 
mRNA expression vs. copy number in human ovarian cancer.  Data are from TCGA.  
Mutations are denoted with special symbols. 86% of 316 human ovarian cancer cases 
demonstrate NF1 deletion (Table 2-2). P value is for ANOVA between Hetloss and 
Diploid groups, indicating expression levels significantly correlate with genomic 
deletion status. (B) Overall survival plot of NF1 altered vs. unaltered human ovarian 
cancer cases.  Patients with NF1 alteration have longer overall survival.  Key: 
Horizontal gray bars are the means of each group.  Blue X’s represent individual 
tumor or normal samples.  Homdel = homozygous deletion, Hetloss = heterozygous 
deletion, Amp = high level amplification. Graphs were generated using the cBio 
Cancer Genomics Portal (www.cbioportal.org/public-portal/). 
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Table 2-2: NF1 Copy Number Alteration in Human Cancers 
      
Studies with Mutation Data Data Status Homozygous and 
Heterozygous 
Deletion 
Colon and Rectum Adenocarcinoma  (TCGA, Provisional) 8.80% 
Glioblastoma  (TCGA) 9.80% 
Prostate Cancer  (MSKCC) 2.40% 
Sarcoma  (MSKCC/Broad) 21.50% 
Serous Ovarian Cancer  (TCGA) 85.80% 
      
Studies without Mutation Data     
Bladder Urothelial Carcinoma  (TCGA, Provisional) 2.60% 
Brain Lower Grade Glioma  (TCGA, Provisional) 1.20% 
Breast Invasive Carcinoma  (TCGA, Provisional) 23.10% 
Cervical Squamous Cell Carcinoma  (TCGA, Provisional) 2.80% 
Head and Neck Squamous Cell Carcinoma  (TCGA, Provisional) 4.20% 
Kidney Renal Clear Cell Carcinoma  (TCGA, Provisional) 4.10% 
Kidney Renal Papillary Cell Carcinoma  (TCGA, Provisional) 0% 
Liver Hepatocellular Carcinoma  (TCGA, Provisional) 5.70% 
Lung Adenocarcinoma  (TCGA, Provisional) 3.20% 
Lung Squamous Cell Carcinoma  (TCGA, Provisional) 14.60% 
Pancreatic Adenocarcinoma  (TCGA, Provisional) 0% 
Prostate Adenocarcinoma  (TCGA, Provisional) 4.90% 
Stomach Adenocarcinoma  (TCGA, Provisional) 2.90% 
Thyroid Carcinoma  (TCGA, Provisional) 0% 
Uterine Corpus Endometrioid Carcinoma  (TCGA, Provisional) 11.80% 
Legend: Copy numbers calls are made by GISTIC.  Cancers having >10% of cases 
with NF1 CNA are underlined.  
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NF1 is a negative regulator of the RAS signaling pathway that stimulates the 
GTPase activity of RAS, pushing it to the inactive state. NF1 is important for 
negatively regulating the pro-growth factor mTOR, which is stimulated by RAS 
(Figure 2-6B). Tumor cells of patients with Acute Myelogenous Leukemia (AML) 
having NF1 deficiency demonstrate an elevated level of activated RAS and sensitivity 
to the mTOR inhibitor Rapamycin 25. To assess the functional impact of Nf1 deletion, 
we examined the level of activated RAS and found it to be dramatically higher in 
Chaos3 mammary tumor cells deleted for Nf1 (Figure 2-6A). We hypothesized that if 
the elevation of RAS signaling in Nf1-deleted mammary tumor cells is important for 
their maintenance, then inhibition of downstream pathways would compromise the 
growth of these cells. Chaos3 mammary tumor cell lines were markedly sensitive to 
MAPK/MEK1 and/or mTOR inhibitors, PD98059 and Rapamycin respectively 
(Figure 2-6C). Identification of NF1 as a tumor driver in a subset of breast cancers, 
and possibly other cancer types such as ovarian cancer, can provide guidance for 
patient treatment. Firstly, suppression of the RAS pathway would be an appropriate 
target. Secondly, there is reason to believe that tamoxifen, the estrogen receptor (ER) 
inhibitor that is standard treatment for ER+ breast cancers, may not be appropriate for 
women whose cancers involve NF1 mutations. NF1 depletion was reported to confer 
resistance of human breast cancer (MCF7) cells to tamoxifen, and tamoxifen-treated 
patients whose tumors had lower NF1 expression levels had poorer clinical outcomes 
26
.  Based on global cancer statistics 27,28 and the frequency of NF1 mutation and 
deletion (Figure 2-4C), we project that ~383,330 women (~63,450 in the United 
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States) will develop breast cancer with NF1 deficiency annually, underscoring the 
need for NF1 testing in the clinic. 
The mechanism responsible for generating recurrent CNAs in Chaos3 mice is 
likely related to the destabilized MCM2-7 replicative helicase 29, which may be 
predisposed to stalling at particular genomic regions that are difficult to replicate. 
Frequent deletion of NF1 may be due to a combination of factors including fragile 
sites (Figure 2-8), a complex chromatin structure, and/or its large genomic size. 
Indeed, replication fork stalling near Nf1 has been noted at a 5 kb isochore transition 
zone conserved between human and mouse, separating early and late replicating 
chromatin 30. Furthermore, collisions between replication and transcription complexes 
cause instability at fragile sites in the longest human genes 31. Loss or decrease of NF1 
may trigger more than RAS pathway activation, as NF1 has been shown to bind to 
Focal Adhesion Kinase (FAK) and has multiple isoforms of unknown functions 32. 
Additionally, siRNA-mediated NF1 knockdown in epithelial-like breast cancer cells 
induced the expression of epithelial-to-mesenchymal transition-related transcription 
factors 33. In addition to Nf1 deletion, Ube4b and Kif1b were also frequently deleted in 
Chaos3 and MMTV-neu mammary tumors, as in human breast tumors (26%) (Table 
2-1, Figure 2-9). Genes in these regions (Table 2-1; Table A2-10) are excellent 
candidates to validate susceptibility genes underlying spontaneous or heritable forms 
of breast cancer. 
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Figure 2-8: Genomic sequence around Nf1 is prone to CNA and contains a genomic 
rearrangement.  Colored vertical bars represent the deleted region in 7 Chaos3 mammary 
tumors as detected by aCGH, and the percentages reflect how many of these tumors contain 
CNA for a given mouse gene.  Gene names in red denote the Chaos3 critical region.  Mouse 
and human genomic orientations of the Nf1 region are depicted.  TRUE/FALSE indicates 
TCGA Level 4 (unpublished limited dataset) analysis of a subset of invasive breast 
carcinomas for segmental CNAs; it is possible that the intervals between NOS2 and NF1 are 
actually part of more inclusive deletion events.  Numbers in bold with small arrows indicate 
positions of interest:  1. Proximal to Nf1, a breakpoint of chromosomal inversion between 
human and mouse occurred between and including Wsb1 to Aldoc.  This is a site of both 
human and mouse tumor CNA, and the human CNA begins with NF1.  2. The mouse critical 
CNA begins at Ksr1, which has flipped orientation in humans and starts/forms a second 
smaller CNA, with the caveats mentioned above.  3. The mouse genome has gene insertion 
between Nlk and Nos2, where human CNA ends.   
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Figure 2-9: Ube4b and Kif1b, deleted in over half of Chaos3 mammary tumors, show 
frequent deletion in human breast tumors.  (A) Recurrent Chr 4 deletions specific to 
mammary tumors (MT). Horizontal bars represent tumors examined by aCGH. Red portions 
of bars indicate deleted regions in Chaos3 and MMTV-neu mammary tumors.  Cancer-related 
genes are in red.  Note that Chaos3 non-mammary tumors do not demonstrate this deletion.  
(B) Oncoprints of Ube4b and Kif1b alterations in 320 human breast tumors (unpublished 
TCGA).  Rows contain bars representing individual tumors, and samples are aligned for 
visualization of alterations within the same tumor across multiple genes.  Hmx1 does not have 
a known role in cancer and was used as a control gene for qPCR.  (C) Percentage of Ube4b 
and Kif1b CNA in 55 Her2-Enriched, 125 Luminal B, and 93 Basal human breast tumors 
(unpublished TCGA).  Note that ~40% of HER2-Enriched and Luminal B tumors have 
hemizygous deletion of Ube4b and Kif1b, and 27% of Basal breast tumors.  
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2.3 Methods and Notes 
Animals—Chaos3 mammary tumors originated in mice congenic in 
C3HeB/FeJ except 16898. 16898 arose in a mixed C57BL/6J and C3HeB/FeJ 
background 7,11. MMTV-neu and PyVT mammary tumors arose in FVB.  
Microarray Expression Profiling—RNA was hybridized to custom murine 
Agilent microarrays and normalized as described 4,34. Data were deposited into GEO 
(Accession # GSE36240). Chaos3 tumors were clustered in relation to other GEMMs 
using an unsupervised analysis, and differentiation score was calculated as described 
4,35
. SAM results were used to define a Chaos3 gene signature (upregulated, FDR 0%) 
and compared to the UNC337 human tumor dataset 35.  
Partial Exome Resequencing—A custom mouse 5Mb Sequence Capture 
array (NimbleGen) was used to enrich DNA corresponding to ~1200 breast cancer 
candidate gene exons (Table A2-4), followed by Illumina GAIIx sequencing. 
Candidate genes were selected and ranked based on breast cancer specificity and 
frequency in primary literature, existing cancer arrays, and cancer databases; see Table 
A2-2 through Table A2-4.  
Capture Array Handling—Genomic DNA libraries of ~200 bp fragment size 
were constructed for four Chaos3 mammary tumors and one inbred C3H WT spleen 
following the standard protocol of Illumina (San Diego, CA). One microgram of 
tumor and control library DNA was hybridized to the 385K or 720K capture array 
using an X1 mixer on the NimbleGen Hybridization System (Roche-NimbleGen) at 
42°C for 3 days. Arrays were washed; then the captured molecules were eluted from 
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the slides using a NimbleGen Elution Station.  Eluted molecules were vacuum-dried 
and amplified by LM-PCR.   Real-time PCR of eight control amplicons was 
performed in the pre-capture library and post-capture library to estimate the target fold 
enrichment, which varied from 30-744x (Table A2-5).  
Computational Analysis—The read data from each sample were aligned to the 
mouse C57BL/6, NCBI Build 37 (mm9) reference sequence using Novoalign 
(http://novocraft.com, v 2.05, academic version).  Default alignment settings were 
used, but non-uniquely mapped reads or reads failing on alignment quality were 
discarded (-r NONE -Q 9). The percentage of on-target reads for mutant samples 
ranged from 34.5% to 62.9%, reflecting a 230 fold average enrichment for the target 
breast cancer candidate genes (Table A2-5 and Table A2-6).  Genome Analysis 
Toolkit (GATK) version 1.04413 was used sequentially for base quality recalibration, 
depth of coverage estimation (Table A2-6 and Table A2-7), variant calling, and 
variant evaluation 36.  Substitution variants discovery and genotyping were performed 
with the GATK Unified Genotyper across all samples simultaneously.  Single sample 
SNP calling was used to complement joint-sample SNP calling.  The raw SNP calls 
were filtered per GATK recommendations with standard hard filtering parameters or 
variant quality score recalibration 36.  Criterion required SNP loci to have ≥5x 
coverage, variant frequency in ≥25% of reads, missing bases < 30%, no significant 
strand bias, and not overlapping indels.  Indels were called with GATK 
IndelGenotyperV2 under both single sample and paired sample modes using C3H as 
the “normal” tissue to identify novel indels against C3H.  No novel indels were 
identified in targeted coding regions.  Known SNPs between C3H and C57/B6 were 
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mined from the Mouse Genome Database 
(http://www.informatics.jax.org/mgihome/projects/overview.shtml#snp), dbSNP 37, 
and Sanger Mouse Genome Project 38 
(http://www.sanger.ac.uk/resources/mouse/genomes/).  There were 3097 known C3H 
SNPs in seqcap target regions from traditional Sanger sequencing.  GATK joint 
estimation from in-house data identified 2990 filtered SNPs, representing a 96.6% 
sensitivity.  Known C3H SNPs were filtered out, and novel SNPs were identified for 
annotation and validation.  Variation consequence was annotated with Ensembl 
Variation API (http://www.ensembl.org/info/docs/api/variation/index.html) and 
custom perl scripts.   BAM, BED and VCF files were generated to visualize 
alignments and variations using the Integrative Genomics Viewer (IGV) software 39.  
Variants were manually examined in IGV before proceeding to Sanger sequence 
validation. 
Validation—Sequence reads of putative mutations were manually viewed 
using Integrative Genomics Viewer (IGV, Broad Institute).  Variant positions were 
amplified in corresponding tumor samples and inbred C3H control genomic DNA.  
Following Fast AP and Exo1 (Fermentas) treatment, PCR products were Sanger 
sequenced and analyzed using SeqMan.  GeneCard, Ingenuity Pathway Tool, Biocarta, 
and KEGG databases were used to annotate genes. 
aCGH data analysis, and data sources—Genomic DNA from tumor and 
reference samples were hybridized to Nimblegen 3x720K mouse CGH arrays. Two 
reference samples were used independently. CNAs were visualized using Nimblegen, 
IGV, and KCsmart software 40. Select genes were validated via qPCR (Table A2-11 
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and Table A2-12). Critical regions within each Chaos3 CNA were identified as the 
region with the greatest overlap across multiple Chaos3 tumors and compared to 
human datasets (Table A2-13 and Table A2-14).  
Five micrograms of genomic DNA from tumor and reference samples were 
labeled and hybridized to 3x720K mouse Nimblegen CGH whole genome tiling 
arrays.  The arrays consist of 50-75mer probes and a median spacing of 3.5kb, with a 
subset of probes concentrated on exons.  Two reference samples were used 
independently to ensure recurring CNAs were not artifacts caused by the reference 
sample.  The first reference sample was collected from a C3H WT inbred mouse, and 
run with samples 2044b, 12351, and 12353.  The second reference sample selected 
originated from a C3H congenic Chaos3+/+ mouse and run as the reference for the 
remaining samples.  DNA labeling, hybridization, and post-hybridization processing 
was performed according to the manufacturer’s protocol.  Nimblegen software was 
used to normalize test/reference ratios and perform background correction.  Copy 
number changes were identified and segmented with Nimblegen CGH-segMNT 
algorithm using unaveraged and 10x averaging windows. The significance threshold 
was set at +/- 0.15 Log2 ratio and required a minimum of two consecutive probes to 
exhibit change in order to call a segment.  Amplifications and deletions were 
visualized using Nimblegen software and confirmed by manually examining Log2 
ratios for regions of interest.  In addition to using Nimblegen software, the normalized 
log2 ratio data were also analyzed using KC-smart software 40, to identify significantly 
recurrent CNAs.  The kernel width was 1 Mb, and the resolution of the sample point 
matrix was 5 Kb.  Simple Bonferroni multiple testing correction p<=0.025 was used as 
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threshold for declaring significant regions.  Select genes within CNAs were validated 
via qPCR.  See Table A2-17 for the primer list.  Critical regions within each Chaos3 
CNA were identified as the region with the greatest overlap across multiple Chaos3 
tumors (Table A2-13 and Table A2-14).  Of Chaos3 tumors with CNAs in recurring 
regions, the percentage of those containing the critical region is as follows: Chr4 
132M= 86%; Chr4 148M= 71%; Chr5 = 86%; Chr11 = 86% (100% for Nf1, Ksr1, 
Wsb1). 
Human breast cancer data and CNA calls for comparison with Chaos3 CNAs 
(Figure 2-4B; Table A2-13 and Table A2-14) were taken from the publicly available 
unpublished TCGA portal (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp) 2010 
update. The regions considered to have undergone segmental deletions by the 
unpublished TCGA analysis (“Level 4” dataset) are those indicated in Figure 2-4B, 
Table A2-13, and Table A2-14.  The MSKCC cBio portal provides a breakdown by 
mammary tumor subtype for individual genes (http://www.cbioportal.org/public-
portal/index.do). Recurrent segmental CNA data in human breast cancers were pulled 
from limited level 4 unpublished dataset from TCGA).  The Chr 11 deletions are 
single events in mice, and it is possible that the interval between NOS2 and NF1 may 
also be deleted as single events in human breast cancers, since the intervening genes 
are present in the hemizygous state in a high percentage of tumors according to 
extended TCGA datasets. According to the extended data available as of March 2012 
through the MSKCC cBioPortal, the genes between NOS2 and NF1 interval (which 
were not classified as significantly segmentally deleted in the limited Level 4 dataset 
mentioned above),  are hemizygously deleted at rates similar to Nf1 itself.  
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Active RAS Pull-down and Western Blotting—Levels of activated RAS 
were obtained using an active RAS pull-down kit (Thermo Scientific). Rabbit anti-
NF1 (Novus Biologicals) was used at 2ug/ml for Western analyses. 
Cell Culture, Karyotyping, and Drug Treatment—Primary Chaos3 tumor 
biopsies were homogenized, cultured, treated with colcemid, and metaphase spreads 
were made 2. Imaged chromosomes were counted using ImageJ. Tumor cell lines were 
treated with the MEK1 Inhibitor PD98059 or MTOR inhibitor Rapamycin 41,42. Cell 
Proliferation was assessed via MTT assay (Sigma) and values read on a 96-well 
ELISA plate reader. 
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One Sentence Summary: Tln1 and other cancer susceptibility and resistance loci are 
identified using cancer-prone Chaos3 mice in controlled environmental and genetic 
backgrounds.  
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3.1 Abstract 
An estimated ~25% of breast cancer cases have a familial inherited basis, but 
the majority of susceptibility genes underlying these heritable cases remain unknown. 
Identification of genomic variants contributing to cancer susceptibility is complicated 
by both the breadth of genetic diversity between individuals and populations as well as 
differing environmental factors.  These issues can be overcome using cancer mouse 
models with defined genetic backgrounds in a controlled environment.  Here we 
utilize C3H x C57BL/6 F2 Chaos3 mice, which bear a point mutation in the Mcm4 
DNA replication gene that leads the animals to spontaneously develop tumors, in order 
to identify susceptibility and resistance loci of mammary tumorigenesis and other 
cancer types.  Conducting a quantitative trait loci (QTL) analysis, we find mammary 
tumor susceptibility and resistance loci which contain genes involved in cell 
proliferation (Fgfr3), DNA repair (Msh4, Fancg, Fancc, Rad51ap1), cell signaling 
(Fbxw7, Sfrp1, Ptc1, Tln1, Pax5), and cancer associated genes (Rab2a, Rab28, Styk1, 
Mycbp2).  A Chr 4 mammary tumor susceptibility locus contains Tln1, a gene 
involved in integrin activation, in which a germline point mutation was discovered in 
the Chaos3-C3H stock line.  C3H congenic Chaos3 mice of both mutant and wild-type 
Tln1 status were aged, and a significantly higher proportion of Chaos3 Tln1 mutants 
developed mammary tumors compared to mice with the Chaos3 mutation alone, 
validating Tln1 impact on mammary tumor susceptibility.     
.  
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Introduction 
 
Twin and family studies indicate that ~25% of breast cancer cases have a 
familial genetic basis 1.  However, mutations in the most penetrant known 
susceptibility genes, BRCA1 and BRCA2, account for only ~5% of breast cancer cases 
in the general population 2-4.  The majority of susceptibility genes underlying heritable 
breast cancer remain unknown.     
To identify additional susceptibility genes, large-scale cancer genome 
resequencing projects have been conducted 5-9.  The emergent picture is that many 
mutations, most of which occur de novo and not inherited, collectively contribute to a 
given neoplasm 5.  Overall, it appears that the majority of genetically-based breast 
cancers are caused by low-penetrance modifier alleles 10, and also a large number of 
relatively rare breast cancer predisposition (driver) alleles.  This complicates attempts 
at genetic mapping by GWAS in humans, and also confounds the goals of cancer 
genome resequencing efforts. 
Whereas the heterogeneity of human populations and the diversity in breast 
cancer etiology complicates genetic analysis, inbred mouse strains are a powerful tool 
for studying cancer genetics because the genetic backgrounds are precisely defined.  
Within a given cancer mouse model, the tumors that arise have a consistent underlying 
basis.  These models can be used to identify genetic loci that modify cancer risk.  Mice 
bearing a mutation in the Apc gene (Min) have been used to discover a modifier of 
Min (Mom1 or Pla2g2a) that affects tumor multiplicity and size of intestinal tumors 11.  
Other studies have mapped genetic modifiers affecting mammary tumor frequency, 
multiplicity and latency in Trp53 mutant animals 12-14.   
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However, the majority of mouse models have drawbacks for breast cancer 
research.  Currently, the most widely used mouse models of mammary cancer are 
transgenics in which the Mouse Mammary Tumor Virus (MMTV) is driving 
overexpression of an oncogene 15,16. This is artificial and may not be relevant to the 
human situation.  Additionally, despite the powerful genetics in mice, there has been 
little success in cloning modifier loci or identifying new mammary cancer drivers on a 
large scale.  To identify cancer modifier loci, we have utilized the Chaos3 mouse 
model, which is not genetically engineered or treated with carcinogens, in order to 
overcome the disadvantages of traditional mouse models.   
We isolated the Chaos3 breast cancer mouse model in a genetic mutagenesis 
screen for mutations causing genomic instability (GIN) 17.  Chaos3 is an allele of 
Mcm4, and the protein is a subunit of the highly conserved MCM2-7 DNA replicative 
helicase, essential for DNA replication and involved in preventing cells from over-
replicating DNA.  Most remarkably, nearly all Chaos3 homozygous nulliparous 
females in the C3H strain inbred background succumbed to mammary 
adenocarcinomas with a mean latency of 12 months.  However, while the mice were 
being bred to be congenic in C3H, some Chaos3 mice of mixed background between 
C3H and C57BL/6J ("B6") developed lymphomas 18.  This suggested that Chaos3 
predisposes to cancer, but other loci in the genome determine tumor type 
susceptibility.  These other loci could either be mammary tumor predisposition genes 
(in C3H) and/or mammary tumor preventative genes (in B6).  As described below, 
tumor type is strongly influenced by genetic background, and we exploited this to 
identify breast cancer modifiers. 
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3.3 Results 
 
Genetic background strongly influences tumor type and latency  
 
To determine the impact of genetic background on Chaos3 tumorigenesis, an 
F2 cross between Chaos3 C3H vs. C57BL/6J strains, was conducted (Figure 3-1A).  
Animals from the two congenic populations were intercrossed to make F1s, then F1s 
were intercrossed to make F2s.  From these crosses, 19 F1 females and 219 F2 females 
were aged to a terminal endpoint of 16 months or until tumors developed.   
F1s had low mammary tumor incidence (23.8%), suggesting that either B6 has 
dominant suppressors, or that C3H has recessive susceptibility loci.  F2s developed a 
range of disease phenotypes, predominantly histiocytic sarcomas (50.5%), while 
mammary tumor incidence was 15.1% (Figure 3-1B-C, Table A3-1).  F2s had 
statistically significantly different time to onset of tumorigenesis associated with 
specific tumor types as well as compared to Chaos3-C3H mammary tumor latency.  
Chaos3 C3HxB6 have significantly increased time to mammary tumor onset (14.5 
months) over Chaos3-C3H mammary tumors (12.3 months) (Log-rank/Mantel-Cox 
Test, p=.002; Gehan-Breslow-Wilcoxon Test, p=.006) (Figure 3-1D).  Median tumor 
free survival for Chaos3 C3HxB6 mice developing other tumor types is also 
increased: Osteosarcomas (13.3 mo), Lymphoma (15.5 mo), Histiocytic Sarcoma 
(16.1 mo). 
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Figure 3-1: Altering background strain impacts tumor latency, tumor 
susceptibility, and eliminates mammary tumor specificity. (A) Chaos3 C3HxB6 
Mating Scheme. (B) Chaos3 C3HxB6 F2 non-mammary tumors.  (C) Tumor spectrum 
of Chaos3 C3HxB6 F2 animals.  HSTSC=histiocytic sarcoma, MT=mammary tumor, 
BT=bone tumor, LYMPH=lymphoma, HLTHY=healthy (no detectable cancer).  (D) 
Chaos3 tumor latency by cancer type.  Chaos3 C3HxB6 F2s have significantly 
increased time to mammary tumor onset  (14.5 mo median tumor free survival) 
compared to 12.3 month median Chaos3-C3H mammary tumorigenesis (Log-
rank/Mantel-Cox Test, p=.002; Gehan-Breslow-Wilcoxon Test, p=.006).  Median 
tumor free survival for Chaos3 C3HxB6 mice developing other tumor types is also 
increased: Osteosarcomas (13.3 mo), Lymphoma (15.5 mo), Histiocytic Sarcoma 
(16.1 mo).  
Chaos3 C3HxB6 Mating Scheme
Chaos3/Chaos3 
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Chaos3/Chaos3 C3HxB6 F1
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Identification of loci containing mammary tumor susceptibility and resistance 
genes   
 
The decreased proportion of mammary tumors in the F2s, compared to C3H, 
suggested a segregation of modifier alleles.  A QTL analysis was conducted to identify 
modifier loci that cause resistance or susceptibility to mammary tumors.  SNP Chips 
were used to genotype the mice at 377 SNPs (217 informative between C3H vs. 
C57BL/6J) genome-wide (Figure A3-1).  This represented an average spacing of about 
16 Mb, ideal for F2 QTL or modifier mapping crosses, which have relatively few 
recombination events.  The recombination fraction (RF) plot shows successful high 
quality genotyping and mapping (Figure A3-2A). 
Composite Interval Mapping (CIM), Multiple QTL Mapping (MQM), and 
SMA (single marker analysis) were used to analyze the data.  The significance of 
mammary adenocarcinoma association for each marker was calculated as a LOD 
score.  Figures 3-2A and A3-2B show the effects identified for makers at/near QTLs 
identified by cross-controlled single QTL analysis.  Animals homozygous for C3H 
alleles are consistently associated with increased mammary tumor susceptibility 
(Figure 3-2B).  Notably, studies of other mammary tumors models in which mice with 
Trp53 or ApcMin mutations are mammary tumor-susceptible on some backgrounds 
(FvB, BALB/c) but not on B6, have all identified recessive susceptibility loci 12-14.  A 
genome-wide two-dimensional QTL scan was performed on chromosomes with strong 
or suggestive QTLs found in at least 1 method used in the one-dimensional scan.  As 
shown in Figures 2C and A3-2C, there is evidence of QTL epistasis.  Remarkably, in 
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animals inheriting some single modifying alleles, mammary tumor incidence is 
doubled from 15.1% to 30% or reduced to <5% (Figure 3-3). 
QTL analysis revealed specific regions on several chromosomes associated 
with modifying mammary tumor susceptibility (Figure 3-2A).  Candidate genes in 
these regions are involved in cell proliferation (Fgfr3), DNA repair (Msh4, Fancg, 
Fancc, Rad51ap1), cell signaling (Fbxw7, Sfrp1, Ptc1, Tln1, Pax5), and are associated 
with cancer (Rab2a, Rab28, Styk1, Mycbp2) (Table 3-1 and Table A3-2).  Though 
SNP data for the substrain C3HeB/FeJ is not available, Fancc, Tln1, Styk1, and Cdkl2 
have known non-synonomous SNPs between strains C3H/HEJ and C57BL/6J (Table 
3-1).  Examination of these genes in the Catalogue Of Somatic Mutations In Cancer 
(COSMIC) database provided additional insight into candidates where amino acid 
change is associated with cancer.  
Osteosarcomas arose in 14% of the F2 animals, and QTL analysis for 
modifying alleles was conducted as it was for mammary tumors.  Table A3-3 shows 
associated loci.  Interestingly, two loci where B6 homozygosity was associated with 
increased bone tumor incidence, C3H homozygosity was associated with mammary 
tumor susceptibility (Figure 3-3B).   
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Figure 3-2: Mammary Tumor QTL analysis. (A) Comparison of 1-dimensional 
QTL scan, composite interval mapping, and multiple QTL mapping methods of QTL 
analysis.  Red dots indicate the consensus of the most significant genomic regions 
associating with mammary tumors. (B) Effect plot of top mammary tumor QTL 
chromosomes.  Additive effects are in blue; positive additive values indicate the 
increasing allele arises from the C3H background strain, and negative additive values 
indicate the increasing allele originates from C57/B6.  Note that the top mammary 
tumor QTLs arise as expected from the C3H background, indicating these regions are 
either C3H mammary tumor susceptibility loci or mark an absence of C57/B6 
mammary tumor resistance loci.  Dominance effects are in red; positive values 
indicate a dominant effect of the increasing allele, while negative values indicate a 
recessive effect of the increasing allele.  Note that the QTL on chromosome 14 
appears to have a dominant effect from C3H.  (C) Calculated Main and epistasis 
effects for QTLs using Bayes Factor analysis. 
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Table 3-1: Mammary Tumor QTL Candidate Genes (Condensed) 
Location (Mb) Size 
(Mb) 
Effect 
Type 
Gene Can Gene Description  
COSMIC 
Mut 
2.9 C3H 
RS 
Lamb3 Laminin beta 3 (cell attachment, migration, and 
organization)  
18 
    Hhat Hedgehog acyltransferase (SHH signaling) 13 
    Kcnh1 Potassium voltage-gated channel, subfamily H 
(Overexpression growth advantage to cancer cells) 
16 
    Irf6 Interferon regulatory factor 6 (Regulates 
mammary epithelial cell proliferation by similarity) 
7 
chr1:194.3-
197.2 
    Traf3ip3 TRAF3 interacting Jun N terminal kinase (JNK) 
activating modulator 
12 
chr3:79-87 8.4 C3H 
RS 
Fbxw7 F-box/WD repeat-containing protein 7 (Notch 
Signaling) 
289 
6.0 C3H 
RS 
Msh4 MutS protein homolog 4 (DNA damage repair) 2 chr3:148-154 
    Fubp1 Far upstream element-binding protein 1 (c-myc 
activation) 
3 
5.1 C3H 
RS 
Tln1 Talin 1 (Integrin Activation) (rs27831179) 29 
    Fancg Fanconi anemia group G protein homolog 3 
chr4:41.6-46.6 
    Pax5 Paired box protein Pax-5 (TF for B cell lineage) 135 
11.7 C3H 
RS 
Fgfr3 Fibroblast growth factor receptor 3 2398 
    Bodl biorientation of chromosomes in cell division 6 
chr5:33.6-45.4 
    Rab28 Ras-related protein Rab-28 (TGF-B signaling, Ras 
family) 
2 
14.6 C3H 
RS 
Rassf6 Ras association domain-containing protein  8 
    Cdkl2 Cyclin-dependent kinase-like 2 (rs31762832) 12 
    Epha5 Ephrin type-A receptor 5 (tyrosine kinase) 50 
chr5:79.1-93.7 
    G3bp2 Ras GTPase-activating protein-binding protein 2 8 
12.9 C3H 
RS 
Mcm7 DNA replication licensing factor 5 
    Rasa4 Ras GTPase-activating protein 4 0 
chr5:127-140 
    Cldn15 Claudin 15 3 
11.4 B6 RR Styk1 Tyrosine protein-kinase STYK1 (apoptosis, 
angiogenesis) (rs30473070) 
6 chr6:120.5-
131.9 
    Rad51ap1 RAD51-associated protein 1 0 
chr7:37.6-47.7 10.1 B6 RR Ccne1 G1/S-specific cyclin-E1 1 
10.0* C3H 
RS 
Map2k6 Dual specificity mitogen-activated protein kinase 
kinase 6 
9 
    Socs3 Suppressor of cytokine signaling 3 (JAK-STAT, anti-
apoptosis) 
1 
    Aatk Serine/threonine-protein kinase LMTK1 10 
    Sumo2 Small ubiquitin-related modifier 2 1 
    Cbx4 E3 SUMO-protein ligase CBX4 3 
chr11:110-112 
    Sox9 Transcription factor SOX-9 8 
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     Srsf2 Serine/arginine-rich splicing factor 2 (pre-mRNA 
splicing, apoptosis) 
95 
10.0* Fancc Fanconi anemia, complementation group C 
(rs33850907) 
1 
  
C3H 
RS, B6 
RR Ptc1 Patched homolog 1 (SHH Receptor) 333 
chr13:60.3-
70.3 
    Hsd17b3 Testosterone 17-beta-dehydrogenase 3 
(Androgen, estrogene, progesterone biosynthesis-
>Estradiol 17beta-dehydrogenase) 
0 
19.6 C3H 
DS 
Pibf1 Progesterone immunomodulatory binding factor 1 7 
    Dach1 Dachshund 1 (Transcription factor, lost in some 
forms of metastatic cancer, correlated with poor 
prognosis) 
8 
chr14:87.2-
106.9 
    Mycbp2 MYC binding protein 2 (MYC regulation/activation) 37 
COSMIC = Catalogue Of Somatic Mutations In Cancer; Mut=Mutation.  Underlined genes have known non-
synonomous SNPs between C3H/HEJ and C57BL/6J with dbSNP in ( ).  *Single informative SNP in large region. 
RS=Recessive Susceptibility, RR=Recessive Resistance, DS=Dominant Susceptibility. 
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Figure 3-3: Effect of individual alleles of significance on tumor formation.  (A) 
Effect plots of mammary tumor susceptibility and resistance loci.  The y-axis is the 
percentage of the total number of animals that develop mammary tumors for an allelic 
genotype given on the x-axis.  AA represents allelic homozygosity from the C57/B6 
strain, AB represents heterozygosity between C3H and C57/B6, and BB represents 
homozygosity from C3H.  Given F2 mammary tumor incidence in 15.1% of cases, 
genotypes deviating from the rate of incidence indicate loci of mammary tumor 
susceptibility or resistance.  Note the markers for loci on chromosomes 1, 3, and 4 
where less than 10% of the of the animals of the AA and AB genotypes develop 
mammary tumors, but ~30% of the animals with C3H homozygosity develop 
mammary tumors.  The homozygous B6 genotype at SNP rs3720735 on Chr 7 and 
rs3712144 on Chr 13 are associated with mammary tumor resistance.  C3H 
homozygosity on the Chr 13 SNP is also associated with mammary tumor 
susceptibility.  (B) Effect plots comparing mammary tumor and bone tumor incidence 
at two loci.  F2 bone tumor incidence was 14%.  At two loci where C3H 
homozygosity was associated with mammary tumor susceptibility, B6 homozygosity 
confers bone tumor susceptibility.  MT=Mammary Tumor, BT=Bone Tumor. 
Chr3:80665680
Chr4:41604056 (Tln1)
Chr13:65287243
Chr7:37568559
B
A
Chr3:148028505-153987532 Chr6:131940471 
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Identification of Talin1 as a mammary tumor susceptibility gene 
 
Within a Chr 4 mammary susceptibility locus, we identified a nonsynonomous 
Talin 1 (Tln1) mutation at Chr4: 43550665 in the Chaos3–C3H stock mice.  Analysis 
of 18 mouse strains, using the MPD/Jax Lab SNP database, detected no known SNPs 
in the Tln1 gene at the Chr4: 43550665 locus.  Additional Sanger sequencing validated 
that inbred C3H, B6, and 129 mice were homozygous WT (Table A3-4).  The Tln1 
mutation was detected in both tumor and normal tissues, indicating the Tln1 mutation 
was present in the germline.  Testing both the Chaos3-C3H and Chaos3-B6 colonies 
revealed the Tln1 germline mutation arose in the Chaos3-C3H population (Figure 3-
4A, Table A3-4), likely late and spontaneously in crossing Chaos3 into C3H to make 
the Chaos3 mutation congenic in the strain.  As few animals are used to generate the 
next generation, the Tln1 mutation swept through the colony in the resulting progeny.   
This Tln1 mutation, occurring at a residue conserved in vertebrates, causes an 
E1910K glutamine to lysine, polar acidic to polar basic amino acid change.  Tln1 is 
responsible for linking vinculin to integrin.  This bound complex creates mechanical 
force, triggering conformational changes, coupling integrin to cytoskeletal actin.  It is 
the last common element of cellular signaling cascades that control integrin activation 
19
.   
Tln1 mutation bore a significant impact on tumor type.  Given C3HxB6 
Chaos3/Chaos3 Tln1/+ F1 parents, the expected Tln1 genotype ratios in the F2 
generation are 1:2:1 under a null hypothesis (that the Tln1 mutation has no effect on 
tumor type).  However, the F2 cohort of animals that developed mammary tumors 
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demonstrated twice the genotype frequency for Tln1 mutant homozygosity (p=0.03) 
and increased mutant allele frequency (p=0.006) (Table A3-5).   
To determine the role of Tln1 as a mammary tumor modifier, Chaos3-C3H 
mice with homozygous mutant, heterozygous, and wild-type Tln1 status were aged.  
While tumor latency was not significantly impacted, Tln1 status significantly altered 
Chaos3 mammary tumor incidence, where 92% of homozygous mutants developed 
mammary tumors compared to 72% of heterozygous animals (p=0.002) and 55% Tln1 
wild-type animals (p=5.5 x 10-5) that developed mammary tumors.  (Figure 3-4B-C).  
However, wild-type Tln1 alleles did not convey a resistance to all cancer types, as the 
animals developed a different type of cancer instead of mammary (Figure 3-4C).  
These results validate QTL findings and show that Tln1 is a mammary tumor modifier.  
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Figure 3-4: Tln1 mutation increases mammary tumor susceptibility. (A) Tln1 
trace files showing germline Tln1 mutation in the Chaos3-C3H colony.  Refer to 
Tables A3-4 and A3-5.  (B) Tumor-free survival of Chaos3 x Tln1 animals.  The 
survival curves do not significantly differ (Log-rank/Mantel-Cox Test, p=0.14).  (C) 
Chaos3 x Tln1 C3H-N10 tumor spectrum.  All animals are congenic in C3H.  The ‘A’ 
allele is mutant; the ‘G’ allele is Wild-type; Mut=Homozygous Mutant, 
Het=Heterozygous, WT=Wild-type.  MT=Mammary Tumor; ACT =Additional 
Cancer Type; NMT=Non-Mammary Tumor.  Note that Tln1 status has significant 
impact on mammary tumor susceptibility (Chi Square values compared to Tln1 
homozygous mutant mammary tumor incidence: Tln1 HET p=0.002; Tln1 WT p=5.5 
x 10-5).   
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3.4 Discussion 
 
Tln1, validated here as a modifier of mammary tumorigenesis, has previously 
been shown to promote cancer progression and metastasis 20,21.  Tln1 overexpression 
results in pro-survival, resistance to anoikis, and progression to metastasis, and TLN1 
has been suggested as a biomarker for tumor progression 20.  TLN1 expression 
significantly increased in prostate cancer and has also been identified as a candidate 
driver in human breast cancer with low passenger mutation probability, as calculated 
by Wood et al. 6,20.  The COSMIC database shows TLN1 mutation in 29 of 616 
tumors, with 5 being in breast tumors and 3 in ovarian tumors (Figure A3-3).  Our 
newly discovered Tln1 mutation at the 1910 amino acid position falls within a cryptic 
vinculin binding domain 22.  This suggests a mutation at this residue may alter how 
Tln1 interacts with vinculin and thus affect integrin activation and downstream 
signaling processes such as cell growth, adhesion, migration, division, survival, 
differentiation, and apoptosis.  The rs27831179 SNP also causes a change in the TLN1 
coding sequence between the C3H/HEJ and C57BL/6J strains.  In the dbSNP 
database, there are 11 nonsynonomous SNPs and 2 SNPs in the UTRs of TLN1 
present in >1% of the human population, which would be interesting to examine for 
association with reproductive cancers (Table A3-6).  
Candidate genes in other loci identified in this study are frequently mutated in 
cancer, such as FGFR3 particularly in urothelial carcinoma 23.  Fancg and fancc are 
Fanconi anemia (FA) genes, which are involved in the homologous recombination 
(HR) pathway for DNA repair.  The HR pathway is altered in 51% of all ovarian 
cancer cases 24, and this pathway also includes BRCA1 and BRCA2, the most 
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penetrant genes known in heritable forms of breast cancer.  Lastly, 5 RAS-related 
genes appeared in 4 of the 13 QTL regions.  The RAS pathway is misregulated in 
many cancer types, including recent studies implicating it in breast cancer 25-27.  
Together our findings identify loci and implicate candidate genes that modify 
susceptibility and resistance to mammary adenocarcinomas. 
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3.5 Methods and Notes 
 
Chaos3 C3HeB/FeJ N10 animals were crossed to Chaos3 C57BL/6J N10 
animals to generate C3HxB6 F1s, which were intercrossed to generate the F2 
generation.  ~200 F2s were aged to a terminal endpoint of 16 months or until animals 
showed signs of disease.  Tumor samples were collected, fixed in 10% formalin, 
embedded in paraffin, and examined histologically to classify tumor type. 
Genomic DNA was collected from 189 Chaos3 C3HxC57/B6 F2 females and 
hybridized to Goldengate Mouse LD Linkage BeadChips along with C3HxC57/B6 F1, 
C3H inbred, and C57/B6 inbred control DNA.  Informative SNPs between C3H and 
C57/B6 were filtered for analysis.  Allelic ratios were examined for accordance with 
expected 1:2:1 distribution and Hardy-Weinberg Equilibrium.   
Animal SNP data were categorically analyzed between mammary tumor and 
non-mammary tumor groups.  R/QTL version 1.19 28 and R/qtlbim 29 were used to 
statistically analyze the SNP data.  Composite Interval Mapping (CIM), Multiple QTL 
Mapping (MQM), and SMA (single marker analysis) methods were used to analyze 
the data.  
Genome-wide one-dimensional scan 
Pseudo-markers were generated at 2-cM spacing for each chromosome, and a 
whole genome scan. QTL with thresholds above LOD score 2 were treated as strong 
QTLs. Both full and additive models were analyzed.  Bayesian mapping in R/qtlbim 
was used 29, treated as binary traits, cross as the GxE used, and epistasis was included.  
Interval mapping in R/QTL was used. Full model includes QTL, covariates (Talin) 
and QTL*covariates interaction effects. The additive model includes only additive 
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QTL and covariates effects. Binary trait coding was used. MQM interval mapping in 
R/QTL was used. Co-factors selected from top QTLs identified with R/qtl additive 
models were used as starting set, and the default setting to trim down the set of 
cofactors.  Alternatively, Co-factors were selected automatically by picking 50 
markers and then backward eliminated.  Binary trait coding used.  Composite interval 
mapping in R/QTL was used. Traits were coded as numerical traits as CIM not 
support binary traits.  
Genome-wide two--dimensional scan 
Pair-wise scans were performed on all-markers. The likelihood from the full 
model (pseudo-marker pair and the interaction between them) and the null model (no 
genetic effect) was compared and LOD scores were calculated. In addition, LOD 
scores from comparing the likelihood from the full model and the additive model 
(with only the main effects of pseudo-markers and but no interaction) were also 
calculated.  qb.scantwo, implemented in R/qtlbim, scanned the Baysian models for 
epistasis.   
Multiple regression 
QTL and possible QTL*QTL interactions identified from a one and two-
dimensional scans were fit into multiple regression models. From the model, 
variations of the phenotype in the models were estimated. Probabilities (p-values) for 
the significance of terms in the multiple regression models were calculated.  
SMA  
A simple linear regression model for genotypic tests was used to provide a 
general test of association in disease-by-genotype tables.  
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One Sentence Summary: Perturbation of DNA damage response/repair pathways 
impacts carcinogenesis in a gender-specific manner in mice with defective DNA 
replication machinery. 
 70 
4.1 Abstract 
Many genes are misregulated or altered at low frequencies in human cancers, 
but together comprise significant alterations in key pathways, particularly DNA 
checkpoint and repair pathways.  Recent studies show that defective DNA replication 
machinery can result in genomic instability (GIN) and carcinogenesis.  To understand 
the roles of DNA damage repair (DDR) genes on carcinogenesis in mutants defective 
for core DNA replication machinery, we utilized the novel Mcm4Chaos3/Chaos3 
(“Chaos3” or “C3”) cancer mouse model.  MCM4 is a highly conserved subunit of the 
MCM2-7 DNA replicative helicase, required for DNA replication and DNA licensing 
mechanisms to prevent re-replication of the genome.  We generated double mutant 
lines between Chaos3 and Atm, p21, Chk2, Hus1, and Blm.  We find that Chaos3 
animals deficient in the Atm pathway have decreased tumor latency and/or increased 
tumor susceptibility.  Tumor latency and susceptibility differed between genders, with 
females demonstrating an overall greater cancer susceptibility to Atm and p21 
deficiency than males.  These findings indicate that deficiency in the ATM DDR 
pathway impacts tumor susceptibility and latency in MCM-deficient cancer-prone 
mice, and this impact is modified by gender.   
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4.2 Introduction 
 
Genomic studies have shown that many genes are misregulated or altered at 
low frequencies in human cancers, but together comprise significant alterations in key 
pathways 1-3.  Of particular interest is the role that DNA checkpoint and repair 
pathways play.  Breast and ovarian cancer type 1 susceptibility and 2 (BRCA1 and 
BRCA2) are known susceptibility genes in inherited forms of human breast and 
ovarian cancer 4-6.  These two genes are altered in 33% of serous ovarian cancer cases 
and contribute to an overall 51% of cases deficient in the Homologous Recombination 
(HR) pathway 2.  In HR, DNA damage sensors such as Ataxia Telangiectasia Mutated 
(ATM) detect DNA damage including double-strand breaks and trigger BRCA1, the 
Fanconi Anemia (FA) core complex, and subsequent downstream signaling for HR-
mediated repair 7.  ATM and Ataxia-Telangiectasia-and-Rad3-related (ATR) head 
additional DNA checkpoint and repair pathways, including signaling to Tumor Protein 
53 (TP53), the tumor suppressor most frequently compromised in human cancer 
(Figure 4-1) 8.  DNA damage response (DDR) pathways are responsible for helping 
maintain genomic stability and suppressing tumorigenesis.  DDR genes also target 
components of the core DNA replication complex, including the MCM helicase.  
MCM2 is a direct target of ATR, and MCM3 is a target of ATM 9,10.   
Accumulating evidence shows associations between defects in, or 
missregulation of, core replication machinery and cancer.  The highly conserved 
MCM2-7 DNA replicative helicase is an essential component of pre-replication (pre-
RC) complexes 11.  These complexes are “licensed” at replication origins for activation 
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in S phase, and regulatory mechanisms inhibit reloading of the MCMs during S phase 
to prevent re-replication of the genome 11.  MCM mutation and deficiency results in 
phenotypes of synthetic lethality, growth retardation, decreased cellular proliferation, 
GIN, and early onset of cancer in mice 12.  MCM2 deficiency leads to GIN and 
aggressive tumor susceptibility in mice, specifically lymphomas 12-15.  Elevated 
expression of CDT1, a protein that helps load MCMs onto the origins of replication, is 
associated with increased chromosomal instability and tumor growth in lung cancers 
when p53 is mutated 16. 
To understand the roles of DDR genes on cancer incidence and tumor-free 
survival in MCM deficient mice, we utilized the Mcm4Chaos3/Chaos3 (“Chaos3”) cancer 
mouse model.  The Mcm4Chaos3 mutation demonstrated that mutant alleles of essential 
replication proteins can cause GIN and cancer 17,18.  The Chaos3 cancer model was 
isolated in an N-ethyl-N-nitrosourea (ENU) mutagenesis screen for mutations causing 
genomic instability (GIN) 17.  The nonsynonomous mutation identified in Mcm4 
caused a dramatic (20 fold) increase in micronuclei, a hallmark of GIN 18.  In Chaos3 
mouse embryonic fibroblasts (MEFs), significant chromosome breakage (compared to 
wild-type controls) occurred only under conditions of replication stress, indicating that 
the damage was a consequence of a defect(s) in some aspect of DNA replication 17,18.  
Work in yeast carrying the Chaos3 mutation suggests that the stress can cause the 
replication fork to collapse, leading to double-strand breaks which then activates the 
HR (homologous recombination) pathway 19.  Evidence from other model systems 
support the conclusion that MCM dysfunction can cause DNA damage and 
rearrangements 20.  Chaos3 cells demonstrate increased levels of RAD51 and BLM 
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foci 21.  Additionally, upregulation of p53 and p21 are observed in Chaos3 MEFs 22.  
Chaos3 mice succumb to cancer at a mean latency of 12 months 17.  Chaos3 animals 
also deficient for p53 have decreased time to cancer onset 22.  This evidence indicates 
that defective DNA replication machinery sensitizes cells to replication stress, and 
DDR pathways are activated.  Therefore, models in which the DNA replication 
machinery is defective may be sensitive to DDR perturbation.  Here we generate 
double mutant lines between Chaos3 and an additional DDR gene to examine the 
impact of components in DDR pathways on carcinogenesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-1: DNA Damage Response Pathways.  Key genes in DDR pathways are 
shown with ATR and ATM DNA damage sensors emphasized in gray boxes.  Genes 
perturbed in this study to determine impact on carcinogenesis are indicated by red 
ovals.  
BASC 
(BRCA1 
Associated 
Genome 
Surveillance 
Complex)
Homologous 
Recombination
Replication 
Inhibitors
Bulky 
Lesions
DNA 
Breaks
ATR ATM
RAD17
CHK1
CHK2
p53
p21 BAX
BRCA1
Cell Cycle Arrest 
Apoptosis
DNA Repair Cell Cycle 
Arrest
Apoptosis
HUS1
RAD1
RAD9
BLM
M
S
H
2
M
S
H
6
NBS1
MRE11 RAD50
 74 
4.3 Results 
To determine the impact of DDR deficiency on carcinogenesis in Chaos3 
mice, we generated Chaos3 mice deficient for Atm, p21 (Cdkn1a), Chk2 (checkpoint 
kinase 2, Chek2), Hus1, or Blm.  Mice were aged for eighteen months or until animals 
showed clinical signs of disease.   
Atm deficiency impacts Chaos3 viability, cell proliferation, tumor latency, and 
tumor susceptibility 
ATM is a serine/threonine kinase that senses DNA double-strand breaks 
(DSBs) and triggers several key events, such as H2AX phosphorylation at the site of 
breaks and phosphorylation of downstream targets such as CHK2, to activate the DNA 
damage checkpoint leading to cell cycle arrest or apoptosis (Figure 4-1) 23.  ATM 
deficiency is associated with the development of lymphomas and leukemias in humans 
and mice, with Atm-/- mice developing malignant lymphomas at 2-4 months of age 
24,25
.  Generating the Chaos3 x Atm mice, the Chaos3/Chaos3 (C3/3) Atm-/- genotype 
resulted in semi-lethality with only 25 observed animals out of 65 expected in 648 
weanlings (Figure 4-2A).  Timed-matings indicated that embryonic lethality occurred 
between E13.5 and E18.5, with small and underdeveloped C3/3 Atm-/- embryos 
observed at E18.5 (Figure 4-2A).  This semi-lethality suggested that cells were 
accumulating unrepaired DNA damage beyond the point of viability.  Alternatively, a 
separate checkpoint pathway may have been activated and triggered cell death.  
To determine the impact of Atm deficiency on Chaos3 cell proliferation, cell 
proliferation assays were conducted on Chaos3 x Atm MEFs.  C3/3 Atm+/- cells grew 
significantly slower than C3/3, C3/+ Atm+/-, or C3/+ Atm+/+ cells (Figure 4-2 B).  
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When Chaos3 x Atm mice were aged, the strong lymphoma phenotype of Atm 
homozygous mutants obscured the effect on mammary tumorigenesis.  C3/3 Atm-/- 
mice have significantly decreased time to tumor onset compared to C3/3 alone, but 
they succumb to lymphoma at ~2-4 months of age, similar to Atm-/- mice (Figure 4-
2C, Table A4-1) 24.  However, the impact of Atm deficiency on mammary 
tumorigenesis was evident in C3/3 Atm+/- and C3/+ Atm+/- animals.  C3/3 Atm+/- 
females have a median tumor latency of  10.95 months and C3/+ Atm+/- females have 
a median tumor latency of 9.3 months, a significantly decreased latency compared to 
C3/3 alone (14.95 months) (Respectively: LRMCT p=0.001, p=0.0027; GBWT 
p=0.0031, p=0.0005). C3/3 Atm+/-  males neared statistical significance for decreased 
tumor latency (LRMCT p=0.0751; GBWT p=0.0729), and C3/+ Atm+/- male tumor 
latency was similar to C3/3 alone (LRMCT p=0.472; GBWTp=0.4339) (Figure 4-2C, 
Table A4-1).  The tumor spectrum of Chaos3 x Atm mice shifts away from histiocytic 
sarcomas (from 33% to ≤5% in females and from 52% to ≤6% in males) to an 
increased incidence of lymphoma and other cancer types.  The spectra also differ 
between genotype and gender, with C3/+ Atm+/- females being more susceptible to 
cancer than males.   
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Figure 4-2: Atm deficiency impacts Chaos3 viability, cell proliferation, tumor 
latency, and tumor susceptibility. (A) Top-Genotype distribution of 648 Chaos3 x 
Atm weanlings.  The C3/3 Atm-/- genotype causes semi-lethality (Chi square p=. 
6.03*10-6; Fisher’s Exact p=4.5*10-5).  Bottom- Littermate pups from embryonic 
day 18.5.  Note the poor development of the C3/3 Atm-/- embryo.  (B) Chaos3 x Atm 
MEF cell proliferation assay.  C3/3 Atm+/- cells grow significantly slower than C3/3, 
C3/+ Atm+/-, or C3/+ Atm+/+ cells.  (C) Chaos3 x Atm tumor latency.  C3/3 Atm-/- 
mice have significantly decreased time to tumor onset, similar to Atm-/-.  C3/3 Atm+/- 
and C3/+ Atm+/- females have significantly decreased tumor latency compared to 
C3/3 alone (Respectively: LRMCT p=0.001, p=0.0027; GBWT p=0.0031, p=0.0005). 
C3/3 Atm+/-  males neared statistical significance for decreased tumor latency 
(LRMCT p=0.0751; GBWT p=0.0729), and C3/+ Atm+/- male tumor latency was 
similar to C3/3 alone (LRMCT p=0.472; GBWTp=0.4339). LRMCT= Log-
rank/Mantel-Cox Test;  GBWT= Gehan-Breslow-Wilcoxon Test.  (D) Tumor 
spectrum of Chaos3 x Atm mice.  HSTSC=histiocytic sarcoma, MT=mammary tumor, 
BT=bone tumor, LYMPH=lymphoma, HLTHY=healthy (no detectable cancer), 
PCT=plasma cell tumor, RCT=round cell tumor, GCT=granulosa cell tumor, 
LIP=lipoma, LUT=luteoma, SKIN=skin tumor, LIVER=liver tumor, 
PUAD=pulmonary adenoma, MYLHPL=myeloid hyperplasia, ADGLNRM=adrenal 
ganglioneuroma, UTMR=unknown tumor type.  Note that tumor spectrum differs 
between genotype and gender, and that C3/+ Atm+/- females are more susceptible to 
cancer than males. 
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Chk2 deficiency impacts tumor latency in Chaos3 females and cancer 
susceptibility in males 
CHK2 is a phosphorylation target of ATM and serves as a downstream effector 
of the DSB checkpoint response 26.  When activated, the CHK2 can phosphorylate 
p53, protecting it from ubiquitination by MDM2 and subsequent degradation 26.  In 
addition to p53, CHK2 can also phosphorylate BRCA1, meaning that CHK2 
activation can lead to cell cycle arrest through p21 inhibition of cyclin-dependent 
kinases (CDKs), apoptosis through BAX, or homologous recombination through 
BRCA (Figure 4-1).  Unlike Atm null mice, Chk2 null mice do not spontaneously 
develop tumors 27.  Chaos3 x Chk2 mice were aged, and C3/3 Chk2-/- females were 
found to have decreased time to tumor onset compared to C3/3 alone (LRMCT 
p=0.0189, GBWT p=0.027) (Figure 4-3A, Figure A4-1, Table A4-1).  Interestingly, 
C3/+ Chk2+/- male mice are more susceptible to cancer than C3/+ alone (Figure 4-
3B).  
 
 79 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3: Chk2 deficiency impacts tumor latency in Chaos3 females and cancer 
susceptibility in males. (A) Chaos3 x Chk2 tumor latency.  C3/3 Chk2-/- female mice 
have significantly decreased time to tumor onset than C3/3 alone (“DDR C3/3 cohort” 
GBWT p=0.0581; “C3/3 C3HxB6 F2 cohort” LRMCT p=0.0189, GBWT p=0.027; 
see Methods and Figure A4-1. GBWT=Gehan-Breslow-Wilcoxon Test ; LRMCT= 
Log-rank Mantel-Cox Test. (B) Tumor spectrum of Chaos3 x Chk2 mice.  
HSTSC=histiocytic sarcoma, MT=mammary tumor, BT=bone tumor, 
LYMPH=lymphoma, NTMR=no tumor, SKIN=skin tumor, LIVER=liver tumor, 
PUAD=pulmonary adenocarcinoma, UAC=uterine adenocarcinoma, LUC=lung 
carcinoma, UTMR=unknown tumor type.  Note that C3/+ Chk2+/- male mice are 
more susceptible to cancer than C3/+ alone. 
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p21 deficiency impacts tumor latency in Chaos3 mice and tumor susceptibility in 
Chaos3 females 
p21 is a cyclin-dependent kinase inhibitor and downstream target of p53 that 
halts cell cycle progression when activated (Figure 4-1).  It functions by blocking the 
activity of cyclin-CDK complexes (CDK2 and CDC2), and can inhibit proliferating 
cell nuclear antigen (PCNA) and therefore DNA replication 28.  Unlike Atm deficient 
mice, p21 deficient mice do not have an increased susceptibility to cancer 29.  A 
previous study suggested that p21 upregulation was unlikely to contribute to tumor 
suppression in Chaos3-C3HxB6 mice because the mean tumor latency was similar to 
Chaos3-C3H mice 22.  However, this did not take the delayed cancer onset of C3/3 in 
B6 or C3H x B6 backgrounds into consideration, and C3/3 C3H x B6 or B6 controls 
were not included in that report.  Here we expand that study to include both male and 
female mice and additional genotypes, including C3/3 controls, as well as examination 
of cancer incidence.  When Chaos3 x p21 mice were aged, both C3/3 p21-/- males and 
females had significantly decreased time to tumor onset than C3/3 alone (GBWT male 
p=0.046, female p=0.0055) (Figure 4-4A, Table A4-1).  C3/3 p21+/- females, but not 
males, also had significantly decreased tumor latency compared to C3/3 alone (GBWT 
female p=0.0223, male p= 0.3813) (Figure 4-4A, Table A4-1). Female C3/+ p21-/- 
and C3/+ p21+/- mice had increased cancer susceptibility.  Cancer developed in 55% 
of C3/+ p21-/- females and 42% of C3/+ p21+/- females, compared to only 21% of 
female C3/+ alone and 18% of male C3/+ p21+/- mice (Figure 4-4B).   
 
 81 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4: p21 deficiency impacts Chaos3 tumor latency in males and females 
and tumor susceptibility in females. (A) Chaos3 x p21 tumor latency.  C3/3 p21-/- 
male and female mice have significantly decreased time to tumor onset than C3/3 
alone (GBWT male p=0.046, female p=0.0055). C3/3 p21+/- females, but not males, 
also have significantly decreased tumor latency compared to C3/3 alone (GBWT 
p=0.0223, p= 0.3813).  GBWT= Gehan-Breslow-Wilcoxon Test .  (B) Tumor 
spectrum of Chaos3 x p21 mice.  HSTSC=histiocytic sarcoma, MT=mammary tumor, 
BT=bone tumor, LYMPH=lymphoma, NTMR=no tumor, PCT=plasma cell tumor, 
SKIN=skin tumor, LIVER=liver tumor, PUHYPL=pulmonary hyperplasia, 
HMGSC=hemangiosarcoma, GI=Gastro-intestinal, UAC=uterine adenocarcinoma, 
LEUK=leukemia, UTMR=unknown tumor type.  Note that C3/+ p21-/- females are 
more susceptible to cancer than C3/+ alone, and C3/+ p21+/- females are more 
susceptible to cancer than males. 
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Hus1 deficiency impacts body size but not tumor latency or cancer susceptibility 
in Chaos3/3 mice 
The study of genes in the ATR pathway is complicated by lethality that arises 
when any of the components are null.  However, mice with hypomorphic alleles of 
Hus1 are viable 30.  Compared to wild-type levels, Hus1 mutant expression is as 
follows: Hus1neo/+ 71.4%, Hus1∆/+ 43.5%, and Hus1∆/neo 20.8% 30.  Using 
hypomorphic allele combinations of Hus1, we were able to examine the effects of 
ATR pathway deficiency on Chaos3 development and carcinogenesis.  Chaos3 
Hus1∆/neo mice have dwarfed body size with abnormal craniofacial features, similar 
to Hus1 x Atm mice 31, and significantly reduced body weights (Figure 4-5A). Chaos3 
Hus1∆/+ females also have significantly lower body weights (Figure 4-5A).  
However, C3/3 x Hus1 mice do not have significantly different time to tumor onset 
than C3/3 alone (Figure 4-5B, Table A4-1).  Interestingly, Chaos3 males in the C3H x 
FVB background are more resistant to tumorigenesis than females (Chi Square 
p=0.004) (Figure 4-5C). 
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Figure 4-5: Hus1 deficiency does not impact tumor latency or cancer 
susceptibility in Chaos3/3 mice. (A) Chaos3 x Hus1 body weight.  C3/3 x Hus1 
det/neo animals have significantly lower body weights than C3/3 alone (ANCOVA: 
male p=5.96*10-08; female p=4.04*10-12). C3/3 Hus1 det/+ females also have 
significantly lower weights than C3/3, but greater than C3/3 Hus1 det/neo (ANCOVA: 
respectively p=4.31*10-06; p=7.32*10-4).  (B) Chaos3 x Hus1 tumor latency. C3/3 x 
Hus1 mice do not have significantly different time to tumor onset than C3/3 alone 
(Female: Log-rank Mantel-Cox Test p=0.2872, Gehan-Breslow-Wilcoxon Test 
p=0.1402; Male: Log-rank Mantel-Cox Test p=0.5117, Gehan-Breslow-Wilcoxon Test 
p=0.7731). (C) Tumor spectrum of Chaos3 x Hus1 mice. HSTSC=histiocytic sarcoma, 
MT=mammary tumor, BT=bone tumor, LYMPH=lymphoma, PCT=plasma cell 
tumor, RCT=round cell tumor, GCT=granulosa cell tumor, LIP=lipoma, 
LUT=luteoma, SKIN=skin tumor, LIVER=liver tumor, PUAD=pulmonary adenoma, 
MYLHPL=myeloid hyperplasia, ADGLNRM=adrenal ganglioneuroma, 
PUAD=pulmonary adenocarcinoma, UAC=uterine adenocarcinoma, LUC=lung 
carcinoma, UTMR=unknown tumor type, NTMR=no tumor. Note that males in the 
C3H x FVB background are more resistant to Chaos3 tumorigenesis than females (Chi 
Square p=0.004). 
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Blm deficiency has cryptic effects on tumor latency and cancer susceptibility in 
Chaos3 mice 
BLM is a member of the Rec-Q helicase family and component of the BRCA1 
Associated Genome Surveillance Complex (BASC) involved in control of 
homologous recombination 32.  Inherited autosomal recessive Blm mutation in humans 
causes Bloom’s Syndrome, and affected individuals have a significantly increased risk 
of developing cancer with early onset 33,34.  Complete absence of Blm in mice results 
in lethality (site ref), so C3/3 Blm+/- and C3/+ Blm+/- were aged.  C3/3 Blm+/- 
females do not have significantly different time to tumor onset than C3/3 alone 
(LRMCT p=0.8469, GBWT p=0.9013) (Figure 4-6A, Table A4-1).  Interestingly 
however, C3/3 Blm+/- males near statistical significance for delayed tumor onset 
(LRMCT p=0.059, GBWT p=0.081) (Figure 4-6A, Table A4-1). Additionally, male 
C3/3 Blm+/- mice may have increased resistance to tumorigenesis compared to their 
female counterparts or to C3/3 alone.  However, C3/+ Blm+/- males do not have a 
delayed tumor onset or and have increased cancer susceptibility compared to C3/+ 
Blm+/- females or C3/+ alone.  Therefore, the role of Blm deficiency on tumor onset 
and progression in Chaos3 cancer-prone males is unclear.  
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Figure 4-6: Blm deficiency has cryptic effects on tumor latency and cancer 
susceptibility in Chaos3 mice. (A) Chaos3 x Blm tumor latency. C3/3 Blm+/- 
females do not have significantly different time to tumor onset than C3/3 alone, but 
males near statistical significance for delayed tumor onset  (Female: LRMCT 
p=0.8469, GBWT p=0.9013; Male: LRMCT p=0.059, GBWT p=0.081). 
LRMCT=Log-rank/Mantel-Cox Test;  GBWT=Gehan-Breslow-Wilcoxon Test.  (B) 
Tumor spectrum of Chaos3 x Blm mice.  HSTSC=histiocytic sarcoma, MT=mammary 
tumor, BT=bone tumor, LYMPH=lymphoma, SKIN=skin tumor, LIVER=liver tumor, 
UTMR=unknown tumor type , NTMR=no tumor.  Male C3/3 Blm+/- mice may have 
increased resistance to tumorigenesis compared to their female counterparts or to C3/3 
alone.  However, C3/+ Blm+/- males may equally have increased cancer susceptibility 
compared to females or C3/+ alone.   
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4.4 Discussion 
 Together, the Chaos3 x DDR mutants consistently show that deficiency in the 
Atm DDR pathway results in decreased tumor latency and/or increased tumor 
susceptibility.  This evidence supports the dependence upon an intact p53 pathway and 
replication arrest in response to damage occurring in the Chaos3 mice.   
Interestingly, tumor latency and susceptibility differ between genders, with 
females demonstrating an overall greater cancer susceptibility to Atm and p21 
deficiency than males.  Cancer incidence was 24% and 48% higher in C3/+ p21+/- 
and C3/+ Atm+/- females respectively compared to males.   C3/+ p21-/- females had a 
34% increase in cancer incidence compared to C3/+, whereas C3/+ p21-/- males only 
showed an 11% increase.  Atm and p21 inherited polymorphisms in humans lead to 
decreased DDR response and efficiency, which is associated with significantly 
increased risk of developing lung cancer specifically in African American women 35.  
Interestingly, C3/+ Chk2+/- males showed a marked 40% increase in cancer incidence 
over C3/+ alone compared to females’ 16%.  These results not only mark the 
importance of intact DDR pathways in protection from carcinogenesis, but underscore 
that gender and genetic background significantly impact cancer susceptibility and 
latency when DDR pathways are compromised. 
 C3H x B6 F2 C3/3 females are largely resistant to mammary tumors (15% 
incidence), compared to C3/3 C3H congenic animals (>80% incidence).  Due to the 
strong impact of background strain on the type of cancer that develops, shifts in tumor 
spectrum must be analyzed with caution.  It is interesting to note however, a shift in 
mammary tumor susceptibility in the Chaos3 (C3H) x Chk2 (B6) mice.  The 
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mammary tumor incidence in C3/3 Chk2-/- females increased from 15% to 37%.  
Littermate C3/+ Chk2+/- females do not demonstrate this shift in mammary 
tumorigenesis, suggesting that rather than a factor of genetic background effect, the 
increased mammary tumorigenesis observed in the C3/3 Chk2-/- females may be due 
to Chk2 homozygosity itself.  In women, inherited Chk2 mutation is known to convey 
a 2-3 fold increased breast cancer risk 36. 
 Overall tumor latency and susceptibility were not altered in Chaos3 mice 
deficient for Blm or Hus1 as they were when the Chaos3 mice lacked Atm, Chk2, or 
p21.  This suggests that DNA damage occurring in the Chaos3 mice may not rely as 
heavily on the ATR or homologous recombination pathways for repair, or that these 
two pathways have sufficient alternative sub-routes to bypass the need for Blm and 
Hus1 for DNA damage repair.  There were however, specific genotypes that appeared 
impacted but conflicted with results from other genotypes. C3/3 Hus1∆/+ males had a 
~25% increase in cancer incidence compared to all other Chaos3 x Hus1 genotypes.  If 
this cancer susceptibility is due to genotype, it is unclear why the C3/3 Hus1 neo/+ or 
C3/3 Hus1 ∆/neo males would not also share susceptibility, or at least differing 
susceptibilities from each other and/or to the Hus1+/+ males.  Additionally, C3/3 
Blm+/- males had a 25% decrease in cancer incidence compared to C3/3 alone, while 
C3/+ Blm+/- mice had a 22% increased incidence over C3/+ alone.  It is possible that 
there are thresholds for damage that some allelic combinations surpass (such as C3/3 
Blm+/- or semi-lethality in C3/3 atm-/- animals), taking cells beyond the threshold for 
viability rather than leading to tumorigenesis.  This kind of damage threshold has been 
found to occur in BRCA1/2 deficient tumor cells that are treated with poly(ADP-
 89 
ribose) polymerase (PARP) inhibitors 37-39.  When PARP is inhibited, DNA single-
strand breaks (SSBs) degenerate to DSBs, requiring homologous recombination for 
repair.  PARP inhibition becomes synthetic lethal to cells that are impaired for DDR 
genes essential for homologous recombination, such as BRCA or CDK1 40,41.  This 
has proven to be a successful therapeutic strategy in the clinic 42-44.  In the context of 
decreased tumor incidence in C3/3 Blm+/- male mice, it is possible that Blm 
deficiency sufficiently compromises the HR pathway to resemble the synthetic lethal 
phenotype observed in PARP inhibited/HR deficient cells.  Our results suggest that 
gender and genetic background may impact the efficacy of these therapeutic 
treatments. 
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4.5 Methods and Notes 
Animals & Samples 
p21 mice (B6;129S2-Cdkn1atm1Tyj/J) were purchased from the Jackson Laboratory.  
Hus1 mice were obtained from R. Weiss 30.  Chk2, p21, and Blm mutants were 
congenic in C57BL/6J.  Atm and Hus1 animals were congenic in FVB.  Chaos3 
C3HeB/FeJ congenic animals were crossed to DDR mutants to generate double 
mutant animals that were of mixed genetic background.  Progeny were genotyped as 
described by Leveitt et al.30 and the Jackson laboratory (http://jaxmice.jax.org).   
Double mutants and littermates of the same gender were aged to a terminal endpoint 
of eighteen months or until animals showed clinical signs of disease.  Prism 
(GraphPad 5) statistical software was used to analyze survival curves and generate 
Kaplan-Meier plots. 
MEFs 
Timed matings were conducted for Chaos3 x Atm animals.  Embryos were collected at 
embryonic day 12.5, 13.5, and 18.5.  MEFs were generated, cultured, and cell 
proliferation assays were conducted as previously described 17. 
Histology 
Tumor samples were formalin-fixed and embedded in paraffin for sectioning and 
histological analysis.  Slides were stained with hematoxylin and eosin (H&E) and 
examined for pathology. 
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One Sentence Summary:  Mcm4Chaos3-C3H is an ER+ mammary tumor mouse model 
that mimics the human protective effect of oophorectomy against breast cancer. 
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5.1 Abstract 
 
 Almost all female Mcm4Chaos3-C3H (Chaos3) mice succumb to spontaneous 
mammary tumors at a median of twelve months of age.  Estrogen and progesterone 
control DNA replication in uterine epithelial cells by regulating Mcm4 transcription, 
MCM proteins, and CDT1, the protein that facilitates loading the MCMs onto 
replication origins where the MCM complex acts as the DNA helicase during S phase.  
Estrogen and progesterone’s role in regulating MCMs in other tissues is poorly 
understood.  We examined the impact of reproductive hormones in mammary 
tumorigenesis in Chaos3 mice.  Chaos3 females have higher levels of estrogen at 
twelve months of age compared to wild-type.  The majority of Chaos3 mammary 
tumors expressed  ERα, though the mammary tumors of most mouse models do not.  
We find that oophorectomy, but not pregnancy, has a profound protective effect 
against mammary tumorigenesis in Chaos3 mice.  However, Chaos3 oophorectomized 
mice were significantly more susceptible to developing other types of cancer, 
including histiocytic sarcomas, lymphomas, and osteosarcomas.   Chaos3 mammary 
tumor cells injected into oophorectomized WT mice did not reestablish as well as WT 
mice with intact ovaries.  Together, our results signify the involvement of estrogen 
and progesterone in mammary carcinogenesis in these MCM-deficient mice. 
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5.2 Introduction 
The mcm4Chaos3 (Chaos3) nonsynonomous point mutation in the C3H genetic 
background is the only endogenous gene mutation in mice that leads exclusively to 
mammary carcinogenesis 1.  MCM4 is a highly conserved subunit of the MCM2-7 
DNA replicative helicase, an essential component of pre-replication (pre-RC) 
complexes 2.  These complexes are “licensed” for activation in S phase, and regulatory 
mechanisms inhibit reloading of the MCMs during S phase to prevent re-replication of 
the genome 2.  Chaos3 mice have high levels of Genomic instability (GIN), a 
destabilized MCM helicase, a pan-reduction of all MCMs, a decreased number of 
dormant origins, and ultimately succumb to cancer at a mean latency of 12 months 3-7.  
GIN, recurring copy number alterations (CNAs), background strain, additional 
mutations in mammary tumor modifier genes, and loss of DNA damage response 
(DDR) pathways, are all variables that contribute to Chaos3 carcinogenesis (Wallace, 
Manuscript Chapters 2-4) 1,6,7.  However, additional mechanistic variables, such as 
reproductive hormones and their receptors, may tie MCMs to Chaos3 carcinogenesis 
and mammary tumor specificity.  
The reproductive hormones estrogen and progesterone control DNA 
replication in uterine epithelial cells by regulating MCM proteins 8.  Progesterone 
inhibits DNA synthesis by decreasing Mcm transcription (particularly Mcm4), MCM 
protein levels, and CDT1, the protein that facilitates loading MCMs onto replication 
origins.   Progesterone also leads to the sequestration of MCMs into the cytoplasm 
even though these proteins are primarily nuclear 8.  Progesterone may regulate the 
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MCMs through miRNAs in uterine epithelial cells 9, and normal MCM levels are 
restored in Chaos3 cells with the dicer or drosha pathways are knocked down 5.  In 
contrast to uterine epithelial cells, mammary tissue increases proliferation in response 
to progesterone 10.  In mammary tissue, progesterone causes ductal cell proliferation, 
leading to ductal enlargement or widening and side branching, while estrogen 
concentrates cell proliferation at the terminal end buds (TEBs) and ductal elongation 
and branching 10.  In normal human breast cells, progesterone increases transcription 
of the Mcms and other DNA licensing factors 11.  Mammary epithelial cells also 
demonstrate increased proliferation with an increase in Progesterone Receptor (PR).  
Breast cancer type 1 susceptibility (BRCA1) is involved in posttranscriptional 
downregulation of PR, and mice lacking BRCA1 exhibit increased PR, and 
subsequent increased mammary ductal growth and tumors 12.     
In a cancer susceptibility study including 186 Chaos3 C3HxB6 F2 females, 
28% demonstrated cystic endometrial hyperplasia (CEH) or other abnormal uterine 
cell growth before 16 months of age (Wallace, QTL Manuscript—Chapter 3).  This is 
particularly interesting in the context of reproductive hormonal regulation of the 
MCMs in uterine cells and suggests the Chaos3 mutation may perturb these 
interactions, be it through the destabilized helicase, the pan-reduction of MCMs, or an 
additional mechanism triggered directly or indirectly by the mutation.  Most cases of 
CEH result from high levels of estrogens, or insufficient levels of progesterone, which 
ordinarily counteracts estrogen's proliferative effects in uterine tissue 13.  Related 
conditions such as pyometra and mucometra, which were observed in the Chaos3 F2s, 
also arise due to endometrial hyperplasia (Wallace, QTL Manuscript—Chapter 3) 13.  
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Endometrial hyperplasia is a significant risk factor for the development of endometrial 
cancer, and one Chaos3 F2 female progressed to scirrhous endometrial carcinoma 
(Wallace, QTL Manuscript—Chapter 3) 13,14.  Scirrhous endometrial carcinoma is a 
type of uterine cancer associated with excessive estrogen exposure and often develops 
with CEH 15.  The high incidence of endometrial hyperplasia in Chaos3 mice suggests 
the presence of high levels of estrogen, insufficient levels of progesterone, or that 
progesterone is incapable of downregulating Chaos3 MCMs and thereby replication in 
uterine tissue, resulting in hyperplasia.  Here we explore the impact of reproductive 
hormones on carcinogenesis in the Chaos3 mouse model. 
 
 
5.3 Results 
 
Chaos3 mice have higher levels of estrogen, and Chaos3 mammary tumors 
express ERα 
To examine the importance of reproductive hormones in the Chaos3 model, 
blood samples were collected from Chaos3-C3H virgins at 3 and 12 months of age, 
and estrogen and progesterone levels were quantified by ELISA and RIA, 
respectively.  Chaos3 animals have an overall higher level of estrogen than WT at 12 
months (Figure 5-1A).  Mice have four day cyclic estrous cycles with bursts of ductal 
development.  Ducts proliferate into the fat pad during proestrus and estrus, then 
regress or involute during metestrus and diestrus 16-19.  Due to variability in hormone 
levels within each stage of estrous 17,20, distinguishing differences based on stage is 
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difficult.  However, significant differences in increased hormone levels are observed 
in Chaos3 females during proestrous and diestrous (Figure 5-1A).  Approximately 
75% of all human breast tumors are ER+, and growth of these tumors can be 
stimulated by estrogen 21.  qRT-PCR analysis of ERα mRNA levels in Chaos3 
tumors was conducted.  Six out of eight (75%) Chaos3 mammary tumors examined 
showed expression of ERα.   
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Figure 5-1: Chaos3 animals have higher levels of estrogen at 12 months, and 
mammary tumors express ERα.  (A) Top: Chaos3 estrogen and progesterone 
levels in blood at 3 and 12 months of age.  C3/3: 3 months (n=20), 12 months (n=29).  
C3+/+: 3months (n=20), 12 months (n=26). Error bars show Standard Error of the 
Mean (SEM). Chaos3 animals have higher levels of estrogen than WT at 12 months. 
Bottom: Estrogen and progesterone levels in blood at 12 months by estrous stage. 
Prgst=Progesterone, Est=Estrogen. P=Proestrous, E=Estrous, M=Metestrous, 
D=Diestrous. (B) qRT-PCR analysis of ERα mRNA levels in Chaos3 tumors. Levels 
were normalized to Actin and compared to expression of a normal estrous mammary 
gland. Error bars show Standard Error of the Mean (SEM). Note the similarity in 
ERα expression in tumors from the same animal (denoted with ‘A’ and ‘B’).  
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Pregnancy does not strongly impact mammary tumorigenesis in Chaos3 mice  
Reproductive hormones and their receptors have a profound impact on 
mammary tumorigenesis.  Nulliparous women have twice the risk of developing breast 
cancer as women who have undergone a full term pregnancy before 20 years of age 22.  
In women, multiple early pregnancies confer a lifelong reduced risk of breast cancer 
23,24
.  This protection can be mimicked in rodents through administration of estrogen 
and progesterone treatments 25,26, and hormonal treatment causes increased long-term 
expression of Trp53 and other pro-apoptotic genes 23,24.   
To determine if Chaos3 mammary tumor growth is impacted by reproductive 
hormones, we aged Chaos3 breeder females.   Breeders were classified into two 
groups: Group A and B.  Group A breeders were required to have at least two litters, 
with their first litter being birthed before the mother reached three months of age.  
Group B breeders had their first litter after three months of age and were only required 
to have one litter.  Thus, Group A represents a cohort of breeders with multiple, early 
pregnancies, while Group B females represent a cohort of later-life pregnancies.  
When Chaos3 breeders were aged, tumor latency did not differ between Group A 
breeders (12.5 months) and virgin controls (13.1 months) (LRMCT p=0.8453; GBWT 
p=0.5173) (Figure 5-2A).  Tumor latency was decreased in Group B (11.5 months) in 
GBWT analysis (p=0.0344) but not LRMCT (p=0.1046) (Figure 5-2A).  Mammary 
tumor latency specifically was similarly decreased in Group B (GBWT p=0.0471; 
LRMCT p=0.0548).  Incidence of mammary tumors did not significantly differ 
between Chaos3 breeders (A=77%, B=81%) and virgins (92%) (FET group A 
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p=0.1385, group B p=0.4189) (Figure 5-2B).  These data show that pregnancy does 
not confer a strong protective effect against mammary tumorigenesis in Chaos3 mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-2: Multiple, early pregnancies do not reduce tumor latency or 
significantly reduce mammary tumor susceptibility. (A) Tumor-free survival of 
Chaos3 breeders. PREG A=females with 2 or more litters, with their first litter being 
born before the females reached 3 months of age.  PREG B=female breeders not 
fulfilling the previous criteria.  Tumor latency did not differ between Group A 
breeders (12.5 months) and virgin controls (13.1 months) (LRMCT p=0.8453; GBWT 
p=0.5173).  Tumor latency was decreased in Group B (11.5 months) in GBWT 
analysis (p=0.0344) but not LRMCT (p=0.1046). LRMCT=Log-Rank Mantel-Cox; 
GBWT=Gehan-Breslow-Wilcoxon Test. (B) Tumor Spectrum of Chaos3 breeders.  
MT=mammary tumor; ACT=additional cancer type; NMT=non-mammary tumor. 
Incidence of mammary tumors did not significantly differ between Chaos3 breeders 
and virgins (FET group A p=0.1385, group B p=0.4189).  
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Oophorectomy strongly protects against mammary tumorigenesis in Chaos3 mice   
Premenopausal women who have undergone oophorectomy have a significant 
reduction in breast cancer risk 27,28.  The lifelong protective effect of oophorectomy 
extends to BRCA mutant carriers, with BRCA1 carriers having a 56% reduction in 
breast cancer risk and 15% increase in survival to age 70, and 46% breast cancer 
reduction and 7% increase in survival for BRCA2 carriers 29-31.  Mice with a 
conditional Brca1 mutation also have reduced breast cancer incidence following 
oophorectomy 32.   
To determine if Chaos3 mammary tumor growth is impacted by or dependent 
upon reproductive hormones, we bilaterally oophorectomized 21 Chaos3 female 
weanlings.   Chaos3 oophorectomized mice had significantly delayed tumor onset (14 
months) compared to unoophorectomized mice (13.1 months) (Log-Rank Mantel-Cox 
p=0.0083; Gehan-Breslow-Wilcoxon Test p=0.0379) (Figure 5-3A).  Oophorectomy 
significantly impacted mammary tumorigenesis (FET p=0.0012), with mammary 
tumor incidence decreased by 44% (Figure 5-3B).  Partial ovarian tissue regrowth was 
observed histologically in 6 of the 21 oophorectomized mice, 5 of the 10 total animals 
in which mammary tumors were observed.  This suggests that oophorectomy may 
have an even stronger protective effect against mammary tumorigenesis in the mice.  
However, cancer susceptibility remains constant, with oophorectomized animals 
developing non-mammary tumors such as bone tumors, lymphomas, and histiocytic 
sarcomas (Figure 5-3B).  To further explore the protective effect of oophorectomy, 
we examined the impact of oophorectomy on recapitulation of mammary tumors.  
Chaos3 tumor cells were surgically implanted into the right abdominal mammary 
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gland of WT C3H mice.  Oophorectomized mice formed smaller tumors, by size and 
weight, than unoophorectomized controls (Figure 5-3C).  These results show that 
oophorectomy confers a lifelong protective effect against mammary tumorigenesis in 
Chaos3 mice.   
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Figure 5-3: Oophorectomy delays tumor onset in Chaos3 mice and decreases 
susceptibility to mammary tumorigenesis, but mice are susceptible to other 
cancer types. (A) Tumor-free survival of Chaos3 oophorectomized mice. 
oophorectomized mice had significantly delayed tumor onset (14 months) compared to 
unoophorectomized mice (13.1 months) (Log-Rank Mantel-Cox p=0.0083; Gehan-
Breslow-Wilcoxon Test p=0.0379). (B) Tumor Spectrum of Chaos3 ovariecomized 
mice.  MT=mammary tumor; ACT=additional cancer type; NMT=non-mammary 
tumor; HSTSC=histiocytic sarcoma, BT=bone tumor; LYMPH=lymphoma; 
UTMR=undetermined tumor of non-mammary origin.  Note that incidence of 
mammary tumors in Chaos3 oophorectomized mice is significantly impacted (FET 
p=0.0012), decreasing by 44%.  However, cancer susceptibility remains constant, with 
oophorectomized animals developing non-mammary tumors such as bone tumors, 
lymphomas, and histiocytic sarcomas. (C) Impact of oophorectomy on recapitulation 
of mammary tumors by size and weight. Error bars show Standard Error of the Mean 
(SEM). Chaos3 mammary tumor cells injected into C3H WT mice formed smaller 
tumors in oophorectomized (n=5) vs. unoophorectomized controls (n=3).  
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5.4 Discussion 
The dual nature of the protective effect of reproductive hormones in pregnancy 
or their absence in oophorectomy highlights the complexities surrounding breast 
cancer mechanisms.  Understanding the mechanisms of these effects is an area of 
active research.  During pregnancy, the mammary gland is exposed to high levels of 
ovarian (estrogens and progestins), pituitary (prolactin and growth hormone), and 
placental (placental lactogens) hormones 33.  One hypothesis is that pregnancy 
removes a highly cancer-susceptible mammary epithelial cell population by inducing 
differentiation, removal, or modification of the cells 33,34.  Alternatively, after 
pregnancy, mammary cells have enhanced DNA repair capabilities 33.  Post-partum 
there is also a reduction in hormone levels and receptors in the mammary gland 35.  
Preventative treatment therapy for young women against breast cancer by 
administering hormonal injection during the teenage years is controversial, but 
research and drug treatments are moving forward in clinical trials 36. 
Interestingly, pregnancy Group B Chaos3 females who bore their first litter 
later in life showed decreased tumor latency by GBWT analysis compared to virgins 
(Figure 5-2A).  Women over the age of 35 having their first full-term pregnancy have 
an increased risk of developing breast cancer 37,38, and women over age 30 have an 
even higher risk of breast cancer soon after delivery 39-42.  This increased susceptibility 
to breast cancer extends up to 20 years after first delivery in women greater than 30 
years of age 43,44.  These risk effects are limited to hormone-responseive breast cancers 
(ER+/PR+) 45.  This is consistent with Chaos3 Group B mammary tumorigenesis 
occurring earlier than in virgins (median tumor-free survival 11.5 vs 13.1 months). 
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Notably, while Chaos3 oophorectomized mice had significantly decreased 
mammary tumor incidence, the animals developed other forms of cancer instead 
(Figure 5-3B).  One human study with 24 years of follow-up finds that females with 
bilateral oophorectomy have decreased risk of breast and ovarian cancer, but these 
women have an increased risk of all-cause mortality, including fatal coronary heart 
disease and lung cancer 46.  This raises the prospect that humans prone to reproductive 
cancers who undergo prophylactic-oophorectomy may subsequently increase their risk 
for developing other disease phenotypes.   
Mammary tumors in most mouse models are ER-, indicating that the tumor 
growth is not stimulated by estrogen as in the majority of human breast cancer cases 
47,48
.  We have shown that Chaos3 mammary tumors express ERα and that mammary 
tumor incidence is greatly attenuated in Chaos3 oophorectomized mice.  Additionally, 
the Chaos3 mammary tumor expression signature more closely resembles the 
differentiation signature of mature human luminal cells than all other mouse models 
analyzed, and the tumors develop recurring copy number alterations (CNAs) that 
overlap with human breast tumors (Wallace, Nf1 Manuscript—Chapter 2).  Together, 
these characteristics make Chaos3 a highly relevant model to study human breast 
cancer. 
 
5.5 Methods and Notes 
Animals  
For oophorectomy studies, Chaos3 C3HeB/FeJ congenic and inbred C3HeB/FeJ 
animals were aged to a terminal endpoint of eighteen months or until animals showed 
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clinical signs of disease.  Prism (GraphPad 5) statistical software was used to analyze 
survival curves and generate Kaplan-Meier plots.   
Estrogen and Progesterone Levels 
Blood was collected from Chaos3 C3HeB/FeJ congenic and inbred C3HeB/FeJ mice 
at 3 and 12 months of age.  Blood was allowed to clot at room temperature for 90 
minutes and then centrifuged at 2000 g for 15 minutes.  Serum was removed and 
stored at -20.  Mouse estradiol was quantified by ELISA (Calbiotech), and 
progesterone was quantified by RIA, both at the UVA ligand core.  Estrous stage was 
determined from histological examination of H&E sections from the reproductive 
tracts. 
Surgeries 
Mice were anesthetized with an intraperitoneal (IP) injection of 0.15 ml Avertin/10 g.  
Bilateral oophorectomy survival surgeries were performed following standard SOPs 
when females were three weeks of age, before the onset of sexual maturity.  An 
incision through the peritoneal wall above the fat pad was made, the bursa opened, and 
then the ovaries were removed. The incision was sutured and a wound clip was used to 
close the skin.  For WT mice in the tumor recapitulation study, Chaos3 tumor cells 
were injected using Hamilton syringe directly into the right abdominal mammary fat 
pad.  Mammary glands were not cleared.  Wound clips were used to close the skin.  
Mice were placed on a slide warmer tray while recovering from anesthesia and then 
placed in a clean cage. After surgery, 0.1 ml Ketoprofen was injected subcutaneously 
(SubQ).  24 hours after surgery, 0.1 ml Ketoprofen injected SubQ.  The mice and 
surgery site were observed daily for nine days until the wound clips were removed.   
 112 
Histology 
Tumor samples were formalin-fixed and embedded in paraffin (FFPE) for sectioning 
and histological analysis.  Slides were stained with hematoxylin and eosin (H&E) and 
examined for pathology. 
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CHAPTER 6 
 
Summary & Discussion 
 
 
 
6.1 Mammary Tumor Carcinogenesis 
 Breast cancer research faces many challenges and limitations in the human 
system.  In human tumors, the prevalence of passenger mutations, heterogeneity, and 
the diversity of tumor etiologies and subtypes complicates conclusions about putative 
drivers 1-3.  The majority of genetically-based breast cancers are caused by low-
penetrance modifier alleles, complicating attempts at genetic mapping by GWAS in 
humans 4.  These challenges necessitate a comparative oncogenomic approach, for 
which mouse models are a powerful tool.  The environment and genetic backgrounds 
can be precisely defined, and within a given cancer mouse model, the tumors that arise 
have a consistent underlying basis.  Additionally, mice can be experimentally 
manipulated to solidify evidence of candidate genes and validate genomic findings. 
Here I have utilized the Chaos3 mouse model, which is not genetically 
engineered or treated with carcinogens, in order to study spontaneous mammary 
tumorigenesis.  Using this model I have been able to identify mammary tumor drivers 
and susceptibility loci as well as examine the role of DDR and reproductive hormones 
on carcinogenesis when the core DNA replication machinery is defective.  
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6.2 Genomic Analysis of Mammary Tumors and Identification of Driving 
Mechanisms 
Genomic analysis of Chaos3 tumors culminated in several important findings.  
Chaos3 tumors model key human features.  Luminal breast tumors are the most 
prevalent type in humans 5.  Expression profiling of Chaos3 mammary tumors 
revealed that they cluster near luminal mouse models, and the Chaos3 gene signature 
was the most highly expressed in the human luminal subtypes.  Chaos3 tumors have a 
distinct gene expression pattern from all other mouse models, including dramatic 
upregulation of Mucl1, a diagnostic marker in human breast cancer 6.  Also, Chaos3 
tumors more closely resemble mature human luminal cells than any mouse model 
analyzed to date.  Partial exome resequencing of Chaos3 mammary tumors revealed 
few somatic point mutations, indicating that elevated intragenic mutagenesis is not the 
primary mechanism driving Chaos3 carcinogenesis.  aCGH showed that Chaos3 
mammary tumors have recurring CNAs that overlap with those found in human breast 
cancer, including loss of the Nf1 tumor suppressor.  aCGH using higher density chips 
(1.4 million probes versus 385 or 720 thousand) has now been conducted on an 
additional 15 Chaos3 tumors, and the data are currently being analyzed.  The higher 
density chips will allow for higher resolution detection of small amplifications and 
deletions to identify additional candidate drivers.  The recurrence of Chaos3 CNAs, 
despite high levels of aneuploidy in tumor cells, and similarity to human CNAs 
indicated that recurring amplifications and deletions were a driving mechanism of 
mammary tumorigenesis in Chaos3 mice. 
 
 118 
6.3 Nf1, a prevalent breast cancer driver  
Nf1 has not previously been implicated in spontaneous breast cancer.  I found 
that Nf1 is lost in almost all Chaos3 mammary tumors, and this loss leads to 
hyperactivation of the RAS oncogene, which controls cell proliferation and anti-
apoptosis pathways.  These tumors are sensitive to drugs targeting the RAS pathway.  
Analysis of unpublished TCGA data revealed that NF1 deficiency is present in 27.7% 
of all human breast tumors, including >40% of Her2-enriched and basal-like subtypes. 
These data implicate NF1 deficiency as a major breast cancer driver, and should 
inform treatment of the ~63,450 Americans who develop breast cancer with NF1 
deficiency annually. 
An Nf1 knockdown experiment is currently underway in C3H WT inbred 
females that have been surgically injected with Chaos3 mammary epithelial cells 
containing a construct of Nf1-shRNA.  These cells were injected into the cleared right 
abdominal mammary gland fat pad, while untreated Chaos3 cells were injected into 
the cleared left abdominal mammary gland fat pad as a control.  If animals develop 
tumors more frequently in the right abdominal mammary gland, it will provide further 
evidence that Nf1 deficiency is driving tumorigenesis.  Long-term, the role of Nf1 
deficiency as a driver of mammary tumorigenesis will be addressed by generating and 
aging Chaos3/3 x Nf1+/- and Chaos3/+ x Nf1+/- C3H females.  75% of animals 
heterozygous for Nf1, with neo cassette replacement of a portion of exon 30 and 31, 
develop tumors over 27 months, compared to 15% of wild-type animals 7.  
Furthermore, the tumor spectrum observed in the Nf1+/- animals was similar to those 
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in wild-type mice, suggesting that the mutation may accelerate development of tumor 
types to which the animals are already susceptible 7. 
In the near future, an Nf1 add-back/rescue experiment will be conducted 
similar to the Nf1 knockdown experiment.  For the rescue experiment, an Nf1 
construct will be transfected into Chaos3 tumor cells.  Tumor cells with and without 
the Nf1 construct will be surgically injected into female C3H mammary fat pads to 
determine the impact of Nf1 on mammary tumor recapitulation and growth.  The Nf1 
construct has almost all intronic regions removed, and given the gene’s large size and 
multiple isoforms, proper expression of the gene is a potential technical problem for 
the experiment.  However, if Nf1-bearing cells show delayed tumor reformation and 
growth, it will contribute evidence of the role of Nf1 in mammary tumor suppression.   
Chaos3 tumor cells are sensitive to rapamycin (MTOR inhibitor) and PD98059 
(MEK1 inhibitor).  There are additional drugs that also target the RAS pathway, 
including Tipifarnib, Sorafenib, LY294002, Salirasib, Temsirolimus, and Everolimus 
(Fig 1).  Among these, it would be beneficial to determine (in Chaos3 and human Nf1 
deficient tumor lines) which combination has the greatest impact on cell proliferation.  
Additional markers predicting sensitivity could be extrapolated from tumor profiles.  
Based on drug treatment outcome in cell lines, Chaos3 mice could then be treated to 
determine efficacy in vivo.   
Tipifarnib was being tested in phase II clinical trials for use in stage II and 
stage III breast cancer as well as hormone-receptor positive breast cancer 8,9.  Despite 
promising results, clinical trials were suspended after the FDA disapproved the drug 
for treatment of acute myeloid leukemia (AML), citing the lack of a randomized study 
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and that many of the patients were suitable candidates for standard induction therapy 
10
.  A phase II trial of salirasib for treatment of lung adenocarcinomas patients with 
KRAS mutations found that the given dosage and schedule had insufficient activity to 
warrant further evaluation 11.  Salirasib would have been the most ideal inhibitor as it 
specifically targets RAS and could block progression of both the PI3K and MAPK 
pathways.  Sorafenib is currently approved to treat hepatocellular carcinoma and 
advanced renal cancer.  Temsirolimus and Everolimus are two other mTOR inhibitors 
that are approved for the treatment of renal cell carcinoma.   
In the absence of an approved RAS inhibitor in humans, a powerful strategy 
for treatment of Nf1-defcicient mammary tumors may be a combination of drugs to 
target both the PI3K and MAPK pathways.  Additionally, clinical trials may advance 
more quickly by using drugs that have already been approved for treatment of other 
cancer types.  Thus, the most promising combinations to test are 
Sorafenib/Temsirolimus and Sorafenib/Everolimus. 
As evidence accumulates of Nf1 as a major breast cancer driver, impacting 
~1/4 of all human cases, clinical testing of Nf1 will be critical for personalized 
treatment.  Tamoxifen, the estrogen receptor (ER) inhibitor that is standard treatment 
for ER+ breast cancers, may not be appropriate for women whose cancers involve 
NF1 deficiency. NF1 depletion confers resistance of human breast cancer (MCF7) 
cells to tamoxifen, and tamoxifen-treated patients whose tumors had lower NF1 
expression levels had poorer clinical outcomes 12.   
Frequent NF1 deletion may be due to a combination of factors including 
fragile sites (Fig. S6), a complex chromatin structure, and/or its large genomic size. 
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Indeed, replication fork stalling near Nf1 has been noted at a 5 kb isochore transition 
zone conserved between human and mouse, separating early and late replicating 
chromatin 13. Furthermore, collisions between replication and transcription complexes 
cause instability at fragile sites in the longest human genes 14.  Due to these factors, in 
context of the Chaos3 mutation, the unstable DNA replication helicase may have 
difficulty progressing through this region, leading to frequent deletion, which 
subsequently contributes to driving carcinogenesis. 
 
Figure 6-1: RAS signaling pathway and inhibitors.  Drug inhibitors are shown in 
red type. Note, Temsirolimus and Everolimus are mTOR inhibitors, like rapamycin, 
but not shown.  Ftase = farnesyltransferase. RTK = receptor tyrosine kinase. The 
curved blue line near the top depicts the cell membrane. Gltn = Galectin, a protein that 
binds farnesylated Ras to the cell membrane. Not all downstream targets are shown. 
 
6.4 Mammary Tumor Susceptibility and Resistance Loci 
While an estimated ~25% of breast cancer cases have an inherited familial 
basis, the majority of susceptibility genes underlying these heritable cases remain 
unknown 15.  QTL analysis of Chaos3 C3H x B6 F2s allowed for identification of 
mammary tumor susceptibility and resistance loci.  Candidate genes are involved in 
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cell proliferation (Fgfr3), DNA repair (Msh4, Fancg, Fancc, Rad51ap1), cell signaling 
(Fbxw7, Frp1, Ptc1, Tln1, Pax5), and cancer associated genes (Rab2a, Rab28, Styk1, 
Mycbp2).  To bolster the number of mammary tumors analyzed, a new cohort of 
mixed C3H, B6, and FVB backgrounds from the DDR experiments was genotyped on 
a 3rd SNP chip of higher density.  Analysis is currently underway to identify additional 
cancer susceptibility and resistance loci. 
Tln1, a gene required for integrin activation, was identified in the Chaos3 QTL 
experiment as a candidate gene for mammary tumor susceptibility.  Tln1 was 
previously identified as a candidate driver in human breast cancer with a low 
passenger mutation probability 16.  Within the Chaos3-C3H colony, Tln1 was 
discovered to have a nonsynonomous germline point mutation.  When aged, Chaos3 
Tln1 mutants had a significantly higher mammary tumor incidence than Chaos3 alone, 
validating Tln1 impact on mammary tumor susceptibility.  The Tln1 mutation falls 
within a cryptic vinculin binding domain 17, which may interfere with how the proteins 
interact with integrin for activation.  As a first step to understand the mechanism by 
which Tln1 is contributing to mammary susceptibility, components of the Integrin 
pathway could be examined for altered levels of activation, predicting hyperactivation.  
However, understanding this mechanism may prove to be a long-term endeavor, as the 
mechanism of BRCA1 and BRCA2 mutations on specifically breast and ovarian 
cancer susceptibility remains unclear despite intense research.  Other genes identified 
in the Chaos3 aCGH and F2-QTL experiments are also excellent candidates for future 
studies. 
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6.5 Interaction between TLN1/Integrin and NF1/RAS pathways 
There is growing evidence for the use of TLN1 expression as a prognostic 
marker in tumor progression and as a therapeutic target 18.  TLN1 overexpression leads 
to pro-survival and progression to metastasis 19.  There is significant cross-talk 
between the talin/integrin and RAS pathways (Figure 6-2).  TLN1-induced integrin 
activation triggers the formation and activation of the focal-adhesion complex, 
including FAK, which then activates the PI3K/AKT survival pathway (Figure 6-2) 18.  
This results in anoikis resistance, angiogenesis, and survival after cellular detachment 
from the extra cellular matrix (ECM) 18.  The focal-adhesion complex also activates 
the MAPK pathway through phosphorylation of ERK1/2.  NF1 also binds FAK, but 
the functional consequence of this is unknown 20.  Ras GTPases mediate integrin–talin 
interactions 21.  Furthermore, binding of GRB2/SOS to FAK plays a significant role in 
activating the RAS pathway 22.  Additional RAS family proteins impact integrin 
activation as well, including R-RAS, RAP1, RIAM, and Rho-GTPases 23-25.  
Interaction between caveolin-1 and Rho-GTPases promotes metastasis by controlling 
the expression of alpha5-integrin and the activation of Src, Ras and Erk 23.  Together, 
this suggests that concurrent loss of NF1 and TLN1 mutation has a synergistic effect 
to promote carcinogenesis via the PI3K and MAPK pathways. 
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Figure 6-2: Interaction between TLN1/Integrin and NF1/RAS pathways. RTK = 
receptor tyrosine kinase.  ECM=extra cellular matrix.  NF1 inhibits activated RAS-
GTP by increasing its conversion rate into the inactive RAS-GDP state.  Loss of NF1 
leads to increased activated RAS and subsequent downstream activation of PI3K and 
MAPK signal transduction pathways.  TLN1 activates integrin, triggering activation of 
the focal-adhesion complex (including FAK) and subsequent activation of the PI3K 
and MAPK pathways. These pathways control cell proliferation and transcription of 
anti-apoptosis/pro-survival genes. NF1 also binds FAK, but the functional 
consequence of this is not known.  Not all downstream targets are shown. 
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6.6 The role of DDR on tumor suppression when core DNA replication 
machinery is defective 
Defects in the DNA replication machinery are only recently being appreciated 
for their role in driving carcinogenesis, specifically MCM deficiency 26-29.  MCMs are 
direct targets of ATM and ATR 30,31, the damage sensors in the DDR pathways 32,33, 
which are frequently altered in human cancers 16,34,35.  To understand the role of the 
DDR pathways on carcinogenesis when there is a deficiency of MCMs, I generated 
double mutants of Chaos3 with an additional DDR mutation.  Together, the Chaos3 x 
DDR mutants consistently show that deficiency in the Atm DDR pathway results in 
decreased tumor latency and/or increased tumor susceptibility.  This evidence supports 
the importance of an intact p53 pathway for tumor suppression.  Tumor latency and 
susceptibility differed between genders, with females demonstrating an overall greater 
cancer susceptibility to Atm and p21 deficiency than males.  Chk2 deficiency increased 
mammary tumor incidence and decreased tumor latency in Chaos3 females and 
increased cancer susceptibility in males.  These results mark the importance of intact 
DDR pathways in protection from carcinogenesis when the DNA replication 
machinery is defective, and underscore that gender and genetic background 
significantly impact cancer susceptibility and latency when DDR pathways are 
compromised.   
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 6.7 The role of reproductive hormones and their receptors on carcinogenesis in 
MCM-deficient mice  
Estrogen and progesterone control DNA replication in uterine epithelial cells 
by regulating the MCMs 36, but the role of reproductive hormones in regulating 
MCMs in other tissues is poorly understood.  I examined the impact of estrogen and 
progesterone on mammary tumorigenesis in Chaos3 mice.  Chaos3 females have 
higher levels of estrogen at twelve months of age compared to wild-type.  This is 
consistent with the high incidence of CEH observed in the mice.  The majority of 
Chaos3 mammary tumors expressed  ERα, similar to humans, though the mammary 
tumors of most mouse models do not 37,38.  A tissue microarray of 100 Chaos3 tumor 
and mammary gland samples is currently being constructed in order to examine ER 
and PR by standard IHC methods.  Oophorectomy, but not pregnancy, had a profound 
protective effect against mammary tumorigenesis in Chaos3 mice.  However, Chaos3 
oophorectomized mice were significantly more susceptible to developing other types 
of cancer.   One human study with 24 years of follow-up finds that females with 
bilateral oophorectomy have decreased risk of breast and ovarian cancer, but these 
women have an increased risk of all-cause mortality, including fatal coronary heart 
disease and lung cancer 39.  This raises the prospect that humans prone to reproductive 
cancers who undergo prophylactic-oophorectomy may subsequently increase their risk 
for developing other disease phenotypes.   
Estrogen itself may be playing a larger role than inducing proliferation in 
Chaos3 tumorigenesis.  In tissues prone to estrogen-induced cancer, estrogens can be 
metabolically activated to 4-hydroxylated metabolites 40. Studies indicate the 
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predominant 4-hydroxylation of estrogen occurs in organs prone to estrogen-
associated cancer 40.  Evidence suggests that these metabolites and their 
semiquinone/quinone oxidation products can induce DNA damage by forming DNA 
adducts, causing single-strand breaks, and 8-hydroxylation of guanine bases 40.  
Estrogen has been shown to induce genetic mutations including aneuploidy, structural 
chromosomal aberrations, gene mutations, gene amplification and deletion, and 
microsatellite instability 40.  These studies show that estrogen-induced carcinogenesis 
does not occur solely by receptor-mediated cell proliferation.  Chaos3 cells are 
significantly more sensitive to added replication stress such as aphidicolin treatment 
29,41
.  Therefore in the context of the Chaos3 mutation, estrogen may act as a potent 
genotoxic stress in Chaos3 mammary epithelial tissue where there are fewer backup 
replication origins to fire due to the decreased number of dormant origins. 
 
6.8 Chaos3 as a highly relevant model for ovarian cancer 
Nf1 is frequently lost in both human mammary and ovarian cancers 34,35, 
suggesting that Nf1 deficiency may be a prominent driver in ovarian cancer as well.  
However, Chaos3-C3H mice do not frequently develop ovarian tumors. Nf1 may work 
differently in ovarian tissue in mice versus humans or C3H and B6 background may 
not be susceptible to or may be protecting mice from ovarian tumors.   
Ovarian cancer is the most lethal of the female reproductive cancers, with 
22,280 cases in the United States annually and 15,500 deaths 42.  The epithelial 
subtype constitutes 90% of the cases, and ~5% are the granulosa cell subtype 43,44.  
Currently, there are no ideal mouse models for either subtype due to the artificial 
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context of carcinogens, non-ovary specific driving promoters (leaky systems), infertile 
females, or failure of offspring to develop tumors 43.   
However, the NZC strain has a 17% spontaneous incidence of the ovarian 
granulosa cell tumor subtype at ~2 years of age in virgins (15% breeders) 45.  For 
comparison, C3H inbred female virgins have a 2% spontaneous mammary tumor 
incidence (12% breeders) at typically >18 months of age, which increases to >80% 
incidence at ~12 months when in the presence of Chaos3 homozygosity 29,46.  
Interestingly, all NZC mice developing spontaneous ovarian granulosa cell tumors 
also developed uterine cystic hyperplasia 45.  A high incidence of uterine cystic 
endometrial hyperplasia was observed in Chaos3-C3H mice and quantified at 28% in 
C3HxB6 F2s.  Given that Chaos3 tumor type is dependent upon background strain, 
the driving mechanism of recurrent Nf1 loss in breast and ovarian cancers, and the 
similarity of CEH phenotype, it is plausible that Chaos3-NZC congenic mice would 
demonstrate an extremely high incidence of ovarian granulosa cell tumors.  Chaos3 
tumorigenesis occurs earlier than spontaneous tumors typically develop naturally in 
the background strains (12-18 months vs. >18 months).  Thus, the ovarian tumor 
latency in Chaos3-NZC would also likely be decreased.  As an alternative, NZO mice 
have a 5.5% spontaneous incidence 47; 4% in virgins and 14.3% breeder incidence has 
also been reported 45.  Therefore, generation of a Chaos3 granulosa cell tumor model 
of ovarian cancer may be fairly straight forward. 
Unfortunately, spontaneous tumors of the epithelial subtype have not been 
observed/reported in any specific mouse strain.  Interestingly however, in the 6 of 21 
Chaos3 oophorectomized females in which ovarian tissue re-grew, all were 
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accompanied by ovarian disease.  One animal demonstrated only an ovarian cyst, 3 
animals developed ovarian cysts and tubulostromal hyperplasia, 1 animal developed a 
luteoma (a rare type of ovarian tumor), and 1 animal developed an ovarian 
adenocarcinoma (the epithelial type that comprises 90% of all human ovarian cancers) 
43
.  This indicates it is at least possible to generate ovarian tumors of interest in 
Chaos3 mice. 
p53 is mutated in 96% of serous ovarian cancers, indicating it is a critical step 
in the development of ovarian tumors 35.  It has been shown that Chaos3 x p53 mice 
develop bone tumors, lymphomas, and histiocytic sarcomas.  However, the study was 
conducted in the B6 background.  Given the dependency of tumor type on background 
strain (particularly C3H vs. B6), deficiency of p53 in strains amenable to reproductive 
cancers would be expected to significantly shift the tumor spectrum.  If C3/+ p53+/- 
and C3/3 p53+/- animals were aged in a C3H, FVB, or NZC background, ovarian 
tumors and the incidence of other reproductive cancers would be expected to increase, 
and tumor latency would decrease.  Incidence of ovarian tumors may be enhanced 
further if Chaos3 could be introduced in an ovarian-specific Cre mouse line as well to 
a LoxP (floxed) p53 mouse.  Chaos3/3 Ovar-Cre could then be crossed to Chaos3/3 
LoxP p53, resulting in mice mutant for Chaos3 that had ovarian-specific p53 
deficiency.  It may be equally beneficial to generate Nf1+/- Ovar-Cre LoxP p53 mice 
to achieve the same ends.  While spontaneous models of epithelial ovarian cancer may 
be more difficult to achieve, eventual Chaos3 and Nf1 models of ovarian cancer are 
promising.   
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6.9 Chaos3 Carcinogenesis 
How does a point mutation in a DNA replication gene lead exclusively to 
mammary carcinogenesis?  The defective Chaos3 helicase is unstable 48.  The 
consistency of recurring CNAs, as opposed to somatic point mutations, in Chaos3 
tumors indicates that the mutant helicase may be predisposed to stalling at particular 
genomic regions that are difficult to replicate.  This is consistent with recurring CNAs 
in yeast flanking long terminating repeat (LTR) sites 49.  Chaos3 cells have fewer 
dormant replication origins to fire in response to fork stalls or collapse 50,51.   Despite 
activation of multiple fork recovery pathways, these replication intermediates persist 
into M phase, increasing the number of abnormal anaphase cells with lagging 
chromosomes and/or acentric fragments 50,51.  This results in GIN and the micronuclei 
phenotype originally observed in the Chaos3 mice.  This also helps account for the 
high levels of aneuploidy observed in Chaos3 tumor cells.  Chaos3 animals develop 
tumors in a specific window of time, rarely before ten months of age without 
additional perturbation.  This indicates that other age-related factors are involved that 
may or may not relate to changing hormonal conditions, and this aspect of 
carcinogenesis remains to be explored.  There is a pan-reduction of MCMs in Chaos3 
cells, which can be restored by knocking down Dicer and Drosha 48.  With MCMs 
downregulated, cell cycle is delayed.  Hormones regulate the MCMs through miRNAs 
52
.  This suggests that either hormones cause the pan-reduction of MCMs, or the 
imbalance of the MCMs leaves the hormonal system attempting to resolve the 
imbalance, perhaps through the increased levels of estrogen observed in Chaos3 mice 
at 12 months.  When hormonal conditions and potentially other age-related factors are 
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in place, and tumor suppressors such as Nf1 are lost due to problematic replication, the 
cells transform.  There are several areas that require further research, but these studies 
have helped to make the overall picture of Chaos3 carcinogenesis is much clearer.  
Overall, the Chaos3 model is highly relevant for the study of human cancer and the 
consequences of DNA replication defects on carcinogenesis. 
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APPENDIX  
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure A1-1: Premature morbidity and cancer susceptibility in 
Mcm4Chaos3/Chaos3 Mcm2Gt/+ mice. (A) Kaplan-Meier survival plot of the 
indicated genotypes. Animals of both sexes are combined. ‘‘C3’’ = Chaos3. (B) 
Spleen and liver histopathology of a Mcm4C3/C3 Mcm2Gt/+ male diagnosed with T 
cell leukemic lymphoma. i. H&E stained spleen. Neoplastic cells have abundant 
cytoplasm, 1–2 nucleoli and a high mitotic rate, consistent with lymphoblastic 
lymphoma. Bar = 20 mm. ii. Neoplastic cells in spleen demonstrate immunoreactivity 
with anti-CD3 (brown; immunoperoxidase staining with DAB chromogen & 
hematoxalin counterstain), indicating T lymphocytes. Bar = 200mm. iii. In spleen, 
immunoreactivity (brown) with anti-PAX-5 (a B cell marker) is limited to follicular 
remnants and scattered individual cells. Bar = 200 mm. iv. In liver, neoplastic cells 
surround central veins and expand sinusoids (see also Figure S4) and demonstrate 
immunoreactivity (brown) with the anti-CD3 T lymphocyte marker. Bar = 50 mm. 
doi:10.1371/journal.pgen.1001110.g004.  (C) X-Inactivation in Chaos3 Mcm2 10.5 
day female embryos.  Extreme semi-lethality of Chaos3 Mcm2 females is not due to 
improper X-inactivation.  X-GFP in Chaos3 X-GFP mice was measured by flow 
cytometry. 
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Figure A1-1 Continued 
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Supplementary Table A2-1: Genes Significantly Differentially Expressed 
Between Chaos3 and Other GEMMs  
      
(FDR 0%) Identified in 2-Class SAM 
Analysis     
Current settings 
      
Input parameters 
      
Data type?   Two class unpaired 
Arrays centered?   FALSE  
Delta    1.691  
Minimum fold change   0.000  
Test statistic   standard  
Are data are log scale?   TRUE  
Number of permutations   500.000  
Input percentile for exchangeability factor s0  Automatic choice 
Number of neighbors for KNN  10.000  
Seed for Random number generator  1234567  
      
      
Computed values 
      
Estimate of pi0 (proportion of null genes)  0.636  
Exchangibility factor s0   0.051  
s0 percentile   0.000  
False Discovery Rate (%)   0.000  
      
      
List of Significant Genes for Delta = 1.691 
      
      
      
  
Upregulated 
Genes   
      
Row Gene Name Score(d) Numer. Denom. 
Fold 
Change 
6516 Mucl1 9.910 5.158 0.520 35.708 
4734 H28 6.810 3.373 0.495 10.358 
779 Abpb 4.267 3.053 0.715 8.299 
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54 1110030E23Rik 8.393 2.984 0.356 7.911 
5922 Ltf 4.305 2.868 0.666 7.298 
7770 Pip 4.378 2.836 0.648 7.143 
6512 Muc4 4.760 2.759 0.580 6.769 
3512 Egfbp2 6.809 2.681 0.394 6.413 
5976 Mageb16 8.122 2.650 0.326 6.276 
106 1700008P20Rik 7.928 2.563 0.323 5.910 
7527 Pclo 10.081 2.353 0.233 5.107 
836 Acsm3 6.716 2.246 0.334 4.742 
5560 Klk1b3 7.104 2.077 0.292 4.221 
9437 Slc35f3 5.065 1.989 0.393 3.968 
5561 Klk1b3 6.134 1.973 0.322 3.927 
9222 Sh2d4a 5.558 1.879 0.338 3.677 
3238 Dmrta2 6.273 1.835 0.292 3.566 
7669 Pglyrp1 4.743 1.829 0.386 3.552 
366 2610305D13Rik 4.023 1.762 0.438 3.392 
1183 Ankrd43 5.677 1.734 0.305 3.327 
4100 Fmn2 6.127 1.710 0.279 3.271 
1699 BC051142 8.433 1.686 0.200 3.218 
978 Agr3 4.307 1.674 0.389 3.191 
5645 Lalba 3.809 1.668 0.438 3.178 
11256 Xkr6 8.043 1.632 0.203 3.100 
5559 Klk1b27 4.452 1.630 0.366 3.094 
802 Acbd7 4.332 1.628 0.376 3.092 
3877 Fam20c 4.977 1.521 0.306 2.870 
10243 Thrb 8.051 1.479 0.184 2.787 
4021 Fer1l4 7.674 1.464 0.191 2.759 
4591 Gpr98 5.610 1.443 0.257 2.719 
1121 Amhr2 3.747 1.434 0.383 2.701 
7051 Nxph3 5.409 1.429 0.264 2.693 
3112 Ddx60 3.722 1.425 0.383 2.684 
2481 Cldn1 3.894 1.366 0.351 2.577 
166 1700042B14Rik 5.658 1.365 0.241 2.577 
453 4833424O15Rik 5.429 1.364 0.251 2.575 
5562 Klk1b4 4.234 1.348 0.318 2.545 
888 Adamts18 4.107 1.345 0.328 2.541 
1587 AY026312 4.905 1.344 0.274 2.538 
4415 Gm14446 5.898 1.339 0.227 2.530 
7676 Pgp 3.841 1.338 0.348 2.528 
10317 Tmc5 3.537 1.315 0.372 2.489 
6158 Mei1 5.012 1.309 0.261 2.478 
7604 Pdxk 3.846 1.308 0.340 2.476 
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5139 Igkv14-111 4.636 1.278 0.276 2.425 
1899 C920025E04Rik 3.525 1.274 0.361 2.418 
233 2010106G01Rik 4.395 1.261 0.287 2.397 
5099 Ifng 6.865 1.258 0.183 2.392 
5863 Lrrc26 3.606 1.253 0.348 2.384 
1568 Atxn7l3 5.382 1.252 0.233 2.382 
1032 Ak7 4.249 1.251 0.294 2.381 
6665 Nbea 3.664 1.244 0.340 2.369 
6324 Mospd4 3.711 1.229 0.331 2.344 
2949 Cyp4f41-ps 6.664 1.227 0.184 2.341 
5851 Lrp6 4.437 1.197 0.270 2.293 
2576 Cnnm1 5.311 1.165 0.219 2.243 
5373 Jmjd5 3.689 1.164 0.316 2.241 
9249 Shisa7 4.889 1.158 0.237 2.231 
7055 Oas1d 6.581 1.155 0.176 2.227 
3332 Dpp10 4.101 1.152 0.281 2.222 
4295 Gcc2 4.134 1.132 0.274 2.192 
11321 Zbtb38 5.078 1.127 0.222 2.185 
4354 Gjb1 6.640 1.126 0.170 2.183 
2555 Cmpk2 4.544 1.118 0.246 2.170 
10415 Tmem44 4.198 1.112 0.265 2.162 
6827 Nhsl1 4.174 1.107 0.265 2.154 
4066 Fign 3.874 1.106 0.286 2.153 
6959 Nrcam 3.953 1.103 0.279 2.148 
6657 Nat1 5.526 1.095 0.198 2.136 
3111 Ddx60 3.750 1.088 0.290 2.126 
1685 BC026762 3.543 1.078 0.304 2.112 
9322 Slc16a12 4.005 1.075 0.268 2.106 
8377 R3hdm1 4.607 1.074 0.233 2.106 
1893 C77370 5.644 1.071 0.190 2.100 
10954 Unc80 3.920 1.062 0.271 2.087 
6452 Mtap1b 4.977 1.043 0.210 2.061 
6188 Mfap3l 4.263 1.043 0.245 2.060 
3774 F5 3.575 1.042 0.291 2.059 
6487 Mtmr9 5.510 1.036 0.188 2.050 
3099 Ddx4 5.152 1.035 0.201 2.049 
11602 Zfyve20 4.174 1.034 0.248 2.048 
5161 Il12b 4.429 1.019 0.230 2.026 
697 A430061O12Rik 4.502 1.017 0.226 2.024 
4417 Gm15800 4.456 1.001 0.225 2.001 
5897 Lrrtm3 4.127 0.994 0.241 1.992 
4209 Fzd10 4.794 0.991 0.207 1.988 
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8636 Rgn 3.632 0.988 0.272 1.983 
5415 Kcnh8 3.574 0.985 0.275 1.979 
310 2310057N15Rik 4.812 0.983 0.204 1.977 
5251 Ints4 4.387 0.980 0.223 1.973 
1204 Anp32a 3.758 0.977 0.260 1.968 
8709 Rnase10 5.454 0.977 0.179 1.968 
5875 Lrrc46 4.278 0.974 0.228 1.964 
5769 Lingo2 3.857 0.964 0.250 1.951 
1979 Card14 4.302 0.960 0.223 1.945 
11243 Wtap 4.247 0.935 0.220 1.912 
1337 Arhgap29 3.841 0.929 0.242 1.904 
9335 Slc18a1 4.212 0.917 0.218 1.889 
630 8430419L09Rik 4.385 0.913 0.208 1.883 
7311 Olfr920 5.146 0.908 0.176 1.876 
351 2610021K21Rik 3.679 0.900 0.245 1.866 
9751 Spire2 5.121 0.866 0.169 1.822 
1826 Brwd3 5.013 0.865 0.173 1.822 
9045 Scyl3 3.948 0.852 0.216 1.805 
10471 Tmtc4 3.764 0.852 0.226 1.805 
2746 Crip3 3.964 0.847 0.214 1.798 
2966 D10Bwg1379e 3.906 0.845 0.216 1.796 
1144 Angel1 3.955 0.844 0.214 1.796 
11560 Zfp786 4.417 0.844 0.191 1.794 
3363 Dsg2 3.724 0.836 0.225 1.786 
2298 Ceacam1 4.248 0.816 0.192 1.761 
994 Ahnak 3.601 0.801 0.222 1.743 
6395 Mrps12 3.657 0.800 0.219 1.741 
4180 Fstl4 4.475 0.798 0.178 1.738 
6939 Nr0b1 5.011 0.794 0.158 1.734 
11069 Vgll1 5.150 0.784 0.152 1.721 
5799 Lnx2 3.842 0.781 0.203 1.718 
6946 Nr2e3 4.434 0.780 0.176 1.717 
1551 Atp8b1 4.161 0.780 0.187 1.717 
397 2810474C18Rik 4.197 0.769 0.183 1.704 
5442 Kctd12b 3.544 0.765 0.216 1.699 
10344 Tmem116 4.038 0.753 0.186 1.685 
8857 Rps14 3.614 0.750 0.208 1.682 
3730 Etl4 3.550 0.740 0.209 1.670 
10829 Tyrp1 3.996 0.740 0.185 1.670 
2221 Cdc25a 3.711 0.733 0.198 1.663 
8322 Ptprt 3.630 0.728 0.200 1.656 
1336 Arhgap28 4.236 0.723 0.171 1.650 
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6609 N4bp2 4.312 0.723 0.168 1.650 
10872 Ube2o 3.764 0.719 0.191 1.646 
921 Adh4 4.185 0.713 0.170 1.640 
11269 Xrcc1 3.781 0.713 0.189 1.639 
6144 Med29 3.544 0.712 0.201 1.638 
7060 Oas3 3.624 0.708 0.195 1.634 
2273 Cdk6 3.721 0.706 0.190 1.632 
9095 Selp 4.641 0.690 0.149 1.613 
572 5430411K18Rik 3.904 0.654 0.167 1.573 
9841 Sstr2 3.581 0.646 0.180 1.565 
11275 Xrn1 3.652 0.624 0.171 1.541 
10026 Synrg 4.093 0.618 0.151 1.534 
5688 Lce1g 3.658 0.607 0.166 1.523 
3278 Dnajc5b 4.332 0.604 0.139 1.520 
712 A830093I24Rik 3.691 0.581 0.157 1.496 
11014 Usp42 3.587 0.567 0.158 1.481 
9191 Sfmbt2 3.547 0.562 0.158 1.476 
739 Abca8b 3.941 0.551 0.140 1.466 
4520 Gp5 3.532 0.512 0.145 1.426 
      
      
Downregulated genes (137) 
Row Gene Name Score(d) Numer. Denom. 
Fold 
Change 
8317 Ptprg -13.185 -4.928 0.374 0.033 
7755 Pik3c2g -6.858 -2.721 0.397 0.152 
4759 H60a -6.257 -2.472 0.395 0.180 
885 Adamdec1 -4.578 -2.288 0.500 0.205 
2648 Comp -3.843 -2.128 0.554 0.229 
9159 Serpinh1 -5.786 -2.099 0.363 0.233 
3583 Elf2 -6.086 -1.974 0.324 0.255 
10060 Taf15 -5.207 -1.860 0.357 0.275 
654 9430002A10Rik -9.927 -1.738 0.175 0.300 
2509 Clec4n -4.766 -1.732 0.363 0.301 
6378 Mrpl35 -8.219 -1.725 0.210 0.302 
3842 Fam160a1 -5.243 -1.707 0.326 0.306 
8511 Rasl12 -4.652 -1.701 0.366 0.308 
5789 Lmnb1 -3.472 -1.698 0.489 0.308 
6923 Nphp4 -4.563 -1.673 0.367 0.314 
8202 Psap -5.455 -1.618 0.297 0.326 
9767 Spr -6.492 -1.617 0.249 0.326 
9742 Spic -4.740 -1.615 0.341 0.326 
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6927 Npm3 -3.767 -1.590 0.422 0.332 
6925 Npl -4.721 -1.590 0.337 0.332 
1390 Arl6ip5 -3.847 -1.558 0.405 0.340 
4072 Fkbp10 -3.453 -1.453 0.421 0.365 
3315 Dok7 -6.717 -1.386 0.206 0.383 
4409 Gm11818 -4.220 -1.380 0.327 0.384 
10879 Ube2s -5.367 -1.371 0.255 0.387 
5508 Kifc5b -3.478 -1.369 0.393 0.387 
8465 Raly -4.057 -1.366 0.337 0.388 
6782 Nes -3.886 -1.364 0.351 0.388 
9859 St8sia5 -4.712 -1.342 0.285 0.394 
10500 Tnik -6.163 -1.337 0.217 0.396 
11242 Wsb1 -4.822 -1.333 0.276 0.397 
585 5730437N04Rik -4.442 -1.305 0.294 0.405 
103 1700001P01Rik -5.067 -1.296 0.256 0.407 
7583 Pdgfrb -3.575 -1.291 0.361 0.409 
747 Abcc3 -5.324 -1.288 0.242 0.409 
685 A130022J15Rik -3.553 -1.268 0.357 0.415 
10292 Tlr1 -3.868 -1.263 0.326 0.417 
872 Adam12 -5.826 -1.243 0.213 0.423 
4270 Gas5 -5.356 -1.238 0.231 0.424 
4912 Hmox1 -3.637 -1.227 0.337 0.427 
7071 Ociad1 -5.039 -1.225 0.243 0.428 
8643 Rgs16 -3.616 -1.223 0.338 0.428 
3089 Ddx25 -3.671 -1.216 0.331 0.431 
10958 Unkl -3.478 -1.199 0.345 0.436 
1690 BC030307 -4.613 -1.191 0.258 0.438 
9861 Stab1 -3.679 -1.188 0.323 0.439 
2179 Cd300lf -4.422 -1.184 0.268 0.440 
914 Adcy7 -4.062 -1.183 0.291 0.440 
2698 Cplx2 -3.866 -1.173 0.304 0.443 
9675 Sord -3.549 -1.172 0.330 0.444 
8402 Rab31 -3.513 -1.162 0.331 0.447 
5737 Lhfp -3.706 -1.158 0.312 0.448 
1280 Apoe -3.882 -1.154 0.297 0.449 
8567 Rbpms2 -3.590 -1.150 0.320 0.451 
5325 Itgb3 -4.426 -1.128 0.255 0.458 
8881 Rraga -3.971 -1.124 0.283 0.459 
3150 Dfna5 -3.736 -1.123 0.301 0.459 
8965 Samd14 -4.163 -1.115 0.268 0.462 
5843 Lrmp -3.505 -1.112 0.317 0.463 
9397 Slc27a6 -4.500 -1.108 0.246 0.464 
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10069 Taf8 -5.439 -1.106 0.203 0.465 
10878 Ube2s -4.357 -1.105 0.254 0.465 
3839 Fam154b -5.723 -1.103 0.193 0.466 
10160 Tctex1d2 -4.348 -1.093 0.251 0.469 
4400 Gm10083 -8.231 -1.092 0.133 0.469 
10943 Ulbp1 -3.481 -1.085 0.312 0.472 
2614 Col15a1 -3.622 -1.084 0.299 0.472 
1924 Cadm4 -4.735 -1.084 0.229 0.472 
4226 Gabbr1 -5.145 -1.071 0.208 0.476 
619 6430590A07Rik -6.043 -1.063 0.176 0.479 
10493 Tnfrsf4 -4.348 -1.051 0.242 0.483 
2168 Cd207 -3.591 -1.050 0.292 0.483 
8623 Rftn2 -3.531 -1.047 0.297 0.484 
919 Add2 -3.548 -1.025 0.289 0.491 
136 1700020L24Rik -4.172 -1.020 0.244 0.493 
2781 Csdc2 -3.615 -1.017 0.281 0.494 
7564 Pde1a -3.517 -1.012 0.288 0.496 
541 4933408B17Rik -4.936 -1.010 0.205 0.497 
364 2610301B20Rik -4.919 -1.007 0.205 0.497 
9206 Sfxn4 -4.818 -1.005 0.209 0.498 
5354 Izumo4 -5.728 -0.993 0.173 0.502 
391 2810055G20Rik -4.385 -0.993 0.226 0.503 
1730 Bcl6b -3.705 -0.992 0.268 0.503 
3756 Exosc8 -4.339 -0.988 0.228 0.504 
8421 Rab5c -3.595 -0.983 0.273 0.506 
5760 Limk1 -3.939 -0.971 0.247 0.510 
6300 Mobkl2c -3.509 -0.966 0.275 0.512 
1672 BC017612 -3.931 -0.955 0.243 0.516 
4046 Fgfr1 -4.476 -0.955 0.213 0.516 
4011 Fcrls -3.522 -0.953 0.271 0.517 
1789 Bmp8b -4.028 -0.950 0.236 0.518 
2837 Ctnnbip1 -3.760 -0.939 0.250 0.522 
6999 Nub1 -3.570 -0.929 0.260 0.525 
4137 Foxj3 -4.929 -0.925 0.188 0.527 
1955 Cand2 -4.082 -0.921 0.226 0.528 
6456 Mtap6 -3.757 -0.915 0.244 0.530 
941 Adrb1 -3.530 -0.914 0.259 0.531 
10306 Tm7sf4 -3.712 -0.914 0.246 0.531 
11236 Wnt5a -3.638 -0.913 0.251 0.531 
3995 Fbxw2 -4.693 -0.909 0.194 0.533 
9667 Sod3 -3.913 -0.897 0.229 0.537 
10180 Tekt2 -3.533 -0.897 0.254 0.537 
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2292 Cdrt4 -5.797 -0.896 0.155 0.537 
447 4831426I19Rik -3.724 -0.891 0.239 0.539 
8254 Ptbp1 -4.349 -0.888 0.204 0.540 
11484 Zfp459 -3.798 -0.883 0.232 0.542 
8516 Rassf4 -3.489 -0.868 0.249 0.548 
716 A930005I04Rik -3.757 -0.867 0.231 0.548 
428 3110070M22Rik -5.114 -0.860 0.168 0.551 
3825 Fam125b -3.478 -0.849 0.244 0.555 
8417 Rab44 -3.869 -0.836 0.216 0.560 
1843 Btk -3.539 -0.835 0.236 0.561 
8570 Rcbtb2 -3.948 -0.833 0.211 0.561 
5958 Lzic -3.662 -0.826 0.226 0.564 
556 4933439C10Rik -3.485 -0.825 0.237 0.565 
2334 Cep135 -3.937 -0.816 0.207 0.568 
10737 Ttc12 -3.762 -0.806 0.214 0.572 
2854 Cttn -3.565 -0.782 0.219 0.581 
5861 Lrrc23 -4.208 -0.781 0.186 0.582 
321 2410002O22Rik -3.948 -0.772 0.195 0.586 
2178 Cd300ld -4.191 -0.771 0.184 0.586 
5783 Lmbr1l -4.270 -0.768 0.180 0.587 
304 2310047B19Rik -4.005 -0.759 0.190 0.591 
4618 Grb10 -3.448 -0.757 0.220 0.592 
6003 Manbal -3.599 -0.737 0.205 0.600 
10669 Trpc2 -3.928 -0.729 0.186 0.603 
10492 Tnfrsf25 -4.752 -0.722 0.152 0.606 
1407 Arpc3 -3.718 -0.715 0.192 0.609 
450 4833420G17Rik -3.810 -0.695 0.182 0.618 
4868 Hip1 -3.553 -0.667 0.188 0.630 
959 Aftph -3.806 -0.652 0.171 0.636 
10862 Ube2i -3.493 -0.650 0.186 0.637 
846 Actg-ps1 -3.553 -0.640 0.180 0.642 
3254 Dnaja4 -3.447 -0.626 0.182 0.648 
421 3110021A11Rik -3.574 -0.624 0.175 0.649 
5443 Kctd13 -3.792 -0.565 0.149 0.676 
9048 Sdc3 -3.921 -0.534 0.136 0.691 
      
      
Estimated Miss rates for Delta=1.69072742642906   
 Quantiles Cutpoints Miss Rate(%)  
 0 -> 0.05 
-3.413 -> -
2.091 94.320   
 0.05 -> 0.1 -2.091 -> - 81.430   
 146 
1.626 
 0.1 -> 0.15 
-1.626 -> -
1.317 66.320   
 0.15 -> 0.2 
-1.317 -> -
1.052 45.540   
 0.2 -> 0.25 
-1.052 -> -
0.822 25.010   
 0.25 -> 0.75 
-0.822 -> 
0.859 6.100   
 0.75 -> 0.8 
0.859 -> 
1.077 36.040   
 0.8 -> 0.85 
1.077 -> 
1.327 50.870   
 0.85 -> 0.9 
1.327 -> 
1.653 64.380   
 0.9 -> 0.95 
1.653 -> 
2.154 78.840   
 0.95 -> 1 
2.154 -> 
3.507 92.930   
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Supplementary Table A2-2: Lines of Evidence for Nimblegen 
Sequence Capture Design 
Name Description 
Number 
of 
genes 
Breast Cancer: 
Biomarker 
BioScience 
SuperArray 
BioScience Super Array Oligo GEArray Human Breast 
Cancer Biomarker Microarray (OHS-402). 264 genes 
useful as molecular markers in the prognosis and 
diagnosis of breast cancer. This array is designed with 
clinical researchers and research pathologists in mind. 
The genes in the diagnosis markers group are highly 
associated with breast cancer based on the published 
literature. The genes in the prognosis markers group 
have been successfully used to predict the clinical 
outcome of breast cancer. [Array Details] 
262 
Breast Cancer: 
Mouse Mammary 
Cancer MMV 
Theodorou, et. al., MMTV insertional mutagenesis 
identifies genes, gene families and pathways involved 
in mammary cancer. Nature Genetics 39, 759 - 769 
(2007) [PubMed.] 
33 
Breast Cancer: 
Mutation Profiling 
This list includes only those genes which were found to 
be mutated in breast cancer, as derived from: Roman 
Thomas, et. al, High-throughput oncogene mutation 
profiling in human cancer. Nat Genet. 2007 
Mar;39(3):347-51. [PubMed]. 
6 
Breast Cancer: 
Novel Breast 
Cancer 
Suceptibility Loci 
List derived from DF Easton et. al, Genome-wide 
association study identifies novel breast cancer 
susceptibility loci. Nature. 2007 Jun 
28;447(7148):1087-93. [PubMed] 
11 
Breast CAN-genes, derived from Wood LD, et. al. The 
genomic landscapes of human breast and colorectal 
cancers., 2007 Nov 16;318(5853):1108-13. Epub 2007 
Oct 11. [PubMed]. 
Breast Cancer: 
CAN-genes Score is weighted by CaMP ranking: 6.0 + (140-
rank)/140. The CaMP score (cancer mutation 
prevelance) score reflects the probability that the 
number of mutations observed in a gene reflects a 
mutation frequency that is higher than that expected to 
be observed by chance. 
136 
 148 
Breast Cancer: 
Protein Kinase 
Screen 
This list includes all mutations found in primary breast 
cancer samples and breast cancer cell lines, in a 
survey of 518 protein kinases. The list does not include 
mutations from the hyper-mutator sample PD0119. 
Derived from Philip Stephens, et. al, A screen of the 
complete protein kinase gene family identifies 
diverse patterns of somatic mutations in human 
breast cancer. Nature Genetics 37, 590 - 592 (2005). 
[PubMed]. Primary data obtained from: Sanger Cancer 
Genome Project. 
36 
Breast Cancer: 
Susceptibility 
This list includes all genes which have been linked to 
breast cancer susceptibility, as of Dec. 2007. Derived 
from Michael R Stratton, Nazneen Rahman, The 
emerging landscape of breast cancer susceptibility. 
Nature Genetics, Vol. 40, No. 1. (27 December 2007) 
[PubMed] 
15 
General Cancer: 
Atlas Human 
Cancer 1.2 Array 
Atlas Human Cancer 1.2 Array from Clontech. [Array 
Details] 1114 
General Cancer: 
BioScience 
SuperArray 
BioScience Super Array Oligo GEArray Human Cancer 
Microarray (OHS-802). The Oligo GEArray Human 
Cancer Microarray profiles profiles the expression of 
440 genes that include members of several different 
pathways frequently altered during the progression of 
cancer. This array allows you to examine specific 
aspects of tumor progression. The genes represented 
by this array include but are not limited to tumor 
suppressors, oncogenes, signal transduction 
molecules, growth factors, growth factor receptors, 
and angiogenesis factors [Array Details] 
440 
General Cancer: 
DNA Damage 
Model 
Halazonetis TD, et. al, An oncogene-induced DNA 
damage model for cancer development. Science. 2008 
Mar 7;319(5868):1352-5 [PubMed.] 
15 
General Cancer: 
Land Colon 
Cancer Synergy 
McMurray HR, et. al, Synergistic response to oncogenic 
mutations defines gene class critical to cancer 
phenotype. Nature. 2008 Jun 19;453(7198):1112-6. 
Epub 2008 May 25. [PubMed.] 
95 
General Cancer: 
Mutagenesis in 
p19ARF and p53 
deficient mice 
This list includes the top 346 Common Insertion Sites 
(CIS) identified in: AG Uren et. al., Large-scale 
mutagenesis in p19(ARF)- and p53-deficient mice 
identifies cancer genes and their collaborative 
networks. Cell. 2008 May 16;133(4):727-41. [PubMed] 
309 
 149 
General Cancer: 
Review Paper by 
Hahn and 
Weinberg 
Hahn WC, Weinberg RA., Modelling the molecular 
circuitry of cancer. Nat Rev Cancer. 2002 
May;2(5):331-41. [PubMed]. Gene list derived from 
MSKCC CancerGenes Resource. 
41 
General Cancer: 
Sanger Cancer 
Gene Census 
Sanger Cancer Gene Census, [Census Details] The 
Cancer Gene Census is an ongoing effort to catalogue 
those genes for which mutations have been causally 
implicated in cancer. The original census and analysis 
was published in Nature Reviews Cancer and 
supplemental analysis information related to the paper 
is also available. 
340 
General Cancer: 
Review Paper by 
Volgestein and 
Kinzler 
Vogelstein B, Kinzler KW., Cancer genes and the 
pathways they control. Nat Med. 2004 Aug;10(8):789-
99. [PubMed]. Gene list derived from MSKCC 
CancerGenes Resource.  If implicated with breast 
cancer, score is set to 3.5. Otherwise, defaults to 3. 
112 
Lung Cancer: 
Comb Kinase 
Survey 
Genes in this paper were ranked according to activity 
level and frequency of activation in cell lines and 
tumors. Special Scoring to incorporate this ranking 
may be needed. Rikova K, et. al. Global survey of 
phosphotyrosine signaling identifies oncogenic kinases 
in lung cancer. Cell. 2007 Dec 14;131(6):1190-203. 
[PubMed] 
25 
Lung Cancer: 
Myerson 
Weir BA, et. al., Characterizing the cancer genome in 
lung adenocarcinoma. Nature. 2007 Dec 
6;450(7171):893-8. Epub 2007 Nov 4. [PubMed] 
24 
MCM Associated 
Genes 
Gins complex, mcm, damage checkpoints with dual 
roles in fork stability and fork stalling response, etc. 
Diffley Genes and Dev. 2008, Gambus Trends in Cell 
biology 2007. Forsburg Biochemical Society 
Transactions 2008. Forsburg Molecular and Cellular 
Biology 2008. List manually curated. 
22 
TCGGA: GBM 
Phase 1 
TCGA Target List for Phase 1 of Glioblastoma 
multiforme. 583 
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Supplementary Table A2-3: MCAD Basic Default Scoring 
Category Score 
Mutation or genomic association study: breast cancer specific. 6 
Mutation study: general cancer. 5 
Biological pathways or interactions: breast cancer or MCM4 
specific. 4 
Biological pathways or background: general cancer. 3 
Custom microarray design: breast cancer specific. 2 
Custom microarray design: general cancer. 1 
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Supplementary Table A2-4: Sequence Capture Chip Gene List 
1200003C05Rik Adsl Arnt Bcl9 Cbfa2t3 Cdc6 
1300001I01Rik Aff1 Asl Bcl9l Cbfb Cdc73 
1600014C10Rik Aff3 Asns Bcr Cbl Cdh1 
2010106G01Rik Aff4 Aspm Bex1 Ccdc6 Cdh11 
2310044G17Rik Aif1 Aspscr1 Bgn Ccdc69 Cdh20 
2610207I05Rik Aim1 Astn2 Bid Ccl9 Cdk10 
2810002O09Rik Ak1 Atad2 Bik Ccnb1 Cdk2 
3110082I17Rik Akap1 Atf1 Birc3 Ccnb1ip1 Cdk4 
4930588N13Rik Akap9 Atic Birc5 Ccnb2 Cdk5 
4932417H02Rik Akna Atm Blm Ccnd1 Cdk6 
5330417C22Rik Akt1 Atn1 Blmh Ccnd2 Cdk8 
5430405G05Rik Akt2 Atp2b1 Bmp6 Ccnd3 Cdk9 
5430411K18Rik Alb Atp8a1 Bmpr1a Ccne1 Cdkl1 
5730559C18Rik Aldh4a1 Atp8b1 Bnip3 Ccne2 Cdkl2 
6330527O06Rik Aldh6a1 Atr Braf Ccr7 Cdkn1a 
6330548G22Rik Alk Aurka Brca1 Ccr9 Cdkn1b 
6720460F02Rik Amfr Aurkb Brca2 Ccrk Cdkn1c 
A2m Angpt1 Auts2 Brd4 Cct4 Cdkn2a 
Abat Ank Axin2 Brip1 Cd163l1 Cdkn2b 
Abca1 Ankk1 Axl Btg1 Cd2 Cdkn2d 
Abca3 Ankrd1 B2m Btg2 Cd27 Cdt1 
Abcb1a Anpep Bad Btk Cd34 Cdx2 
Abcb8 Anxa7 Bag1 Bub1 Cd3e Ceacam5 
Abcc4 Ap2b1 Bag3 Bub1b Cd48 Cebpa 
Abcg2 Apc Bard1 C030046E11Rik Cd55 Cenpa 
Abi1 Apc2 Bat2 C130038G02Rik Cd59b Cenpf 
Abi2 Ar Bax C330024D12Rik Cd68 Cenpn 
Abl1 Araf Bbc3 C630035N08Rik Cd70 Centb1 
Abl2 Arfgef2 Bbs7 Cacna1f Cd72 Centd3 
Abp1 Arhgap1 BC033915 Cadm1 Cd97 Centg1 
Acadm Arhgap19 BC059842 Calcr Cdc123 Centg2 
Acads Arhgap24 Bcl10 Camk1g Cdc25a Cep97 
Acsl6 Arhgap25 Bcl11a Car9 Cdc25b Cfp 
Actb Arhgap26 Bcl11b Cars Cdc25c Cgrrf1 
Acy1 Arhgef12 Bcl2 Casc5 Cdc2l5 Chaf1a 
Ada Arhgef2 Bcl2l1 Casp8 Cdc42 Chd1 
Adam12 Arid4a Bcl3 Casp9 Cdc42bpa Chd5 
Adm Armc1 Bcl6 Catsperb Cdc42bpb Chek1 
 152 
Adrbk1 Armc7 Bcl7a Cav1 Cdc45l Chek2 
Chic2 Cp Ddit3 Eif2c2 Etv4 Fgfr1op2 
Chl1 Cpz Ddr1 Eif4a2 Etv6 Fgfr2 
Chn1 Creb1 Ddr2 Eif4e Evi1 Fgfr3 
Chpt1 Crebbp Ddx10 Elavl2 Evl Fgr 
Chst1 Crtc3 Ddx6 Elf1 Ewsr1 Fh1 
Cic Csf1 Degs1 Elf4 Ext1 Fhit 
Ciita Csf1r Dek Elk3 Ext2 Fhod3 
Cirbp Csf3 Dennd3 Ell Ezh2 Fip1l1 
Cit Csk Depdc1a Eml4 Ezr Fkbp10 
Ckmt1 Csnk1d Dffb Eng F2rl1 Flcn 
Cks2 Csnk1g2 Dgka Eno3 Fanca Fli1 
Clcn3 Cspp1 Dhx40 Ep300 Fancc Flna 
Cldn10a Cstad Dhx58 Epha1 Fancd2 Flnb 
Clec12a Ctnna1 Dip2c Epha10 Fance Flnc 
Clic1 Ctnnb1 Dixdc1 Epha2 Fancf Flt1 
Clk1 Ctps Dlg3 Epha4 Fancg Flt3 
Clk2 Ctsb Dpagt1 Epha5 Fas Flt4 
Clk3 Ctsc Dpp10 Ephb1 Fastk Fn1 
Clp1 Ctsd Dpp4 Ephb2 Fbp1 Fnbp1 
Cltc Ctse Dpyd Ephb3 Fbxo15 Fos 
Cnbp Cugbp2 Dst Ephb4 Fbxo31 Fosl1 
Cnbp2 Cxcl1 Dtl Eps15 Fbxo5 Fosl2 
Cnnm4 Cxcl15 Dusp15 Eras Fbxw7 Foxc2 
Cnot8 Cxcr7 Dusp2 Erbb2 Fcgr2b Foxo1 
Cnr2 Cyb5 Dvl1 Erbb3 Fchsd2 Foxo3 
Cntn3 Cyb5r4 Dvl3 Erbb4 Fert2 Foxo4 
Cntn6 Cyc1 Dyrk2 Erc1 Fes Foxp1 
Col11a1 Cyld E2f1 Ercc2 Fev Frap1 
Col19a1 Cyp19a1 E2f2 Ercc3 Fgd6 Frem1 
Col1a1 Cyp1a1 E2f3 Ercc4 Fgf1 Frzb 
Col1a2 Cyr61 E2f5 Ercc5 Fgf10 Fstl3 
Col3a1 D430039N05Rik E330009J07Rik Erg Fgf18 Fus 
Col4a2 Dapk1 Ebf4 Ergic1 Fgf3 Fut8 
Col6a2 Dbf4 Ebi2 Esm1 Fgf4 Fzd2 
Col6a3 Dbn1 Ect2 Espn Fgf6 Fzd5 
Col7a1 Dcc Egf Esr1 Fgf7 Fzd9 
Col9a3 Dck Egfr Esr2 Fgf8 Gab1 
Coro1a Dclk3 Egln1 Etl4 Fgf9 Gabbr1 
Coro2a Dcn Egr1 Ets1 Fgfr1 Gadd45b 
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Cox6c Ddb2 Egr3 Etv1 Fgfr1op Galnt5 
Gapdh Grb2 Hoxa3 Il21r Kif21a Ly6e 
Garnl3 Grb7 Hoxa9 Il22ra2 Kif21b Lyl1 
Gas6 Grin2d Hoxc11 Il2ra Kif3b Lyn 
Gas7 Grk6 Hoxc13 Il6st Kit Mad2l1 
Gata1 Gsdmd Hoxd11 Ilk Kitl Maf 
Gbe1 Gse1 Hoxd13 Ing1 Klf15 Mafb 
Gca Gsn Hps5 Inhbe Klf3 Mafk 
Gcn1l1 Gspt1 Hras1 Ins2 Klf6 Magee1 
Gdf15 Gstm1 Hrasls Ints7 Klk13 Malt1 
Gen1 Gstm3 Hrb Iqgap1 Kpna2 Mamdc4 
Gfi1 Gucy2f Hrbl Irf3 Kras Maml2 
Gfi1b H2afy Hsp90aa1 Irf4 Krt18 Man2b1 
Gga1 Haao Hsp90ab1 Irs4 Krt19 Map2k1 
Ggh Hbegf Hspa5 Itga3 Krt2 Map2k2 
Gins1 Hck Hspa8 Itga6 Krt9 Map2k4 
Gins2 Hdac1 Hspa9 Itga9 Ktn1 Map2k7 
Gins3 Hdac4 Htatip Itgal Lama1 Map3k1 
Gins4 Hdgf Icam5 Itgb1 Lamb1-1 Map3k14 
Git1 Hdlbp Id1 Itgb3 Lasp1 Map3k8 
Glb1 Helz Id2 Itgb4 Lass4 Mapk10 
Glcci1 Hes1 Id4 Itk Lck Mapk11 
Gli1 Hey2 Ifitm1 Itpkb Lcn2 Mapk12 
Gm672 Hgf Ifitm2 Ivns1abp Lcp1 Mapk13 
Gm694 Hgfac Ifnar1 Jag1 Ldha Mapk14 
Gmps Hif1a Igf1 Jag2 Ldhb Mapk3 
Gnai1 Hip1 Igf1r Jak2 Lef1 Mapk7 
Gnas Hist1h4i Igf2 Jarid1a Lfng Mapk8 
Gnaz Hjurp Igf2r Jarid1b Lhfp Mapk9 
Golga5 Hlf Igfbp2 Jazf1 Lifr Mapkbp1 
Gopc Hmga1 Igfbp3 Jdp2 Litaf Mapre1 
Gpc3 Hmga2 Igfbp4 Jmjd1c Lmo1 Mapre2 
Gphn Hmgb2 Igfbp5 Jun Lmo2 Mark4 
Gpr126 Hmgb3 Ihpk2 Junb Lpp Mas1 
Gpr149 Hmgn2 Ikbkb Jund Lrba Mast2 
Gpr180 Hmmr Ikzf1 Kctd15 Lrpap1 Matn3 
Gpr19 Hnf1a Ikzf3 Kdr Lrrc7 Mbd2 
Gpr56 Hnrnpa2b1 Il13 Kdsr Lrrc8d Mbip 
Gpsm2 Hnrnpu Il15 Keap1 Lrrfip1 Mcam 
Grap2 Hoxa11 Il1b Khdrbs1 Lsp1 Mcc 
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Grb10 Hoxa13 Il2 Kif14 Ltf Mccc1 
Mcl1 Mmp13 Myd88 Nmu Paqr3= Plac8 
Mcm10 Mmp14 Myh1 Nono Pard6g Plag1 
Mcm2 Mmp15 Myh11 Nos2 Parvb Pld2 
Mcm3 Mmp17 Myh9 Notch1 Patz1 Plekha6 
Mcm4 Mmp1a Mylc2pl Notch2 Pax3 Plekha8 
Mcm5 Mmp2 Mylk Notch3 Pax5 Plg 
Mcm6 Mmp9 Myo18b Notch4 Pax7 Pltp 
Mcm7 Mn1 Myo1g Npm1 Pax8 Plxdc2 
Mcm8 Mnx1 Myo3a Nr4a1 Pbx1 Pmaip1 
Mcm9 Morc3 Myrip Nr4a3 Pcdhb22 Pml 
Mdm2 Mos Myst4 Nras Pcm1 Pms1 
Mdm4 Mpl Naca Nrg1 Pcna Pms2 
Mds1 Mpp7 Nbea Nsd1 Pcsk7 Pot1a 
Med13 Mprip Nbn Nsmce1 Pctk1 Pou2af1 
Med24 Mpzl2 Nckipsd Ntrk1 Pctk2 Pou5f1 
Mef2d Mrc1 Ncoa2 Ntrk3 Pdcd11 Ppapdc3 
Melk Mre11a Ncoa4 Numa1 Pde4d Pparg 
Men1 Mrpl13 Ncoa6 Nup133 Pde4dip Ppm1e 
Mertk Mrpl15 Ndc80 Nup210 Pdgfb Ppp1r10 
Met Ms4a10 Ndrg1 Nup214 Pdgfra Ppp2cb 
Mgat1 Ms4a7 Ndufa4l2 Nup98 Pdgfrb Prcc 
Mgat4a Msh2 Nedd4l Nusap1 Pdpk1 Prdm16 
Mgmt Msh6 Nf1 Nut Pecam1 Prkaa2 
Mib1 Msi2 Nf2 Oaf Per1 Prkar1a 
Mif Msn Nfatc3 Odz1 Perp Prkca 
Mki67 Mt3 Nfe2 Odz3 Phf10 Prkcb1 
Mkl1 Mta3 Nfkb1 Olig2 Phox2b Prkcbp1 
Mknk2 Mtcp1 Nfkb2 Omd Picalm Prkcc 
Mlf1 Mtdh Nfkbib Orai2 Pigv Prkcd 
Mlf1ip Mtmr2 Nfkbil1 Orc6l Pik3ca Prkcz 
Mlf2 Mtus1 Nid1 Otof Pik3cb Prkd1 
Mlh1 Muc1 Nin Otud7b Pik3cd Prkd2 
Mll1 Muc19 Ninj1 Oxct1 Pik3cg Prkg1 
Mllt1 Mutyh Nkd2 P2ry5 Pik3r5 Pros1 
Mllt10 Mx2 Nkx2-1 Pa2g4 Pim1 Prpf4b 
Mllt11 Myb Nmb Padi1 Pim2 Prps1 
Mllt3 Mybl2 Nmbr Pafah1b2 Pir Prr3 
Mllt4 Myc Nme1 Pag1 Pitx2 Prrx1 
Mllt6 Mycl1 Nme2 Palb2 Pkn1 Psap 
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Mmp11 Mycn Nme3 Paqr3 Pla2g7 Psip1 
Ptbp1 Rcsd1 Runx2 Slc6a3 Syk Thoc5 
Ptch1 Recql4 S1pr1 Slc8a3 Tacc2 Thrap3 
Ptcra Recql5 Satb1 Slc9a10 Taf1 Timeless 
Pten Rel Sbds Slc9a8 Taf15 Timp1 
Ptgis Ret Sbk1 Smad2 Tal1 Tk1 
Ptma Rfc4 Sbsn Smad4 Tal2 Tln1 
Ptn Rfx2 Scml4 Smad7 Taok3 Tlx1 
Ptp4a3 Rgl1 Scn3b Smarcb1 Tap2 Tlx3 
Ptpn1 Rgs2 Sdhb Smg6 Tax1bp1 Tmem123 
Ptpn11 Rhoa Sdhc Smo Tbxa2r Tmem16f 
Ptpn22 Rhod Sdhd Sms Tcea1 Tmem50a 
Ptprc Rhof Sell Socs1 Tcf12 Tmhs 
Ptprcap Rhoh Selplg Sod3 Tcf7 Tmie 
Ptprd Rims2 Sema3d Sorl1 Tcfap4 Tmprss2 
Ptpre Rnf19a Sema4b Sp1 Tcfe2a Tmprss6 
Pvrl4 Rock1 Sema4d Sp110 Tcfe3 Tnf 
Rab11fip4 Rorc Sema5b Specc1 Tcfeb Tnfaip8 
Rab17 Ros1 Sema7a Spn Tcl1 Tnfrsf10b 
Rab37 Rp1l1 Sephs2 Spna2 Tcof1 Tnfrsf17 
Rab40b Rpa1 Serinc3 Src Tdrd6 Tnfrsf18 
Rabep1 Rpgrip1 Serpinb2 Srgn Tec Tnfrsf1b 
Rac2 Rpl11 Serpine1 Ss18 Tecta Tnnt2 
Rad21 Rpl22 Set Ss18l1 Tek Top1 
Rad51 Rpn1 Sfmbt2 Ssbp3 Terf1 Tox3 
Rad51l1 Rprm Sfpq St6galnac5 Terf2 Tpm4 
Raf1 Rps27a Sfrp2 St7 Tert Tpr 
Rai2 Rps6ka1 Sfrs3 Stam Tesk1 Trim24 
Ranbp17 Rps6ka2 Sgms1 Stard10 Tesk2 Trim33 
Rap1gds1 Rps6ka3 Sh3d19 Stard8 Tex15 Triobp 
Raph1 Rps6ka4 Sh3gl1 Stat1 Tfg Trip11 
Rara Rps6kb1 Shh Stat3 Tfpt Trp53 
Rasal2 Rps6kc1 Shisa5 Stat5a Tfrc Trp53bp1 
Rasgrp1 Rras2 Six4 Stil Tg Trpm7 
Rasgrp2 Rreb1 Skil Stk11 Tgfa Tsc1 
Rasl11a Rrm2 Sla2 Stk3 Tgfb1 Tsc2 
Rb1 Rspo2 Slamf6 Stk32b Tgfb2 Tsg101 
Rbl2 Rspo3 Slc14a1 Stmn4 Tgfb3 Tshr 
Rbm10 Rtn4ip1 Slc27a3 Sufu Tgfbr1 Tspan14 
Rbm15 Runx1 Slc2a3 Sulf2 Tgfbr2 Ttl 
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Rcbtb2 Runx1t1 Slc45a3 Suz12 Thbs3 Ttll10 
Ttll12 Zfp668 Vim Wnk1 Wrn Zeb1 
Ttn Zfp710 Vpreb2 Wnt1 Wt1 Zeb2 
Tyk2 Zfp74 Was Wnt2 Xdh Zfp384 
Tyro3 Zfyve26 Wasf2 Wnt3 Xirp1 Zfp385a 
Ubxd5 Zmym2 Wdr91 Wnt3a Xpa Zfp64 
Uhrf1 Znrf1 Wee1 Wnt5a Xpc Zfp646 
Unc45b Veph1 Whsc1 Wnt8b Xrcc6  
Vegfa Vhl Whsc1l1 Wnt9a Zbtb16  
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Supplementary Table A2-5: Sequence Capture Fold Enrichment 
Validation by qPCR 
  
Nimblegen Internal Control 
Genes 
Breast Cancer 
Candidate 
Genes 
Negative 
Control 
Genes 
  
        
        
Sample 
1 
(Runx2) 
2 
(Prkg1) 
3 
(Smg1) 
4 
(Nlk) 
1 
(Brca1) 
2 
(Egfr) 
1 
(Hmx1) 
2 
(Pgr) 
2044B 77.28 324.03 369.73 80.32 136.21 277.88 0.01 0.00 
12352         409.58 567.71 0.70 0.00 
15259         487.30 744.43 1.16 0.01 
2042 30.49 79.27 95.96 38.69 29.63 98.31 0.29 0.10 
C3H 
WT 59.96 198.59 207.55 111.56 65.36 265.64 0.24 0.13 
 
 
 
Supplementary Table A2-6: Sequence Capture Summary Statistics 
Sample Total Reads 
Number & % 
Aligned Reads 
% Aligned 
Reads On- 
Target 
Fold 
Enrichment 
of Target 
Regions 
Average 
Fold 
Coverage 
2044b  8072818 7560670 (93.7%) 62.90% 301.1 36.92 
44 nt- 12188052 
(85.5%) 34.50% 165 32.61 2042 14254508 64 nt- 10592292 
(74.3%) 35.10% 168.1 41.83 
12352 24635029 18975145 (77.0%) 56.50% 270.3 81.29 
15259 23479616 21039263 (89.6%) 58.90% 282 94.02 
C3H 
WT 10352987 9137591 (88.3%) 41.00% 196.4 29.1 
Average 16158992 13248836 (84.7%) 48.10% 230 52.6 
A single 88 nt read length run was conducted on sample 2042, and reads were 
subsequently shortened during analysis to both 64 and 44 nt to reduce error rate.  
The 44 nt length was used for SNP and mutation calling.  Fold enrichment was 
calculated as (% Reads on-target)/(Target region in bases/mm9 genome size in 
bases), where target region = 5.69 Mb, and mm9 genome size = 2,726 Mb. 
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Supplementary Table A2-7: Proportions of Fold Coverage 
Depth for On-Target Sequence Capture Regions 
  
            
  Fold Coverage   
Sample ≥1 ≥3 ≥5 ≥10 ≥25   
15259 100% 99% 98% 95% 86%   
12352 100% 99% 98% 96% 85%   
2044B 99% 95% 92% 82% 55%   
2042 (44 nt) 97% 92% 87% 75% 49%   
2042 (64 nt) 98% 93% 89% 80% 57%   
C3H 97% 91% 85% 72% 44%   
              
A single 88 nt read length run was conducted on sample 2042, and 
reads were subsequently shortened during analysis to both 64 and 
44 nt to reduce error rate.  The 44 nt length was used for SNP and 
mutation calling.   
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Supplementary Table A2-8: Validated Gene Mutations in Chaos3 Mammary 
Tumors 
Sample Name Mutation Effect Description Function 
15259 Myo1g G/A Splice 
Site 
Myosin-Ig   Precursor of minor 
histocompatibility antigen 
HA-2 
2042 Acsl6 G/T E>D Long-chain-
fatty-acid--
CoA ligase 6  
Catalyze formation of 
acyl-CoA from fatty acids, 
ATP, and CoA.  
2042 Tdrd6 T/C H>R Tudor 
domain-
containing 
protein 6  
Required for 
spermiogenesis, 
chromatoid body 
architecture, and 
regulation of miRNA 
expression. 
2042 Ttn C/T D>N Titin 
(Connectin)  
2044b Ttn C/G V>L Titin 
(Connectin)  
Cardiac and skeletal 
muscle protein. Disease 
Associations: Familial 
Cardiomyopathy, Tibial 
muscular dystrophy 
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Supplementary Table A2-10: Cancer and Immunity Related 
Genes in Chaos3 CNAs (Extended) 
  
      
  
Amplified 
  
  
    
Function Chr 16 Chr 12 Chr 17 
Metastasis Tmprss7      
Pluripotency Dppa4, Dppa2  
    
Apoptosis/ 
Necrosis Ift57      
Signal Transduction 
(Integrin, PiK3) Trat1  Adam6    
Immunity/ 
Inflammation 
Btla, CD200, 
CD96, Pvrl3, 
Cd47, Retnlb, 
Retnla  Ig/abParts    
Upregulated in 
Cancer 
Igsf11, Upk1b, 
Gcet2  Tle6-like   
New Candidate 
Region 
  
  
Tcp10 
Cancer & Immunity 
Related Genes 15 6   
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Supplementary Table A2-10: (Continued) 
 
  
Deleted 
  
          
Function Chr 4 Chr 5 Chr 11 Chr 10 Chr 19 
Tumor 
Suppressor 
  
Cdk2ap1 Nf1 Apc2 
Cdk2ap2, 
Pten 
DNA 
Checkpoint/ 
Repair Mtor/Frap1  
Rad9b, 
Kntc1, 
Gtf2h3, 
Setd8 
  Stk11 Rad9 
Apoptosis/ 
Necrosis 
Dffa, 
Aptid1, 
Ube4b, 
Rere, 
Kif1b, 
Wdtc1 Diablo 
Tnfaip1, 
Lgals9 
Atcay, 
Cdc34, 
Dapk3, 
Gadd45b, 
Oaz1, 
Tmprss9   
Signal 
Transduction 
(MapK, Integrin, 
Wnt, PiK3) 
Pik3cd, 
Map3k6 Il31 Nlk, Ksr1 
Csnk1g2, 
Gna15, 
Gng7, 
Mknk2 
Rps6kb2, 
Coro1b, 
Map2k2, 
Ndufs8 
Immunity/ 
Inflammation 
Ptafr, 
Pafah2  
    
Tbxa2r, 
Gpx4, 
Lingo3 
Tcirg1, 
Clcf1 
Other Cancer 
Related 
Eno1, 
Arid1a, 
Fgr, Pdik1l, 
Sfn 
Atp2a2, 
Anapc7, 
Bcl7a, 
Anapc5, 
Sbno1, 
P2rx7   
Matk, 
Mum1, 
Shc2  
Minpp1, 
Rhod  
New Candidate 
Region 
        
Syt12 
Cancer & 
Immunity 
Related Genes 16 13 5 18 11 
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Supplementary Table A2-11 Legend: Chaos3 CGH Deleted Regions (Top) and 
Amplified Regions (Bottom).  qPCR values are presented in percent of genomic DNA 
compared to C3H wild-type.  Orange coloration indicates deletion (<80%), and blue 
indicates amplification (>115%).  Cancer-related genes, deleted at high frequency in 
mammary tumors specifically, are underlined.  Nf1 deletion was validated at the 5' and 
3' ends of the gene (Omg lies within an Nf1 intron near the 3' end).  Note that copy 
number differences between Nf1 5' and 3' are observed in some tumors, indicating a 
breakpoint within the Nf1 gene.  Deletion calls were made as follows: Heterozygous = 
15-80%; Homozygous = <15%; If either Nf1 or Omg were <15%, the tumor sample 
was called homozygous deleted because full Nf1 transcripts cannot be made.  
Nucleotide positions are from the mm9 mouse assembly.
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Supplementary Table A2-11: qPCR Analysis of Amplifications and 
Deletions in Chaos3 Mammary Tumors  
  
                  
    Chaos3 Mammary Tumor Samples 
    1 2 3 4 5 6 7 8 
Deletion Regions 15259 
12351 
L 
12353 
A 12352 
2044B 
CL 
11929 
A 16168 16898 
Chr 4 Kif1b 53.0 141.1 77.8 25.9 61.3   96.5   
  Pik3cd 55.8 134.6 89.9 29.2 55.4   103.3   
  eno1 58.7 87.3 105.3 39.3 51.5   108.4   
  Rere 51.7 108.9 104.4 32.4 48.9   100.6   
Chr 5 Rad9b 67.9   62.9 23.7 90.9 70.5   93.0 
  Anapc7 94.5   96.8 34.7 130.5 97.7     
  Atp2a2 82.5   93.0 46.5 124.4 97.5     
  Bcl7a 92.9   65.8 30.3 56.9 100.0     
  Il31 93.6   55.3 15.4 52.1 78.6     
  Diablo 87.1   94.1 41.6 55.5 103.6     
  Kntc1 44.7   52.5 39.5 55.2 97.8     
  Setd8 59.0   47.8 8.0 80.7 44.6     
  Gtf2h3 51.7   50.6 7.4 60.6 42.6     
Chr11 Slc46a1 82.2             36.7 
  Tnfaip1 92.9 71.4 79.3   65.0 83.4 59.8   
  Nlk 103.6 63.5 105.4   67.5 116.0 50.5   
  Nos2 105.1 142.37 48.2 14.8 108.6 87.8   60.36 
  Lgals9 34.3 107.0 67.6   109.3 56.0 53.8   
  Nf1 (5') 17.4 35.5 25.5 12.7 63.7 16.7 9.2 9.6 
  
Omg (Nf1 
3') 52.9 12.0 16.7 0.7 48.0 16.3   75.1 
  Rab11fip4 49.8            65.9 
Amplification Regions               
Chr 12 Tle6-like 89.2 92.1 113.1 133.0 107.5 77.4 93.4 746.2 
  Adam6b 148.1 176.7 173.7 10.8 150.9 119.4 170.0   
Chr 16 Cd47 98.9 137.0 84.9 121.5 115.8 109.1 88.7   
  Cd200 96.0 123.3 59.7 19.1 135.4 92.5 106.0   
  Igsf11 85.8 153.3 86.2 119.2 106.2 106.6 94.6   
  Btla 96.5 105.4 193.9 295.1 89.8 232.7 106.2   
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Supplementary Table A2-12 Legend: qPCR values are presented as the percentage 
vs C3H DNA.  Nf1 probes were at the 5' and 3' ends of the gene. The 3’ probe 
corresponds to the Omg gene that lies within an Nf1 intron near the 3' end.  Note that 
copy number differences between the Nf1 5' and 3' are observed in some tumors, 
indicating a breakpoint within Nf1.  Deletion calls were made as follows: 
Heterozygous = 15-80%; Homozygous = <15%. If either Nf1 or Omg were <15%, the 
tumor sample was called as homozygous deleted because full Nf1 transcripts cannot be 
made. MT = mammary tumor. 
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Supplementary Table A2-12: qPCR analysis of Nf1 locus in tumors 
 
Geno & Type Tumor # Nf1 5' Nf1 3' (Omg) 
   
    
Chaos3 MT 15259 17.4 52.9 
Chaos3 MT 12351 L 35.5 12.0 
Chaos3 MT 12353A 25.5 16.7 
Chaos3 MT 12352 12.7 0.7 
Chaos3 MT 2044B CL 63.7 48.0 
Chaos3 MT 11929A 16.7 16.3 
Chaos3 MT 16168 9.2 ND 
Chaos3 MT 16898 9.6 75.1 
Chaos3 MT 12115B 31.2 38.7 
Chaos3 MT 2042 CL 78.9 92.3 
Chaos3 MT 919 CL 51.8 0.1 
Chaos3 MT 21040 0.1 0.1 
Chaos3 MT 21253 0.3 0.2 
Chaos3 MT 20317 29.5 48.7 
Chaos3 MT 19957 32.7 5.4 
Chaos3 MT 19958 11.2 12.4 
Chaos3 MT 19959 14.4 72.4 
Chaos3 MT 20783 7.0 10.4 
Chaos3 MT 20164 20.6 22.8 
Chaos3 MT 20888 27.3 26.0 
Chaos3 MT 20892 6.4 34.9 
Chaos3 MT 20893 7.4 24.5 
Chaos3 MT 20138 41.1 10.8 
Chaos3 MT 21039 68.4 66.7 
Chaos3 MT 21809 62.0 60.0 
Chaos3 MT 20894 85.1 67.1 
Chaos3 MT 20889 12.0 18.4 
Chaos3 MT 21333 40.8 71.4 
Chaos3 MT 20626 36.7 22.6 
Chaos3 MT 20318 14.5 24.9 
Chaos3 MT 20890 13.6 38.9 
Chaos3 MT 20891 2.5 1.4 
Chaos3 MT 21123 34.7 39.0 
Chaos3 MT 19660 44.8 48.3 
Chaos3 MT 20459 53.7 69.8 
Chaos3 MT 21597 28.6 5.3 
Chaos3 MT 22182 62.6 78.2 
Chaos3 MT 21416 63.8 56.8 
Chaos3 MT 22236 31.6 8.0 
Chaos3 MT 22418 24.9 24.2 
Chaos3 MT 22180 23.9 49.0 
Chaos3 MT 22235 8.1 8.2 
Chaos3 MT 22166 21.7 21.0 
Chaos3 MT 22168 8.0 7.6 
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Chaos3 MT 22238 3.4 3.4 
Chaos3 MT 21417 3.3 14.8 
Chaos3 MT 21419 19.2 50.6 
Chaos3 MT 21255 7.0 6.1 
Chaos3 MT 21124 8.5 29.1 
Chaos3 MT 21810 26.3 27.0 
Chaos3 MT 21811 47.3 51.7 
Chaos3 MT 21254 9.5 7.9 
Chaos3 MT 21041 24.4 21.2 
Chaos3 MT 22420 40.5 17.1 
Chaos3 MT 22476 75.5 70.7 
Chaos3 MT 22414 3.3 17.1 
Chaos3 MT 22416 3.5 14.6 
Chaos3 MT 22417 7.1 19.4 
Chaos3 MT 23116 11.2 10.8 
Chaos3 MT 22418 115.0 110.3 
Chaos3 non-MT 19160 198.2 207.5 
Chaos3 non-MT 10658 87.1 ND 
Chaos3 non-MT 16862 98.5 101.2 
Chaos3 non-MT 17883 97.0 88.0 
PyVT  96.3 105.1 
MMTV-neu1  108.6 93.2 
MMTV-neu2  103.8 104.4 
Chaos3 +/+ MT  107.3 109.4 
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Supplementary Table A2-13 Legend:  x= deleted. Tumor Codes: A: 2044B; B: 
12353A; C: 12351L; D: 12352; E: 15259; F: 16168; G: 12115B; H: 16898; I: 11929A.  
Mmu = Mus musculus. Some of the deletions extend further than indicated. The True 
(deleted) and False (not deleted) calls for human gene deletions are from TCGA level 
4 data (see Methods) and refer to whether that locus is deleted at levels statistically 
above background. Human genes in red are potentially cancer-relevant. Red shaded 
regions are the “critical regions” of a deletion set. Note that the Mmu Chr 11 deletion 
cluster is organized in the human genome order, which is inverted and has an 
insertion. Thus, the critical region is actually contiguous. The “Chaos3 CNA” column 
refers to the % of Chaos3 mammary tumors analyzed by aCGH that contained 
deletions of that particular locus. 
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Supplementary Table A2-13: Chaos3 -specific and Mammary Tumor-specific 
Recurrent Deletions Overlapping Human Breast Cancer CNAs 
 
                                                                                                   Tumors 
Mouse CNA  Gene 
Hum 
Chr 
Human 
CNA  
Chaos
3 CNA  A B C D E F G H I 
Mmu Chr 4  SLC2A7 1 FALSE 33%  x   x     
148.4-149.5 
Mb SLC2A5 1 FALSE 50% 
 
x   x x    
 GPR157 1 FALSE 50%  x   x x    
 MIR34A 1 FALSE 50%  x   x x    
 H6PD 1 FALSE 57%  x   x x x   
 SPSB1 1 FALSE 86%  x x   x x x x  
 SLC25A33 1 FALSE 86%  x x   x x x x  
 TMEM201 1 FALSE 86%  x x   x x x x  
 PIK3CD 1 FALSE 86%  x   x x x x x  
 CLSTN1 1 FALSE 71%  x   x x   x x  
 CTNNBIP1 1 FALSE 71%  x   x x   x x  
 LZIC 1 FALSE 71%  x   x x   x x  
 NMNAT1 1 FALSE 71%  x   x x   x x  
 RBP7 1 FALSE 71%  x   x x   x x  
 UBE4B 1 TRUE 71%  x   x x   x x  
 KIF1B 1 TRUE 71%  x   x x   x x  
 PGD 1 TRUE 33%  x  x    x  
 APITD1 1 TRUE 33%  x  x    x  
 CORT 1 TRUE 33%  x  x    x  
 DFFA 1 TRUE 33%  x  x    x  
 PEX14 1 TRUE 33%  x  x    x  
 CASZ1 1 TRUE 33%  x  x      
 TARDBP 1 FALSE 17%  x        
 MASP2 1 FALSE 17%  x        
 SRM 1 FALSE 17%  x        
Mmu Chr 5  CLIP1 12 FALSE 43% x x     x   
122-125 Mb ZCCHC8 12 FALSE 43% x x     x   
 RSRC2 12 FALSE 43% x x     x   
 KNTC1 12 FALSE 71% x x  x   x  x 
 GPR81 12 FALSE 71% x x  x   x  x 
 DENR 12 FALSE 71% x x  x   x  x 
 CCDC62 12 FALSE 71% x x  x   x  x 
 HIP1R 12 FALSE 71% x x  x   x  x 
 VPS37B 12 FALSE 86% x x x x   x   x 
 ABCB9 12 FALSE 86% x x x x   x   x 
 OGFOD2 12 FALSE 86% x x x x   x   x 
 ARL6IP4 12 FALSE 86% x x x x   x   x 
 PITPNM2 12 FALSE 86% x x x x   x   x 
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 MPHOSPH9 12 FALSE 86% x x x x   x   x 
 CDK2AP1 12 FALSE 86% x x x x   x   x 
 SBNO1 12 FALSE 86% x x x x   x   x 
 SETD8 12 FALSE 86% x x x x   x   x 
 RILPL2 12 FALSE 86% x x x x   x   x 
 SNRNP35 12 FALSE 100% x x x x   x x x 
 RILPL1 12 FALSE 100% x x x x   x x x 
 TMED2 12 FALSE 100% x x x x   x x x 
 DDX55 12 FALSE 100% x x x x   x x x 
 EIF2B1 12 FALSE 100% x x x x   x x x 
 GTF2H3 12 FALSE 100% x x x x   x x x 
 TCTN2 12 FALSE 100% x x x x   x x x 
 ATP6V0A2 12 FALSE 43%      x  x x 
 CCDC92 12 FALSE 29%        x x 
 Zfp664 12 FALSE 14%        x  
 Fam101a 12 TRUE 14%        x  
 Ncor2 12 TRUE 14%        x  
 Scarb1 12 FALSE 14%             x  
Mmu Chr 
11 WSB1 17 FALSE 100% x x x  x  x x  
 78-79.6 Mb KSR1 17 TRUE 100% x x x  x  x x  
 LGALS9 17 TRUE 57%  x      x  
 NOS2 17 TRUE 57%  x      x  
 NLK 17 FALSE 43%  x      x  
 TMEM97 17 FALSE 29%  x      x  
 IFT20 17 FALSE 29%  x      x  
 TNFAIP1 17 FALSE 29%  x      x  
 POLDIP2 17 FALSE 29%  x      x  
 TMEM199 17 FALSE 29%  x      x  
 SEBOX 17 FALSE 29%  x      x  
 VTN 17 FALSE 29%  x      x  
 SARM1 17 FALSE 29%  x      x  
 SLC46A1 17 FALSE 29%  x      x  
 SLC13A2 17 FALSE 29%  x      x  
 FOXN1 17 FALSE 29%  x      x  
 UNC119 17 FALSE 17%  x        
 PIGS 17 FALSE 17%  x        
 ALDOC 17 FALSE 17%  x        
 NF1 17 TRUE 100% x x x  x  x x x 
 OMG 17 TRUE 86% x x x  x  x   x 
 EVI2B 17 TRUE 86% x x x  x  x   x 
 EVI2A 17 TRUE 71% x x x  x  x   
  RAB11FIP4 17 TRUE 57% x x x  x        
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Supplementary Table A2-14 Legend:  x= deleted. Tumor Codes: A: 15259; B: 
12353A; C: 12115B; D: 11929A; E: 16898; F: 2044B; G: 16892. Mmu = Mus 
musculus. Hs = Homo sapiens. Some of the deletions extend further than indicated. 
The True (deleted) and False (not deleted) calls for human gene deletions are from 
TCGA level 4 data (see Methods) and refer to whether that locus is deleted at levels 
statistically above background. Human genes in red are potentially cancer-relevant. 
Red shaded regions are the “critical regions” of a deletion set. The “Chaos3 CNA” 
column refers to the % of Chaos3 mammary tumors analyzed by aCGH that contained 
deletions of that particular locus. 
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Supplementary Table A2-14: Chaos3 Mammary Tumor Non-specific Recurrent 
Deletions Overlapping Human Breast Cancer CNAs 
 
Mouse 
Region  Human Gene 
Hs 
Chr 
Human 
CNA  
Chaos3 
CNA  A B C D E F G 
Mmu Chr 4  AIM1L 1 FALSE 43%  x x   x  
132.4-133.5 
Mb LIN28 1 FALSE 71%  x x x  x x 
  DHDDS 1 FALSE 71%  x x x  x x 
  HMGN2 1 FALSE 71%  x x x  x x 
  RPS6KA1 1 FALSE 86%   x x x x x x 
  ARID1A 1 FALSE 100% x x x x x x x 
  PIGV 1 FALSE 100% x x x x x x x 
  ZDHHC18 1 TRUE 86% x x x   x x x 
  SFN 1 TRUE 86% x x x   x x x 
  GPN2 1 TRUE 86% x x x   x x x 
  GPATCH3 1 TRUE 86% x x x   x x x 
  NR0B2 1 TRUE 86% x x x   x x x 
  NUDC 1 TRUE 86% x x x   x x x 
  TRNP1 1 TRUE 86% x x x   x x x 
  FAM46B 1 FALSE 86% x x x   x x x 
  SLC9A1 1 FALSE 71% x  x  x x x 
  WDTC1 1 FALSE 43% x    x  x 
  TMEM222 1 FALSE 43% x    x  x 
  SYTL1 1 FALSE 43% x    x  x 
  MAP3K6 1 FALSE 43% x    x  x 
  CD164L2 1 FALSE 43% x    x  x 
  GPR3 1 FALSE 43% x       x   x 
Mmu Chr 10 PPAP2C 19 TRUE 33%    x x   
 79.4-80.2 Mb MIER2 19 TRUE 33%    x x   
  THEG 19 TRUE 33%    x x   
  C2CD4C 19 TRUE 33%    x x   
  SHC2 19 TRUE 33%    x x   
  ODF3L2 19 TRUE 33%    x x   
  MADCAM1 19 TRUE 33%    x x   
  CDC34 19 TRUE 33%    x x   
  GZMM 19 TRUE 33%    x x   
  BSG 19 TRUE 33%    x x   
  HCN2 19 TRUE 33%    x x   
  POLRMT 19 TRUE 33%    x x   
  FGF22 19 TRUE 33%    x x   
  RNF126 19 TRUE 33%    x x   
  FSTL3 19 TRUE 33%    x x   
  PRSSL1 19 TRUE 33%    x x   
  PALM 19 TRUE 33%    x x   
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  PTBP1 19 TRUE 33%    x x   
  PRTN3 19 TRUE 33%    x x   
  ELANE 19 TRUE 33%    x x   
  CFD 19 TRUE 33%    x x   
  MED16 19 TRUE 33%    x x   
  KISS1R 19 TRUE 50%    x x  x 
  ARID3A 19 TRUE 50%    x x  x 
  WDR18 19 TRUE 50%    x x  x 
  GRIN3B 19 TRUE 50%    x x  x 
  CNN2 19 TRUE 50%    x x  x 
  ABCA7 19 TRUE 50%    x x  x 
  HMHA1 19 TRUE 50%    x x  x 
  POLR2E 19 TRUE 50%    x x  x 
  GPX4 19 TRUE 50%    x x  x 
  SBNO2 19 TRUE 50%    x x  x 
  STK11 19 TRUE 50%    x x  x 
  ATP5D 19 TRUE 50%    x x  x 
  MIDN 19 TRUE 50%    x x  x 
  CIRBP 19 TRUE 33%    x x   
  EFNA2 19 TRUE 33%    x x   
  MUM1 19 TRUE 33%    x x   
  NDUFS7 19 TRUE 33%    x x   
  GAMT 19 TRUE 33%    x x   
  DAZAP1 19 TRUE 33%    x x   
  RPS15 19 TRUE 33%    x x   
  APC2 19 TRUE 33%    x x   
  PCSK4 19 TRUE 33%    x x   
  REEP6 19 TRUE 33%    x x   
  ADAMTSL5 19 TRUE 33%    x x   
  MEX3D 19 TRUE 50%    x x x  
  MBD3 19 TRUE 50%    x x x  
  TCF3 19 TRUE 50%    x x x  
  ONECUT3 19 TRUE 67% x     x x x   
  ATP8B3 19 TRUE 67% x     x x x   
  REXO1 19 TRUE 67% x     x x x   
  KLF16 19 TRUE 67% x     x x x   
  SCAMP4 19 TRUE 67% x     x x x   
  ADAT3 19 TRUE 67% x     x x x   
  CSNK1G2 19 TRUE 67% x     x x x   
  BTBD2 19 TRUE 67% x     x x x   
  MKNK2 19 TRUE 67% x     x x x   
  MOBKL2A 19 TRUE 67% x     x x x   
  AP3D1 19 TRUE 67% x     x x x   
  DOT1L 19 TRUE 67% x     x x x   
  PLEKHJ1 19 TRUE 67% x     x x x   
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  SF3A2 19 TRUE 67% x     x x x   
  AMH 19 TRUE 67% x     x x x   
  JSRP1 19 TRUE 67% x     x x x   
  OAZ1 19 TRUE 67% x     x x x   
  LINGO3 19 TRUE 67% x     x x x   
  LSM7 19 TRUE 33%    x x   
  TMPRSS9 19 FALSE 33%    x x   
  TIMM13 19 FALSE 33%    x x   
  LMNB2 19 FALSE 33%    x x   
  GADD45B 19 FALSE 17%       x       
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Supplementary Table A2-15: Comparison of Chaos3 Commonly Deleted Genes to 
COSMIC Database 
  
        
Chaos3 CNAs  COSMIC Mutations 
 Chr 
# Genes in 
Region(s) 
Total 
Mutations 
Prominantly 
Mutated Mutated in Breast Cancer 
4 105 62 
MTOR (22), 
ARID1A (8), 
MAP3K6 (6) 
MAP3K6 (4), PTCHD2 (1), RHD (1), 
STX12 (1) 
5 58 30 
ANAPC5 (6), 
SBNO1 (6), 
KNTC1 (5), 
P2RX7 (4) 
ANAPC5 (2), CLIP1 (1), GPR81 (2), 
P2RX7 (1), SBNO1 (5) 
10 122 243 STK11 (214)  
ADAT3 (1), APC2 (3), DAZAP1 (1), 
UQCR11 (1)   
11 30 277 NF1 (266)  NF1 (2), NOS2 (1), PIGS (2) 
19 50 2158 PTEN (2140) PTEN (66), RCE1 (1) 
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Supplementary Table A2-16 Legend: MSKCC -Nf1 CGH.  TCGA Breast Cancer 
Samples.  * "Complete Tumors" are tumor samples that have mRNA, CNA, and 
sequencing data. 
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Supplementary Table A2-16: NF1 Loss in 
Human Mammary Tumors 
    
    
Nf1  Complete Tumors* 
2 High Level Amplification 7 2.19% 
1 Gain 45 14.06% 
0 Neutral/No Change 194 60.63% 
-1 Hemizygous Deletion 73 22.81% 
-2 Homozygous Deletion 1 0.31% 
 Mutated   
 Total # of Samples 320   
    
Nf1  All Breast Tumors 
2 High Level Amplification 13 1.66% 
1 Gain 116 14.81% 
0 Neutral/No Change 479 61.17% 
-1 Hemizygous Deletion 170 21.71% 
-2 Homozygous Deletion 5 0.64% 
 Mutated     
 Total # of Samples 783   
    
Nf1  
TCGA Manuscript 
Luminal A/B 
2 High Level Amplification 6 1.90% 
1 Gain 47 14.87% 
0 Neutral/No Change 210 66.46% 
-1 Hemizygous Deletion 53 16.77% 
-2 Homozygous Deletion 0 0.00% 
 Mutated   
 Total # of Samples 316   
    
Nf1  PAM50 Luminal A 
2 High Level Amplification 2 0.91% 
1 Gain 23 10.45% 
0 Neutral/No Change 157 71.36% 
-1 Hemizygous Deletion 31 14.09% 
-2 Homozygous Deletion 0 0.00% 
 Mutated 7 3.18% 
 Total # of Samples 220   
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Nf1  PAM50 Luminal B 
2 High Level Amplification 4 3.15% 
1 Gain 31 24.41% 
0 Neutral/No Change 59 51.18% 
-1 Hemizygous Deletion 27 21.26% 
-2 Homozygous Deletion 0 0.00% 
 Mutated 6 4.72% 
 Total # of Samples 127   
    
Nf1  PAM50 Basal 
2 High Level Amplification 0 0.00% 
1 Gain 8 8.60% 
0 Neutral/No Change 45 48.39% 
-1 Hemizygous Deletion 35 37.63% 
-2 Homozygous Deletion 1 1.08% 
 Mutated 4 4.30% 
 Total # of Samples 93   
    
Nf1  PAM50 Claudin Low 
2 High Level Amplification 0 0.00% 
1 Gain 0 0.00% 
0 Neutral/No Change 6 75.00% 
-1 Hemizygous Deletion 2 25.00% 
-2 Homozygous Deletion 0 0.00% 
 Mutated     
 Total # of Samples 8   
    
Nf1  
PAM50 Her2 
Enriched 
2 High Level Amplification 3 5.45% 
1 Gain 7 12.73% 
0 Neutral/No Change 21 38.18% 
-1 Hemizygous Deletion 22 40.00% 
-2 Homozygous Deletion 2 3.64% 
 Mutated 0 0.00% 
 Total # of Samples 55   
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Nf1  PAM50 Normal-like 
2 High Level Amplification 0 0.00% 
1 Gain 0 0.00% 
0 Neutral/No Change 5 62.50% 
-1 Hemizygous Deletion 2 25.00% 
-2 Homozygous Deletion 0 0.00% 
 Mutated 1 12.50% 
 Total # of Samples 8   
    
Nf1  
Total Breast 
Tumors (TCGA 
Manuscript 511) 
2 High Level Amplification 9 1.78% 
1 Gain 70 13.61% 
0 Neutral/No Change 296 57.89% 
-1 Hemizygous Deletion 120 23.56% 
-2 Homozygous Deletion 3 0.60% 
 Mutated 18 3.55% 
 Total # of Samples 511 aCGH 
 180 
 
 
 
Supplementary Table A2-17: List of PCR & qPCR Primers 
   
Gene Name Primer Name Primer Sequence 
1300001I01Rik 1300001I01RikExon1_L GTGTTTTGTCCCTCGTCGTC 
1300001I01Rik 1300001I01RikExon1_R GAAGACGGTTGTTCCCACC 
Acsl6 Acsl6Exon2_L CACTAGCGATCCCTCCACAG 
Acsl6 Acsl6Exon2_R TGGCTTCTACCTTCTGGAGC 
Adam6b  Adam6b_F AGGCCATCCTACTTGGCGTTACAT 
Adam6b  Adam6b_R GCAACAAGTGTCTGGGCCAAATGA 
AK156805, 
AL837506.3-2 AK156805_L ATGCCGGTTTCCAACGTAT 
AK156805, 
AL837506.3-2 AK156805_R TGGAAACAGATGATTTCGTCA 
Akap9 Akap9Exon27_L TTTTAAATTGGAGTGAGAATTACTGC 
Akap9 Akap9Exon27_R CTTCGCTTTCAGACAGCATC 
AL837506.3-2 AL837506.3-2_L ACCTACTTTGGAAAGAAAACTG 
AL837506.3-2 AL837506.3-2_R TGGAAACAGATGATTTCGTCA 
Anapc10 Anapc10_F GCTGAAGCAAAGCATGTGCTGAGA 
Anapc10  Anapc10_R AGTTCAGCCTCCGTCATTGTGAGT 
Anapc7  Anapc7_F GCTGTGCCAGGTTTAGCGACATTT 
Anapc7  Anapc7_R ACGAGGCAGACTGCTGAGCTTATT 
Ap2b1 Ap2b1Exon11_L AACCTTTGCAGCTTGGAATC 
Ap2b1 Ap2b1Exon11_R AAACGATCATCCCTTTTGAGAC 
Apc ApcExon16_10_L GCAGAGCCCTAGAAAAGTGG 
Apc ApcExon16_10_R AGAGGCTGGAGTCTTGAGGG 
Arid4a Arid4a_L GACGACCAGCTGGAGAAGAG 
Arid4a Arid4a_R GCCTGAGTCCTGTCGTTTTC 
Atm Atm_L TCATGACCTCTGGAAGAGCA 
Atm Atm_R GCAGAAGTCCAACATTTGAAGA 
Atp2a2  Atp2a2_F TGTGTTCTGTCTGCTGGGATGGAT 
Atp2a2  Atp2a2_R TGCACTAGGTGCCACAGAGCTAAA 
Bcl7a  Bcl7a_F TCCAGAAGGTTCCTTGGCAGTGAT 
Bcl7a  Bcl7a_R TGACTTCCCACAGTTCCCTGTGTT 
Brca1 BRCA1_Exon9_F AAT CTC AAG GGC CTG TCA ATC CCA 
Brca1 BRCA1_Exon9_R GCA CTG TCA GAC ATT TGG CGT GTT 
Btla  Btla_F TGACTGATGCCCAGTGGCTTCTAA 
Btla  Btla_R AGGACTGCATTGTCCCTTTGGAGA 
Cd200  Cd200_F AAGGGTAAGCTGTCTGGCATCTGT 
Cd200  Cd200_R ACTGTGTGGCTCTTTCATAGCCCT 
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Cd47  Cd47_F TAATTGGACTTGAAGCCCGAGGGT 
Cd47  Cd47_R AATGCACCATCTGAAGCAGCCTTG 
Diablo  Diablo_F ACACAGACTCAACAGGGAAAGGCT 
Diablo  Diablo_R TCACCAGAGCAAGCTAGCAAGTGA 
Egfr EGFR_Exon28_F TAG TGG GTT TAA CAG CCC TGC ACT 
Egfr EGFR_Exon28_R TCT AGG CTC ATT TGG TGA CTG CCT 
Egln Egln1Exon5_1_L GGGCTCTCTGGTGCTTTATG 
Egln Egln1Exon5_1_R GCCTTGAGGGCAAAATTTAATAG 
Eno1 Eno1_F TCTGTATCCATGCCACCAGAGCAA 
Eno1 Eno1_R CAGGTGCTTTCAGAAGCAAAGGCA 
Eps15 Eps15_L GGAATTCTTTGTTGCTTTACGG 
Eps15 Eps15_R GCCAGCCCTCATGTTTACAA 
Fchsd2 Fchsd2Exon21_3_L AGGACAAAGGCCTACATTGC 
Fchsd2 Fchsd2Exon21_3_R TCTATTATAAGCACTTTGAAGATCAGC 
Fhod3 Fhod3_L ACAGACCTAGGGGAGGAGGA 
Fhod3 Fhod3_R AAGCCCTGAGGAGTGTTGAA 
Gtf2h3  Gtf2h3_F AAGGACCATGAAGCTCTGGTGTCA 
Gtf2h3  Gtf2h3_R TTGATCACCTGCAAACACAGCCAC 
Hjurp HjurpExon1-2_L ctccccttctcgtttccac 
Hjurp HjurpExon1-2_R attgcaaattctaggcccac 
Hjurp HjurpExon8_9_L CACGAGGCCTCTGATGCTAC 
Hjurp HjurpExon8_9_R GTTGTCTGGGCTCAACACTG 
Hmx1 Hmx1_Intron1_F 
TGG GAG CCC ACG GGA ACT TAT 
TTA 
Hmx1 Hmx1_Intron1_R 
ATT CAG GGC GTA CAA GGG ATG 
TCA 
Igsf11  Igsf11_F AGCAGAGCAACAAACGAACTGCTG 
Igsf11  Igsf11_R ACCCTGGGATTAGCATTTCCACCT 
Il31  Il31_F TTACCGTCGCCATGATCTTCCACA 
Il31  Il31_R AGTTACAACAGCCTCTGTCCAGCA 
Jarid1b Jarid1b_L TCTCTAGTGCCCCCTTCTGA 
Jarid1b Jarid1b_R TCCATCACTGGCATGTTGTT 
Kif1b  Kif1b_F ACTAACGCCCAGAAGTGAAGTGGT 
Kif1b  Kif1b_R ACATGCCTGGCAAGCTCTACCTTA 
Klk13 Klk13_L GAGCTATCATGTGGCCCCTA 
Klk13 Klk13_R CTGGGAAATCAGGTCACACA 
Kntc1  Kntc1_F GTGGGAGATTGGTTTGGCTTTGCT 
Kntc1  Kntc1_R AAACACAACACTAGGAGGTCGGCT 
Lgals9  Lgals9_F TTTGAGCTTTGCTTCCTGGTGCAG 
Lgals9  Lgals9_R AGCAAGAGGTGCCTCTGCAGATTA 
Mapre2 Mapre2Exon8_1_L ATTAGGCCTGACACCCCAC 
Mapre2 Mapre2Exon8_1_R TCTGACCAAATTTATGAGAGGAG 
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Mcm4 Mcm4_Intron7_F ATG CTG TTT GCA TCT GTG ACT GGC 
Mcm4 Mcm4_Intron7_R ACT GGC TCA GAA ATC CCT GCT TCA 
Mrpl48-ps, 
AL772394.7 Mrpl48_L CCCTCACGGACAATCTGACT 
Mrpl48-ps, 
AL772394.7 Mrpl48_R CCAGACCAAGGCAACAAAAT 
Myo1g Myo1g_L CATGCACAGAGCTGGCTTAG 
Myo1g Myo1g_R ATCCTGAAGCAAGAGCAGGA 
Nf1  Nf1_F GTGCTGTTTGTGCTGAGCTGTGAA 
Nf1  Nf1_R TCTATTGAACTGCCCATACCCGCA 
Nlk  Nlk_F TGACTGCTGCTGCGTATAGAGCTT 
Nlk  Nlk_R ATGACGCTGACTGGAGATTCCGTT 
Nlk  NSC-0272_Nlk_F CAG CCC CAG CTC AGG TAC AG 
Nlk  NSC-0272_Nlk_R ATG ATG CGA GTG CTG ATG ATG 
Nos2 Nos2_F TCTTTGACGCTCGGAATGTAGCA 
Nos2 Nos2_R ACCTGATGTTGCCATTGTTGGTGG 
Omg Omg_F CAAGCCTCACCAGTGCAACAAAGT 
Omg Omg_R TGCAGTGGTTTCTTCCCTCCGTAA 
Pgr PGR_Exon1_F TCC TTG GAG CAA GAC TCT CCC ATT 
Pgr PGR_Exon1_R 
GCA GGA TGG GCA CAT GGA TGA 
AAT 
Pik3cd  Pik3cd_F GTTGTTGACTTCTTGCTGCCCACA 
Pik3cd  Pik3cd_R TCTGGTCAGTTCCCACACACAGTT 
pisd-ps1,3 pisd-ps1,3_L aactcagcctcctgcactgt 
pisd-ps1,3 pisd-ps1,3_R GAAAAACTCGCTGAGGTTGC 
Prkg1 NSC-0247_Prkg1_F CCC ACC GCC TTC GAC AT 
Prkg1 NSC-0247_Prkg1_R CCT GCT TAC TGT GGG CTC TTG 
Ptn PtnExon3_L TCCACAATCAAGGTGCTGAG 
Ptn PtnExon3_R tttaatataaaCATTAGCTGTCCTTGG 
Rab11fip4  Rab11fip4_F  AACCTTTCAGGCCACCTTTCAAGC 
Rab11fip4  Rab11fip4_R TACGATGGACTTAGCCCAAAGGCA 
Rad9b  Rad9b_F AGCATGACTCTGGAGCAAAGCCTA 
Rad9b  Rad9b_R AGGTTCAAGTGCGAGTGGATGAGT 
Rere Rere_F TGCTTGGCTCTCTGGTGCATAGAT 
Rere Rere_R AAGGGATCTTTGTCAGGTCAGGCA 
Runx2 NSC-0237_Runx2_F CGC ATT CCT CAT CCC AGT ATG 
Runx2 NSC-0237_Runx2_R AAA GGA CTT GGT GCA GAG TTC AG 
Setd8  Setd8_F TGGTCCTCGCTGCATTGTTCTACT 
Setd8  Setd8_R ACACATGGCTTTAATGCCCAGCAG 
Sfi1 Sfi1_L GCAATGCATGTACCAACAGG 
Sfi1 Sfi1_R CGTAGGTGGCTGGAGCTAAG 
sik3, BC033915 sik3_L GGAGGTTTCACTGCACAACA 
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sik3, BC033915 sik3_R GGTGCGGTCGATCTCGTA 
Slc46a1 Slc46a1_F TGGGACTCCAAGCTGATTGGCTAT 
Slc46a1 Slc46a1_R CAAACGCAAAGACCACCATTCCCA 
Smg1 NSC-0268_Smg1_F 
CTC GCT TAA CCA GAC TCA TCT ACT 
GT 
Smg1 NSC-0268_Smg1_R ACT TGG CTC AGC TGT ATG AAG GT 
Supt6h  Supt6h_F  TCTGCTAAGGGAAACGTGCT 
Supt6h  Supt6h_R  TTGCAAAGAGAAAGCCAGGT 
Tdrd6 Tdrd6Exon1_8_L GCCTTGCCAGATATACCGAC 
Tdrd6 Tdrd6Exon1_8_R CTAGGTTGGCCTTTGCTGAG 
Tle6-like Tle6-like_F ACACTATCTTAGGCCTCAAGTTCTCTC 
Tle6-like Tle6-like_R  AGTCATGCCATAGCATCTGACAGT 
Tle6-like  Tle6-like_F  ACACTATCTTAGGCTCAAGTTCTCTC 
Tle6-like  Tle6-like_R  AGTCATGCCATAGCATCTGACAGT 
Tln1 Tln1Exon43_L GTGCCCTTAGGGAGCTGAG 
Tln1 Tln1Exon43_R AACAAGggccatgaactgg 
Tnfaip1  Tnfaip1_F AGCTCAGACTTCATCTGGCACCAA 
Tnfaip1  Tnfaip1_R ACCCTACAGCATCCCACAACTGAA 
Ttn Ttn15259_L CTTCCTACCTTCCACGGACA 
Ttn Ttn15259_R CCTGGTACAAGGAGGAGCAG 
Ttn TtnExon66_L TTGGACTTTTGTGATTCATTGC 
Ttn TtnExon66_R AAGACACCATGAGACCCAGG 
Tyro Tyro3Exon19_1_L CTCAGCGTCATATGGTCGG 
Tyro Tyro3Exon19_1_R CAATTTGGTCCGTCCAGG 
Utp6 Utp6_F CAGATGATGGCTGATGATGG 
Utp6 Utp6_R CCTGCTCACAAAAAGGAAGC 
Zeb2 Zeb2_L GGGCCTCTTCTTACCGTTTT 
Zeb2 Zeb2_R CGCTGTGTTTGGTTGCTAGA 
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Supplementary Table A3-1: Chaos3 F1 and F2 Disease 
Incidence 
Abbreviation Term 
Incidence 
(186 F2) 
Percentage 
(186 F2) 
CE-HPL Cystic Endometrial Hyperplasia 46 24.7% 
PYM Pyometra 5 2.7% 
MUM Mucometra 8 4.3% 
SCEC Scirrhous Endometrial Carcinoma 1 0.5% 
EMP Endometrial polyp  1 0.5% 
EMP-HPL Hyperplastic Endometrial Polyp 1 0.5% 
FCC Ovarian, Bursal, or Follicular Cyst 12 6.5% 
EMH Extramedullary hematopoiesis 39 21.0% 
MYL-HPL Myeloid Hyperplasia 7 3.8% 
LPD Lipidosis 2 1.1% 
HEP Hepatitis 1 0.5% 
HMGSC hemangiosarcoma 2 1.1% 
SCT Spindle Cell Tumor 1 0.5% 
LPMA Lipoma 6 3.2% 
HCC Hepatocellular Carcinoma 1 0.5% 
FBRSC Fibrosarcoma 2 1.1% 
GMS Granulomatous steatitis 1 0.5% 
SM-HPL Smooth Muscle Hyperplasia 1 0.5% 
BA-HPL Bronchioloalveolar hyperplasia 1 0.5% 
HSTCY Histiocytosis 1 0.5% 
BM-HPL Bone Marrow Hyperplasia 2 1.1% 
LEUK Leukemia 1 0.5% 
        
HISTSC Histiocytic Sarcoma 94 50.5% 
MT Mammary Carcinoma 28 15.1% 
BT Osteosarcoma 26 14.0% 
LYMPH Lymphoma 31 16.7% 
HLTHY Healthy 16 8.6% 
CE-HPL* 
Cystic Endometrial Hyperplasia & 
Related (CE-
HPL+PYM+MUM+EMP+EMP-HPL, 
SCEC non overlapping) 52 28.0% 
    
Abbreviation Term 
Incidence 
(21 F1) 
Percentage 
(21 F1) 
RBMSC Rhabdomyosarcoma 1 4.8% 
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MD Myodegeneration 1 4.8% 
EMH Extramedullary hematopoiesis 2 9.5% 
        
HISTSC Histiocytic Sarcoma 10 47.6% 
MT Mammary Carcinoma 5 23.8% 
BT Osteosarcoma 2 9.5% 
LYMPH Lymphoma 3 14.3% 
CE-HPL Cystic Endometrial Hyperplasia  9 42.9% 
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Supplementary Figure A3-1: SNPs assayed for QTL analysis.  Shown are the 263 
SNPs used on the Goldengate Beadchip.  The informative C3H vs. C57/B6 SNP 
subset was used for subsequent QTL analysis. 
 
 
 187 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure A3-2: Mammary Tumor QTL analysis. (A) Recombination 
Fraction (RF) plot quality control showing successful genotyping and high-quality 
mapping.  Markers that are close in physical proximity are strongly linked (red); 
Markers that are distant in physical proximity are independently assorting (blue). (B) 
Multiple QTL Mapping (MQM) analysis of mammary tumor cofactors.  LOD score 
significance threshold was set at 2.0.  Note significant peaks at Chr 1, 3, 4, 5, and 14 
representing genomic loci associated specifically with mammary tumor formation. (C) 
Two-dimensional QTL scan plot.  The upper and lower triagonal matrix represents the 
LOD scores contributed by the epistasis/interactive QTL model.  Note the significant 
epistatic effect between chromosome 12 and 14 as well as between chromosomes 2 
and 3 with chromosome 5.  
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Supplementary Table A3-2: Mammary Tumor QTL Candidate Genes 
(Extended) 
Location Gene Can Gene Description 
Total # 
COSMIC 
Mut 
Repro* 
COSMIC 
Mut 
Lamb3 Laminin beta 3 (cell attachment, migration 
and 
organization)  
18 4 
Hhat Hedgehog acyltransferase (SHH signaling) 13 3 
G0s2 G0/G1switch (Potential oncogene and 
regulator of latent HIV) 
0 0 
Kcnh1 Potassium voltage-gated channel, 
subfamily H (Overexpression may confer 
growth advantage to cancer cells and favor 
tumor cell proliferation) 
16 4 
Irf6 Interferon regulatory factor 6 (Plays a role 
in 
regulating mammary epithelial cell 
proliferation by similarity) 
7 2 
chr1:194325877-
197195432 (2.9 
Mb) 
Traf3ip3 TRAF3 interacting Jun N terminal kinase 
(JNK) activating modulator 
12 3 
Fbxw7 
F-box/WD repeat-containing protein 7 (Notch 
Signaling) 289 25 
chr3:79004814-
87446447 (8.4 Mb); 
C3H Recess Suscept 
Sfrp1 
Secreted frizzled-related protein 2 (Wnt 
Signaling) 2 1 
Msh4 MutS protein homolog 4 (DNA damage repair) 2 1 
chr3:148028504-
153987532 (6 Mb); 
C3H Recess Suscept 
Fubp1 
Far upstream element-binding protein 1 (c-myc 
activation) 3 0 
Chd7 Chromodomain-helicase-DNA-binding protein 7 8 6 
Chr4:5013576-
8730829 (3.7 Mb); 
C3H Recess Suscept 
Rab2a Ras-related protein Rab-2A (Ras oncogene family) 0 0 
Tln1 Talin 1 (Integrin Activation) 4 3 
Fancg Fanconi anemia group G protein homolog 3 2 
chr4:41604056-
46655694 (5.1 Mb); 
C3H Recess Suscept 
Pax5 Paired box protein Pax-5 (TF for B cell lineage) 135 0 
Fgfr3 Fibroblast growth factor receptor 3 2398 6 
Bodl biorientation of chromosomes in cell division 6 6 
chr5:33660148-
45362659 (11.7 Mb); 
C3H Recess Suscept 
Rab28 
Ras-related protein Rab-28 (TGF-B signaling, Ras 
family) 2 1 
Rassf6 Ras association domain-containing protein  8 1 
Cdkl2 Cyclin-dependent kinase-like 2 12 5 
Epha5 Ephrin type-A receptor 5 (tyrosine kinase) 50 5 
chr5:79059370-
93652588 (14.6 Mb); 
C3H Recess Suscept 
G3bp2 
Ras GTPase-activating protein-binding 
protein 2 8 2 
Fis1 
Mitochondrial fission 1 protein (apoptosis) 
1 0 
Mcm7 
DNA replication licensing factor 
5 0 
Rasa4 
Ras GTPase-activating protein 4 
0 0 
chr5:127039809-
139970688 (12.9 
Mb); C3H Recess 
Suscept 
Cldn15 
Claudin 15 
3 1 
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Styk1 
Tyrosine protein-kinase STYK1 (apoptosis, 
angiogenesis) 6 2 
Rad51ap1 RAD51-associated protein 1 0 0 
chr6:120528826-
131940471 (11.4 
Mb); C57/B6 Recess 
Resist 
* Bcl2l13, Ccnd2, Fgf23, Fgf6, Ing4, Ltbr, Mlf2, Tnfrsf1a low freq low freq 
chr7:37568559-
47672477 (10.1 Mb); 
C57/B6 Recess Resist 
Ccne1 G1/S-specific cyclin-E1 1 0 
Map2k6 
Dual specificity mitogen-activated protein 
kinase kinase 6 9 1 
Socs3 
Suppressor of cytokine signaling 3 (JAK-STAT, anti-
apoptosis) 1 1 
Aatk Serine/threonine-protein kinase LMTK1 10 3 
Sumo2 Small ubiquitin-related modifier 2 1 0 
Cbx4 E3 SUMO-protein ligase CBX4 3 1 
Sox9 Transcription factor SOX-9 8 1 
chr11:110022477-
112022477 (10 Mb 
**); C3H Recess 
Suscept 
Srsf2 
Serine/arginine-rich splicing factor 2 (pre-mRNA 
splicing, apoptosis) 95 0 
Fancc Fanconi anemia, complementation group C 1 0 
Ptc1 Patched homolog 1 (SHH Receptor) 333 6 
chr13:60287243-
70287243 (10 Mb**); 
C3H Recess Suscept; 
C57/B6 Recess Resist Hsd17b3 
Testosterone 17-beta-dehydrogenase 3 (Androgen, 
estrogene, progesterone biosynthesis->Estradiol 
17beta-dehydrogenase) 0 0 
Pibf1 
Progesterone immunomodulatory binding factor 1 7 3 
Dach1 Dachshund 1 (Transcription factor, lost in some forms 
of metastatic cancer, and is correlated with poor 
prognosis) 8 3 
Mycbp2 
MYC binding protein 2 (MYC regulation/activation) 37 9 
Commd6 
(Down-regulates activation of NF-kappa-B, inhibits 
TNF-induced NFKB1 activation) 0 0 
Klf5 
Kruppel-like factor 5 (transcription factor, 
maintenance of embryonic stem cell pluripotency, 
regulation of cell proliferation in intestinal 
epithelium) 7 2 
chr14:87238704-
106808620 (19.6 
Mb); C3H 
Dominant 
Suscept 
Spry2 
Sprouty homolog 2 (antagonist of fibroblast growth 
factor FGF) 3 1 
COSMIC = Catalogue Of Somatic Mutations In Cancer; *Repro-Tumors in female reproductive 
tissues; breast, ovary, uterus; **Single informative SNP in large region. 
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Supplementary Table A3-3: Bone Tumor QTLs 
Chr 
Left 
Position 
Right 
Position 
Size 
(Mb) 
Effect 
Type SNP(s) 
3 3785419 3785419 * 
C3H RS, B6 
RR rs13476950 
3 14887895 14887895 * 
B6 RS, C3H 
RR rs13476985 
3 23723842 23723842 * 
B6 RS, C3H 
RR rs13477019 
3 30227687 34034360 3.8 
B6 RS, C3H 
RR 
rs3660588, rs13477048, 
rs6371982 
3 123767337 153987532 30.2 
B6 RS, C3H 
RR 
mCV23483645, rs3657112, 
rs3724562, rs13477504 
6 131940471 145693849 13.8 
B6 RS, C3H 
RR rs3704289, rs6387265 
8 16233576 35610881 19.4 B6 RS 
rs13479622, rs3704385, 
rs3694068 
15 43206205 44053945 0.8 C3H RR CEL-15_43206205, rs3674266 
15 71166963 78182168 7.0 C3H RR 
rs3699312, rs13482641, 
rs3701224 
*Single informative SNP in large region. RS=Recessive Susceptibility, RR=Recessive 
Resistance. 
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Supplementary Table A3-4: Tln1 Mutation Status 
Sample Chaos3 Genotype 
Talin1 
Genotype 
Wild Type Controls 
      
UCSC WT G/G 
C3H Inbred WT G/G 
B6 Inbred Male WT G/G 
B6 Inbred Female WT G/G 
129 Inbred WT G/G 
      
Chaos3 Controls 
  
    
19223 (3 mo, spleen) C3+/+ C3H N10F1 G/A 
20685 (1 mo, spleen) C3/3 C3H N10F2 A/A 
Male (tail) C3/3 B6 N10 G/G 
Female (tail) C3/3 B6 N10 G/G 
      
Chaos3 Tumors 
  
    
12352 Mammary C3/3 C3H N9F2 A/A 
15259 Mammary C3/3 C3H N10 G/A 
2042 Mammary Cell Line C3/3 C3H N8F2 A/A 
2044B Mammary Cell Line C3/3 C3H N8F2 G/A 
17883 Mediastinal* Tumor C3/3 C3HxB6 F2 G/G 
Legend: mo=month. *Mediastinal Tumor represents either lymphoma or 
histiocytic sarcoma 
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Supplementary Table A3-5: Chaos3 F2 Talin 1 Mutation 
            
Total Talin1 Genotyping (n=129) 
0.28 39 A/A Mut     
0.42 58 G/A Het     
0.30 42 G/G WT     
  A= .49 G=.51       
            
Animals not developing mammary tumors (n=105) 
0.25 26 A/A Mut     
0.43 45 G/A Het     
0.32 34 G/G WT     
  A= .46 G=.54       
ChiSquare, Genotype Freq. p= 0.74025     
Fisher Exact, Allele 
Frequency p= 0.7771     
            
Animals developing mammary tumors (n=24)  
0.50 12 A/A Mut     
0.38 9 G/A Het     
0.13 3 G/G WT     
  A= .69 G=.31       
ChiSquare, Genotype Freq. p= 0.03484     
Fisher Exact, Allele 
Frequency p= 0.0061     
            
Legend: All genotyped animals have histopathology calls.     
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Supplementary Figure A3-3: Nonsynonomous Mutations and SNPs in TLN1. (A) 
TLN1 missense mutations in tumors listed in the COSMIC database.  Mutations are 
aligned to mouse orientation with the Chaos3 Tln1 mutation indicated by a red arrow.  
Black arrows indicate locations of mutations in human breast tumors.  Blue arrows 
represent locations of mutations in human ovarian tumors.  (B) TLN1 
Nonsysnonomous and UTR SNPs present in >1% of the human population.  Red text 
= nonsysnonomous SNPs; blue text = UTR SNPs. 
 
 
mouse
rat
human
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Supplementary Table A3-6: TLN1 Non-Synonomous & UTR SNPs in > 1% of the 
Human Population 
dbSNP Chr. Position 
Major 
Allele 
Major 
% 
Minor 
Allele 
Minor 
% Function 
rs11496 Chr9:35697470 T 91.89% C 8.11% 3' UTR 
rs117039868 Chr9:35699043 G 98.33% A 1.67% 
missense R (CGG) 
 W (TGG) 
rs74431517 Chr9:35700238 T 96.59% G 3.41% 
missense T (ACA)  
P (CCA) 
rs35642290 Chr9:35704426 G 94.74% A 5.26% 
missense A (GCT) 
T (ACT) 
rs34723987 Chr9:35706047 A 98.72% G 1.28% 
missense E (GAG) 
G (GGG) 
rs34033956 Chr9:35711593 C 98.49% T 1.52% 
missense P (CCG) 
L (CTG) 
rs2295795 Chr9:35712003 G 80.46% A 19.43% 
missense S (TCG) 
L (TTG) 
rs13298317 Chr9:35714611 G 75.00% A  25.00% 
missense A (GCT) 
V (GTT) 
rs75137786 Chr9:35721781 T 66.67% G 33.33% 
missense N (AAC) 
T (ACC) 
rs116509251 Chr9:35732321 G  98.27% A 1.74% 5' UTR 
rs116886883 Chr9:35710605 A 80.83% G 19.17% 
missense S (TCC) 
P (CCC) 
rs118143084 Chr9:35717293 C 87.50% G 12.50% 
missense A (GCA) 
P (CCA) 
rs76393058 Chr9:35725267 C 98.61% T 1.39% 
nonsense W (TGG) 
 * (TAG) 
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Table A4-1: Median Tumor Latency of Chaos3 x DDR Mice 
  
            
Genotype Gender Strain 
Median 
Tumor 
Latency 
(mo.) 
LRMCT 
p-value 
GBWT   
p-value 
C3/3 M C3H x FVB 18.00 - - 
C3/3 Atm-/- M C3H x FVB 3.90 <0.0001 <0.0001 
C3/3 Atm+/- M C3H x FVB 16.45 0.0751 0.0729 
C3/+ Atm+/- M C3H x FVB 18.00 0.472 0.4339 
C3 x Hus1 M C3H x FVB - 0.5117 - 
C3/3 Hus1 
det/neo M C3H x FVB 18.00 0.4334 0.355 
C3/3 Hus1 det/+ M C3H x FVB 17.95 0.6739 0.7204 
C3/3 Hus1 
neo/+ M C3H x FVB 18.00 0.3714 0.4063 
C3/3 M C3H x B6 17.20 - - 
C3/3 p21-/- M 
B6 N8 (C3H 
mix) 13.00 0.1325 0.046 
C3/3 p21+/- M 
B6 N8 (C3H 
mix) 16.85 0.405 0.3813 
C3/3 M C3H x B6 16.55 - - 
C3/3 Chk2-/- M C3H x B6 14.70 0.4272 0.2542 
C3/3 Blm+/- M C3H x B6 18.00 0.059 0.081 
C3/+ M C3H x B6 18.00 - - 
C3/+ Blm+/- M C3H x B6 18.00 0.9512 0.9068 
C3/3 (DDR) F C3H x B6 16.50 - - 
C3/3 p21-/- F 
B6 N8 (C3H 
mix) 12.20 0.0207 0.0055 
C3/3 p21+/- F 
B6 N8 (C3H 
mix) 13.80 0.0115 0.0223 
C3/3 Blm+/- F C3H x B6 17.15 0.8469 0.9013 
C3/3 Chk2-/- F C3H x B6 14.00 0.1008 0.0581 
C3/3 (QTL) F C3H x B6 F2 15.50 - - 
C3/3 DDR F C3H x B6 16.50 0.4236 0.3606 
C3/3 Chk2-/- F C3H x B6 14.00 0.0189 0.027 
C3/3 F C3H x FVB 14.95 - - 
C3/3 Atm-/- F C3H x FVB 4.10 <0.0001 <0.0001 
C3/3 Atm+/- F C3H x FVB 10.95 0.001 0.0031 
C3/+ Atm+/- F C3H x FVB 9.30 0.0027 0.0005 
C3 x Hus1  F C3H x FVB - 0.4756 - 
C3/3 Hus1 +/+ F C3H x FVB 15.80 - - 
C3/3 Hus1 
det/neo F C3H x FVB 15.20 0.8054 0.7447 
C3/3 Hus1 det/+ F C3H x FVB 16.30 0.5765 0.9122 
C3/3 Hus1 
neo/+ F C3H x FVB 17.10 0.4596 0.5618 
Legend: LRMCT=Log-rank Mantel-Cox Test; GBWT=Gehan-Breslow-
Wilcoxon Test. 
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Supplementary Figure A4-1: Tumor latency compared to 208 Chaos3 C3H x B6 
F2 females. (A) C3/3 C3H x B6 female tumor latency of DDR crosses littermate 
controls (“DDR C3/3) compared to 208 Chaos3 C3H x B6 F2 females (“C3/3 QTL”) 
from Wallace et al. 2012 (QTL study).  The C3/3 survival curves are not significantly 
different from each other (LRMCT p= 0.4236; GBWT p= 0.3606). (B) Female C3/3 
Chk2-/- tumor latency. The limited number of the DDR C3/3 cohort had less statistical 
power to detect smaller effects of DDR deficiency on tumor latency.  Given the 
similarity of the DDR C3/3 and QTL C3/3 survival plots, the QTL C3/3 cohort was 
utilized to gain statistical power to distinguish smaller effects of DDR impact. C3/3 
Chk2-/- mice have significantly decreased time to tumor onset than C3/3 C3H x B6 
F2s (LRMCT p=0.0189; GBWT p=0.027). (A) and (B) LRMCT=Log-rank/Mantel-
Cox Test;  GBWT=Gehan-Breslow-Wilcoxon Test. 
A
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